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ABSTRACT 
Development of Radical Synthetic Methodology Using Solid-Phase Organic Synthesis 
Rehana Karim 
PhD2003 
The synthesis of heterocycles using radical intermediates has become an important area of research 
in recent years. The aim of our research was to develop radical methodologies to construct 
heterocycles on solid-support. Tri-cyclic benzimidazole derivatives are desirable synthetic targets 
with a range of biological activity and are part of certain antitumour agents. Solid-supported radical 
reactions with substituted benzimidazoles were performed under different experimental conditions, 
including different solvents, three different resins (Wang, Merrifield and Rink) and different radical 
reagents. 4-Mercaptobenzoic acid moiety served as a traceless linker in radical ipso-substitution 
reactions of benzimidazole precursors attached to solid-support to construct tri-cyclic and tetra-
cyclic benzimidazole adducts. The solution-phase radical ipso-substitution protocol was quite 
successfully translated onto solid-support. 
Microwave irradiation has also been used on resin-bound benzimidazole derivatives to construct tri-
cyclic systems. It gave successful results compatible with thermal solid-supported radical reactions. 
The advantage of microwave is that the system is automated and takes a very short time (ea. 10-20 
min) for reactions to go to completion. To our knowledge, this is the first use of microwave 
irradiation for solid-phase radical reactions. 
Imidazoles, indole, pyrrole and pyrazole derivatives were synthesised successfully, by radical 
'oxidative' methodology, using various radical mediators. Tributylgermanium hydride mediated 
radical cyclisations onto the above mentioned heteroarenes gave excellent results. The presence of 
electron withdrawing group (ester functionality) on these heterocycles promoted cyclisation. One of 
the objectives was to synthesise heterocycles on solid-support using radical 'oxidative' 
methodology. For That purpose we used a template heterocycle with an electron withdrawing ester 
functionality which can be hydrolysed and resulting acid coupled to resin (Wang, Rink or Quadragel 
or tentage!). We established solution-phase radical 'oxidative' cyclisation protocol and successfully 
applied it to solid-supported pyrazole moiety. 
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CHAPTERl 
GENERAL INTRODUCTION 
1.1 Solid-Phase Organic Synthesis 
The techniques for solid-phase synthesis are based on the pioneering work of Merrifield 1 who used 
solid-phase to synthesise peptides. The revolution in the synthesis of peptides has lead to generation 
of synthetic enzymes, vaccines and antibiotics. Since then it has increasingly been explored for the 
synthesis of polypeptides and oligonucleotides. The field was extensively investigated during 
1970's,2 and interest in the field has re-emerged with the advent of combinatorial chemistry. 
Reactions on solid-supports will be significant in the future for the fast, simultaneous, and multiple 
synthesis of several new compounds if required in the search of lead structures and their 
optimisation for preparation of novel pharmaceutical targets. Recently there has been greater focus 
on the adaptations of other organic reactions to solid-phase? 
1.1.1 Advantages of Solid-Phase Organic Synthesis 
a) Supported synthesis can be automated; this is significant in mutiple parallel synthesis. 
b) Purification and isolation steps are eliminated by the covalent binding of the substrate and 
product to the support. Furthermore, purification is simplified to washing the support with 
an appropriate set of solvents. 
c) The use of support allows the easy handling of toxic compounds. 
d) The properties of the support can be used to modify the reactivity of the functional groups of 
the pendant molecule. 
e) Many supports can be regenerated and reused. 
f) Excess reagents can be employed to drive the reaction to completion without complicating 
purification procedure. 
g) Principle of high dilution; undesired side reactions such as cross-linking and multiple 
couplings can be suppressed by using supports with low loading. 
The common polymer backbone is polystyrene, crosslinked with 1% or 2% divinylbenzene. The 
latter is the preferred one for reactions at higher temperatures or for reactions with organometallic 
1 
reagents. These resins are compatible with a wide range of reaction conditions; 
1. They are compatible with a range of polar and apolar solvents such as DMF, NMP, alcohols, THF, 
acetonitrile and DCM. 
n. Mixing is attained by: vortexing by employing orbital shakers, ultrasonic or magnetic stirrers or by 
bubbling gas through suspensions. 
1.1.2 Disadvantages of Solid-Phase Organic Synthesis 
A. Use of supports makes separation of two different supported compounds impossible in most 
cases. 
B. Supported reactions are usually slower than the reactions of solution-phase analogues reactions. 
C. The support can adversely affect the reactivity of the functional groups of the pendant molecule. 
D. Prolonged use of mechanical stirring can give rise to mechanical damage of the resins. 
E. The temperature range for reactions is about -78 octo 155 °C. 
Solid-phase synthesis is performed by immobilizing a starting material to the solid support as shown 
in (Figure 1). 
Ql----i.____L_In_ke_r ---"1--c:::> 
Resin I I Substrate I 
Figure 1 
1.1.3 Types of Support 
There are different types of support on which chemistry has been performed, these are generally 
categorised as inorganic supports and polymeric supports. Inorganic supports are silica based 
whereas polymeric supports include soluble polymer supports and cross linked polymers. The 
common polymer backbone is polystyrene, crosslinked with 1% or 2% divinylbenzene. The most 
widely used class of support in supported organic chemistry is cross-linked polymer supports.4 
2 
1.1.4 Linkers 
Solid-phase syntheses require a covalent tinker group to attach the small molecule onto the 
polymeric resin. A linker has been described as a bifunctional protecting group which is attached to 
the molecule being synthesised through a bond labile to the cleavage conditions and is attached to 
the solid-support through a more stable bond, but needs to be cleaved selectively at the end of the 
synthesis releasing the desired product from the resin into solution. The selection of a suitable 
linker for a paticular class of target molecules is crucial in designing solid-phase synthesis. As there 
are a wide range of protecting groups in solution-phase organic chemistry, capable of protecting 
many functional groups, hence, there is a wide repertoire of polymer linking groups (Figure 2 ). 
(Y'oU 
1 
Figure 2 
Early tinkers drew simply on protecting groups such as Ellman's polymer bound THP protecting 
group 15 (Figure 2) and the polymer-bound trityl group 2, 6 both draw directly on commonly used 
solution-phase protecting groups. The commonly used tinkers include acid labile, base labile, 
photolabile, traceless and safety catch tinkers. 
Acid Labile Linkers 
Strong acid is one of commonly employed cleavage conditions in solid-phase synthesis. The }ability 
of an acid labile tinker is dependent on the relative stability of the protonated linker versus the cation 
formed upon cleavage. Hence, the more stable the cation formed, the more labile the linker is to 
acid (Figure 3). The stability of the cations (Figure 3) increases from left to right as the number of 
electron donating groups increases. The same trend can be seen when comparing the ester linker 3. 
derived from hydroxymethylpolystyrene, which requires HF for cleavage. The Wang linker 4 
requires 50% TFA/DCM to promote cleavage, and the Sasrin Iinker 5 requires 1-3% TFA/DCM. 
Severallinkers have been reported for the solid-phase synthesis of hydroxamic acids. In one case 
the acid labile 2-chlorotrityl functionalised polystyrene was converted to the corresponding N-Fmoc-
3 
aminooxy-2-chlorotrityl resin 6 (Scheme 1);7 subsequent synthetic steps and acidolysis with 5% 
TFNDCM released the desired hydroxamic acid from resin. 
MeO (t) 
0-j:J 
< < 
4 
Figure3 
Fmoc-NHOH (i) (ii). (iii) ~ 
6 Cl 
Ph 
0-NH 0 
ft"" f ~ 0 N 
~Ph 
(iv) HO-NH 0 ll'"'" 0 N ~Ph Cl 
7 
Scheme 1. Reagents and conditions: i, 2-chlorotrityl polystyrene, (i-Pr)2NEt; ii, Fmoc peptide 
synthesis; iii, DBU, Ph(CH2) 3Br; iv, 5% TFA/DCM. 
Base Labile Linkers 
Two types of cleavage are included under this heading; the more common type involves 
nucleophilic substitution, usually on an ester; the other type involves a base catalysed reaction, for 
instance, elimination or cyclisation. The nucleophilic labile linker can be exemplified by the 
hydroxymethylpolystyrene derived ester 3 (Scheme 2). The true base labile linker is exemplified by 
the tertiary amine linker 8 (Scheme 3). 
4 
R 
G--\Yo--\ 
3 
Scheme2 
~ -elimination 
8 
Scheme3 
Photolabile Linkers 
0 
+-)l ~NaO R 
~ J 
MeO R 
The use of photolabile linkers in solid-phase synthesis is an attractive strategy as photolysis can 
provide an orthogonal non-invasive method of cleavage. The most common type of photolabile 
tinkers are based on a-nitrobenzyllinkers.8·9 Routledge10 has studied the utility and scope of 
thiohydroxamic acid as a photolabile 'traceless linker' for solid-phase synthesis. The tinker is 
immobilised onto the resin (Scheme 4). It is also an efficient traceless linker revealing an aliphatic 
CH bond on photolysis at 350 nm. 
Traceless Linkers 
Traceless tinkers, which enable the attachment of arenes and alkanes to a polymeric support, are 
becoming increasingly popular. These anchoring groups allow chemical transformations on the 
polymer-bound molecules, which can be cleaved from the resin leaving no residual functionality to 
bias a library. A traceless linker can be defined as a linker which upon cleavage leads to the 
formation of a C-H bond on the seceding molecule. The first traceless tinkers for arenes were 
described independently by Ellman11 and Veber.12 The silicon traceless linker developed by Veber 
5 
(Scheme 5) allows the introduction of a proton on the binding site of the silicon moiety by ipso 
substitution on the arenes. 
~Cl + Ho-Q-srr 
~STr 
_....;_(i)'---.,.. ~0~ (ii) .. 
N fj 
~S""-rf"'N 
(iii). ~ M (iv) 
cf'o 
(V) .. (vi) ~ o=) 
\ 
O SH I ~0 
V 
Scheme 4. Reagents and conditions: i, Chloromethyl-polystyrene (0.8 mmol/g), NaH (3 equiv.), 
DMF, 60 °C, 18 h, 98%; ii, TFNDCMIE{JSiH (9:10:1), rt, 1 h; iii, 1,1-thiocarbonyldiimidazole (3 
equiv.), DCM, rt, 18 h, 78%; iv, N-methylhydroxylamine hydrochloride (3 equiv.), triethylamine (6 
equiv.), DCM, rt, 18 h, 73%; v, N-methylindole-3-acetic acid (2 equiv.), DIC (2 equiv.), HOBT (2 
equiv.), DMAP (0.2 equiv.), DCM, DMF, 85%; vi, Bu3SnHffHF (1:40), 30 min, 350 nm, 55%. 
11 
o \I 
'-si 
(i) 
Scheme 5. Reagents and conditions: i, TF A, 25 °C. 
6 
H 
NH 
'sn 
Safety Catch Linkers 
Safety catch linkers rely on a two step cleavage. The first step involves activation of the Iinker, the 
second step involves the cleavage. This is demonstrated by Kenner's safety catch linker 13 (Scheme 
6).13•14 It is stable to both acidic and basic conditions until the nitrogen is alkylated either by 
diazomethane or iodoacetonitrile. Once activated by alkylation, cleavage proceeds under 
nucleophilic conditions. 
activation • 
0 0 ,,,, 
s 0 
'N~ 
R:?! R1 
Scheme6 
0 
Nu )l 
-c'l"'"le-a-va_g_e_..Nu R1 
14 
Once the resin and synthetic route has been chosen, the next problem is how to monitor solid-phase 
reactions and for this, there are number of methods available, which are listed below; 
A. Ff-IR and Ff-Raman spectroscopy. 
B. Elemental analysis. 
C. Photometry (e.g. -NH2 monitored by photometric Fmoc determination). 
D. Solid-state and gel-phase 13C NMR spectroscopy, as well as 1H and 13C correlation NMR 
spectroscopy. 
E. Titration of reactive groups (e.g. -NH2, -COOH, ArOH, -SH). 
F. High resolution 1H MAS and MAS-CH correlation in the gel phase. 
However, analysis of solid-supported substrates is still not accurate enough due to the interference 
of the polymer backbone and the low loadings generally employed. 
1.1.5 Combinatorial Chemistry 
Combinatorial chemistry is a method for the rapid generation of large numbers of compounds. 
Solid-phase is highly suitable to combinatorial chemistry for the following reasons: easy work-up 
7 
procedures; high yield by using excess reagents and its amenability to multiple and automated 
synthesis. The area can be split into three main methods: 
1. Split and Mix Synthesis.15·16 To generate a very large number of products by combinatorial 
synthesis on the solid-support, the 'split and mix' method has been widely used (Figure 4). 
Split , Mix Split 
- 181 181C1 . ' 1~C1 " A18aC1 
A281 A281 C1 282 C1 28:P1 
. , 28s . • .· 281Cs ._ .• ·. .. 282 C3 .. • 2B:P3 
._ .•. s8s <::r-s81Cs : As8:P3<:f.sBsC3 
3 compounds 9compounds 27 compounds 
Figure4 
The synthesis is performed by taking a large number of beads and splitting them into equal 
groups. To each is then added a different substrate. The chemistry is performed, and the 
beads combined, mixed and then split again. Ellman has provided an example of 
combinatorial benzodiazepine synthesis (Scheme 7)17 using 'split and mix' method. One 
major advantage of this method is to build large libraries relatively easily involving few 
synthetic steps. The major limitation of the 'split and mix' synthesis method is the problem of 
screening and deconvolution. 
2. Multiple Parallel Synthesis: In multiple parallel synthesis, the individual compounds are kept 
separate throughout the synthesis. Such procedures are commonly carried out in multi-well 
microtitre plates. The main advantage is that the position on the plate, provides the chemical 
history of the beads, therefore removing any problem of deconvolution. The other advantage 
is that screening can be both on and off bead without loss of information. These factors allow 
the synthesis and screening of discrete quantities of large numbers of compounds. The 
8 
disadvantage of this method is that the library size is relatively small, therefore, the possibility 
of finding a hit is lowered. 
(i) 
0)--..(NH-Fmoc 
NH R2 
(ii), (iii) 
0 
16 
H R3 R3 I I 
N 0 N 0 (v) N 0 ~N):'R, (iv) ~N):'R, ~N):'R, 
17 18 19 
Scheme 7. Reagents and conditions: i, Fmoc protected amino acid fluorides, 4-methyl-2,6-di-tert-
butylpyridine; ii, 20% piperidine in DMF; iii, HOAc/DMF (5/95), 60 °C; iv, lithiated 5-
(phenylmethyl)-2-oxazolidinone in THF, -78 °C, followed by alkyl iodides R31, DMF; v, 
TFA/H20/Me2S (95:5: 10). 
3. Spatially Addressable Synthesis:18 This technique is based on identifying compounds by 
location. One example of this method is light-directed synthesis. A sequence of 
photodeprotection, and coupling are performed, allowing the synthesis of large number of 
peptides whose identity can be determined by their position on the slide. 
9 
hv 
1 U! ill M, 
X X X X 
I I I I 
0 0 0 0 
~ ~ ~ ~ 
//// 
Photodeprotection 
!H hv xx!H lM, 
I I A A X X 
I I I I 
0 0 0 0 
~ ~ ~ ~ Photodeprotection 
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I I OHOHO 0 
~ ~ ~ ~ 
//// 
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I I 0 0 OHOH 
~ ~ ~ ~ 
//// 
X-A couplin~ 
X-G coupling 
Figure 5. Principles of light-directed synthesis. 
1.2 Radical Methodology 
~ Repeat 
Russian-bom chemist Moses Gomberg provided the first example of a free radical in 
1900, in the form of trivalent compound triphenylmethyl radical which was generated when 
triphenylmethyl bromide was treated with silver metal (Scheme 8).19 
(CaHs)sCBr + Ag (C6H5)sC • + AgBr 
SchemeS 
He demonstrated that in oxygen-free solution of benzene the triphenyl methyl radical is in 
equilibrium with its dimer. Although triphenylmethyl radical was observable only because it was 
stabilized by resonance unlike other typical free radical, its chemical properties showed what kind of 
behaviour to expect of free radicals in general and most important of all it showed that such species 
as free radicals could exist. 
:;;::==~- Dimer 
10 
However, the beginnings of synthesis involving radical methodology did not appear until1937 with 
Hey and Waters and the homolytic phenylation of aromatic substrates, as well as with Kharasch and 
the regioselectivity of HBr addition to alkenes, called the peroxide effect or the Kharasch effect or 
anti-Markovinkov. The importance of radical-mediated processes in production of synthetic 
polymers, especially synthetic rubber, gave a major impetus to radical chemistry during the Second 
World War. 
Many biological, combustion and auto-oxidation reactions involve radical processes. Radical 
reactions are important in living systems since they are involved in normal biological processes and 
energy production. They are also induced by external factors such as radiation, medicines and 
foodstuffs. Some biochemical reactions are explained by the formation of free radicals: lipid 
peroxidation, isomerisation by coenzyme B 12, etc. EPR spectroscopy and the spin-trapping 
techniques contribute greatly to the detection and identification of the free radical intermediates in 
this field. A radical has been defined as a molecular entity containing one or more unpaired 
electrons, in practice, some limitations are imposed on this definition. Thus transition metal ions, or 
atoms of the alkali metals would not be referred to as radicals. This definition also includes species 
formed from familiar organic molecules by the loss or gain of a single electron. Examples are the 
amine radical cation 20 and naphthalene radical anion 21. 
Me+. Me 
'N" 
6 
20 
. [CO] 
21 
The presence of unpaired electrons gives radicals the property of paramagnetism. Information about 
the structure of radicals is provided by physical methods (e.g. IR and EPR spectroscopy), by 
calculation and by chemical methods. EPR spectroscopy is the most appropriate and the most 
powerful method for studying species containing one or more unpaired electrons. This method is 
quite sensitive, being capable of detecting free radicals at concentrations of the order of w-s M. It 
provides information about both the nature of the radical and its structure (conformation, 
configuration, delocalization of the unpaired electron). 
11 
1.2.1 Characteristics of Free Radicals 
Free radicals are generated in a number of general ways, e.g. 
A) Through homolytic cleavage of bonds, 
A-B----~ A• 
Scheme9 
B) By reaction of molecules with other free radicals, 
+ 
A-B X
• 
---.:...;.._-1•~ A• + B-X 
Scheme 10 
These procedures are called the initiation step, the second step involves the disappearance of 
radicals, and it is termed as termination. Radical reactions can involve addition, elimination, 
oxidation, reduction and cyclisation. 
• + B A-s 
Scheme 11 
1.2.2 Chemoselectivity of Radicals 
Radical reactions can be performed under mild, neutral conditions. Due to the high 
chemoselectivity of radical reactions, many functional groups will survive radical reaction 
conditions and therefore, protection is unnecessary. Commonly used substrates in radical reactions 
are alkyl iodides and bromides due to ease of fission of C-X bond. The approximate order of 
reactivity for certain leaving groups to generate radicals is as follows, R-Cl < R-SPh < R-N02 < R-
SePh < R-Br < R-1. 
1.2.3 Regioselectivity and Stereoselectivity of Radical Cyclisations 
Radical cyclisation normally consists of intramolecular additions to double or triple bonds. They are 
of great interest as they allow the synthesis of a wide variety of 5- and 6- membered cyclic 
compounds with high regioselectivity and often very good stereoselectivity. For example, the 
12 
cyclisation of the hex-5-en-1-yl radical 22, is irreversible and forms the primary radical 23, derived 
from 5-exo cyclisation, in preference to the thermodynamically more stable secondary radical 24 
(Scheme 12).20 
l(i) 
k=2.3x 1oS s·1 d lf~ 23 
22 --------.... 
k = 4.1 X 1o"s·1 o· 
d64% 
25 
24 26 
Scheme 12. Reagents and conditions: i, Bu3SnH, AIBN, benzene. 
In both instances, the reaction leads to the formation of a C-C o-bond at the expense of a much 
weaker C=C 3t-bond. At 25 °C, the rate of 5-exo cyclisation is 2.3 x HP s-• compared to a much 
slower rate of 4.1 x 1<Y s-1 for 6-endo cyclisation. The preference for 5-exo cyclisation has been 
explained on the basis of stereoelectronic effects favouring a chair-like transition state (which is 
known as the Beckwith model). Following cyclisation, the cyclic radicals 23 and 24 abstract a 
hydrogen atom from tributyltin hydride (at approximately the same rate) to form cyclised adducts 25 
and 26, respectively together with Bu3Sn• which re-enters the chain reaction. Baldwin has outlined 
the rules for ring-closure reactions which describe the size of the ring, the hybridisation state of the 
atom under attack and the resulting regioselectivity of radical cyclisation. 
In the above mentioned example of the hexenyl radical cyclisation, the I ,5-cyclisation observed is a 
5-exo-trig process and the 1,6 cyclisation is termed as a 6-endo-trig process. Factors determining 
the regio- and stereoselectivity include chain length and chain substituents. 
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1.2.4 Synthesis of Heterocycles by Radical Cyclisation Methodology 
1.2.5 Oxidative Radical Cyclisations 
Radical cyclisation for the synthesis of heterocycles is a well documented methodology in the 
literature. Many new methods are being developed to synthesise the wide range of novel natural 
products. The majority of radical cyclisations are carried out using tributyltin hydride but other 
radical generating procedures are becoming increasingly popular. Amongst the huge variety of 
radical cyclisation reactions those with oxidative rearomatisation have been extensively 
studied.21.22 The conditions employed in most cases were oxidative, which is important in 
regenerating the final aromaticity of the desired target. Overall these reactions give cyclisation 
by loss of HX. 
In order to explain these oxidative cyclisation reactions, Bowman proposed the first pseudo SRN 1 
mechanism-pseudo substitution radical nucleophilic unimolecular, for radical cyclisation of aryl 
radicals onto thioamides (Scheme 13).23 
27 28 
Scheme 13. Reagents and conditions: i, Bu3SnH, AIBN, toluene, 24 h, 69%. 
The generated aryl radical cyclises onto the sulfur of the carbon-sulfur double bond to produce a 
delocalised radical. The pseudo SRN1 mechanism relies upon the fact that tributyltin hydride acts 
as a base and liberates hydrogen gas. It was proposed that the tributyltin hydride removes the 
proton bound to the nitrogen to generate the intermediate radical anion 29 (Scheme 14). The 
delocalised radical anion intermediate 29 then undergoes single electron transfer with a molecule 
of starting material to generate the cyclised adduct 28 and a molecule of starting material as 
delocalised radical anion 30 (Scheme 15). The radical anion 30 undergoes dissociation to an 
anion (f) and the initial aryl radical. Prior to dissociation, the radical anion is localised on the 
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carbon-iodine bond and the o-bond is composed of three electrons with the unpaired electron 
residing in the a*-molecular orbital. 
27 
Scheme 14. Formation of the radical anion. 
Bu3SnH deprotonat~ 
Bu3sn++H/! 
(JCN~ s~ 
29 
These types of oxidative radical cyclisation reactions require more than one equivalent of 
tributyltin hydride. Support for the ''pseudo SRN1 mechanism" has been offered by Beckwith and 
Storey.24 The mechanism has not been solved and a common view is abstraction of hydrogen 
hydrogen by a radical in the reaction. For example, Curran findings are in contradiction with the 
"pseudo SRNl mechanism".25 Curran proposes that it is the 2-cyanoprop-2-yl radical (from 
AIBN) that acts as an oxidant (Scheme 16). For these oxidative radical cyclisations an excess of 
AIBN is required. 
Cyclisation of N-(ro-alkyl) radicals onto heteroarenes has been used to annulate pyrrole, 
imidazole and indole. An example of these oxidative radical cyclisations using tributyltin 
hydride is shown in Scheme 17 for the synthesis of [1,2-a]fused pyrroles.26 Treatment of the 
precursors 33 with tributyltin hydride yield N-( ro-alkyl)pyrrole radicals 34 which cyclise onto the 
pyrrole rings to form the cyclised n: radicals 35. In an oxidative step a hydrogen atom is lost to 
yield the [1,2-a]fused pyrroles 36. [1,2-a]Fused imidazoles have also been synthesised by the 
oxidative radical cyclisation methodology.26 
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Scheme 15. Single electron transfer and radical anion dissociation. 
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Scheme 16. Oxidative rearomatisation. 
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Scheme 17. Reagents and conditions: i, Bu3SnH (syringe pump addition), AIBN, CH3CN, 
reflux, 36 (n = 1, 28%; n = 2, 55%; n = 3, 40%). 
Tributyltin hydride mediated 'oxidative' cyclisation protocol has successfully been used for the 
short synthesis of withasomnine 38, one of the few pyrazole natural products (Scheme 18).27 
Ph 
eN 
N 
PhS - J 37 e...,...~ 
(i) 
Ph 
.. PN ~N:~ 
n 38 
Scheme 18. Reagents and conditions: i, Bu3SnH (syringe pump addition), ACCN, toluene, 
reflux, 38 (n = 1, 38%; n = 2, 63% ). 
In this example a side chain alkyl radical generated from the precursor selanide 37 cyclises onto 
the pyrazole ring with subsequent loss of hydrogen atoms. There have been a large number of 
reports of aryl or heteroaryl radical cyclisation onto pendant arenes/heteroarenes.28 A good 
example is the cyclisation of indol-2-yl radicals onto phenyl rings as illustrated in Scheme 19.29 
The precursors 39 (n = 1-3) initially give reactive indolyl radicals 40 which cyclise to yield the 3t 
radicals 41 and after loss of a hydrogen atom yield the tetracyclic isoindolo-[1,2-a]indoles 42. 
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Scheme 19. Reagents and conditions: i, Bu3SnH (syringe pump addition), AIBN, CH3CN, 
reflux, 40 (n = 1, 25%; n = 2, 65%; n = 3, 37%). 
1.2.6 Tandem or Cascade Radical Cyclisations 
The majority of radical cyclisations used for the syntheses of heterocycles proceed via 5-exo-trig 
regioselectivity. The tandem or cascade radical cyclisation approach has been widely used for 
natural product synthesis containing heterocyclic rings. For example, Curran and eo-workers 
have developed a novel radical methodology for the synthesis of the important anticancer 
alkaloid camptothecin 46 (Scheme 20)30·31 and analogues such as mappicine.32 
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Scheme 20. Reagents and conditions: i, PhNC, (Me3Sn)2, PhH, sunlamp, 70 °C, 8 h, 63 %. 
1.2. 7 Ipso-Substitutions 
Intramolecular nucleophilic and electrophilic ipso-substitution reactions are typical aromatic 
substitution processes. Ipso-substitution is substitution at a position already carrying a 
substituent. One possibility is to introduce a group which will participate in ipso-substitution. 
The use of sulfur-based groups has served this purpose and appears to offer a general protocol 
which is distinct from the oxidative radical cyclisations and it may offer possibilities for 
regiocontrolled cyclisation. [1,2-a]-Fused benzimidazoles/3 imidazoles,33 and indoles 34 have 
been synthesised using regioselective (ipso) aromatic homolytic substitution. The [1,2-a]fused 
imidazoles were synthesised from N-(oo-phenylselanyl)alkyl-2-(phenylsulfonyl)-imidazoles by 
cyclisation of intermediate N-(oo-alkyl) radicals, generated using B~SnH, with displacement of 
the phenylsulfonyl groups.33 Similarly, the [1,2-a]fused benzimidazoles were synthesised from 
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N-( ro-phenylselanyl)alkyl-2-(phenylsulfanyl)benzimidazoles with displacement of phenylsulfanyl 
leaving groups. Caddick has successfully demonstrated that a tosyl radical catalysed 
isomerisation can provide an effective route to biologically valuable fused[1,2-a]indole ring 
system.34 An example of the protocol is shown in Scheme 21 for the conversion of the alkynyl 
precursor 47 to the cyclised indole .SO. 
~~Ts ----'(...._i)_ • ., ~Ts ~Nvr-r ~NIC.. rs 
47 48 ~
Ts ~ Ts 
50 
Scheme 21. Reagents and conditions: i, TsSePh (0.25 equiv.), AIBN, benzene, reflux, 72-89%. 
Motherwell reported examples of a number of heterocyclic compounds (Scheme 22).35 Tricyclic 
.52 is a product of the oxidative cyclisation from an initial aryl radical, while biphenyl .53 is the 
product of ipso-substitution-sulfur dioxide is eliminated. The tricyclic adduct .S.S is the result of 
an aryl radical undergoing intramolecular radical cyclisation onto a pyridine ring. 
OMe + 
52 53 
(i) 
... 
55 
Scheme 22. Reagents and conditions: i, Bu3SnH, AIBN, .52 (33%), .53 (10%), .S.S (43%). 
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Coumarins are naturally occurring lactones which possess valuable pharmaceutical properties 
along with crop protection and analytical utilities. A highly efficient route to azacoumarins with 
an unusual mechanism of double ipso-substitutions has been reported by Zhang.36 A radical 
precursor aryl benzoate 57 (Scheme 23) is prepared by 0-acylation of 3-methoxy-2-(lH)-
pyridone 56 with 2-bromobenzoyl chloride in the presence of K2C03 and tetrabutylammonium 
bromide. This intermediate is then treated with TTMSS to afford azacoumarin 58 in 75% yield. 
OMe 
0~ 
H~~ (i) 
56 
Scheme 23. Reagents and conditions: i, 2-bromobenzoyl chloride, K2C03 , TBAB; ii, TTMSS, 
AIBN, benzene, 80 °C, 75%. 
The anticipated direct 1,6-ipso-substitution product 59 is not observed at all. The proposed 
mechanism is illustrated in Scheme 24. 
~·/\OMe 1,5-ipso ~0~ 
60 0 ~~ 
M eO 
1,6-ipso .. 
-MeO· 
62 0 58 
Scheme 24. A double ipso substitution mechanism. 
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Further support for ipso substitution of aromatic carbonyloxy radicals comes from a study by Togo 
and Y okoyama in oxidative cyclisation of o-arylaromatic acids?7 
1.2.8 Reagents for Radical Reactions 
Group 14 metal-hydrogen and metal-metal compounds have been successfully used to mediate a 
wide range of radical transformations such as cyclisations, intermolecular additions, radical 
rearrangements and cascade reactions. Few examples of tributyltin hydride mediated reactions have 
been covered in previous section. Tributyltin hydride and related group 14 hydrides readily act as 
hydrogen atom donors in free radical reactions. The tributyltin hydride radical Bu3Sn· can be easily 
prepared, photochemically or thermally from reaction of B~SnH with peroxides or azo compounds 
(Scheme 25). 
+o· + H-SnBu3 +OH + ·snBu3 
---i· H-SnBu3 +H . + + SnBu3 
CN CN 
Scheme25 
Silicon and germanium hydrides undergo related hydrogen atom transfer reaction (Table 1).38 
Table 1. Absolute rate constants (k) for reaction of group 14 hydrides with the tert-butoxyl radical 
at25 °C. 
Metal hydride k/dm3 mor1 s-1 
H-SnPh3 4.3 X 108 
H-SnBu3 1.9 X 108 
H-Si(SiM~)3 1.1 X 108 
H-GeB~ 9.2 X 107 
H-GePh3 9.2 X 107 
H-Si(SMe3) 3 4.4 X 107 
H-SiPh3 1.1 X 107 
H-SiE~ 5.7 X 106 
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The stronger Ge-H bond (-370 kJ mol-' for Bu3GeH) and the Si-H bond (,...,398 kJ mol-' for E~SiH) 
ensures that these reactions proceed at lower rates than the corresponding tributyltin hydride 
reactions. 
Trialkyltin radicals react in bimolecular homolytic substitution (SH2) reactions with a huge variety 
of organohalides, selenides, sulfides or xanthates to form carbon centred radicals (Scheme 26). The 
rate of reaction of a tin-centred radical with an organohalide depends on both the nature of the 
halogen group and to a lesser extent, the alkyl or aryl group. In general the weaker the carbon-
halogen bond the faster the rate of halogen-atom abstraction. Similar reactions are observed for 
related germanium- and silicon-centred radicals (Table 2)?9 
R3sn· 
Scheme26 
Table 2. Absolute rate constants (k) for reaction between organohalides with B~sn·, B~Ge" and 
silicon radical, E(JSi" and (Me3Si)3Si" radicals at 25 °C . 
Compound B~sn . Bu3Ge" E(JSi" (M~Si)3Si" 
kldm3 mol-1 s-1 kldm3 mol-1 s-1 kldm3 mol-1 s-1 k/dm3 mol-1 s-1 
Br-CH2Ph 1.5 X 109 8x 108 2.4 X 109 9.6 X 108 
Br-C(CH3) 3 1.7-1.4 X 108 8.6 X 107 1.1x1if 1.2 X 108 
Cl-CH2Ph 1.1 X 106 1.9 X 106 2.0x 107 4.6 X 106 
The most commonly used reagent is Bu3SnH but it is toxic and there are problems associated with 
the purification of desired targets. The purification can be made easier by using Bu3SnH 
catalytically. In this methodology Bu3SnCl is reduced in situ with sodium cyanoborohydride or 
sodium borohydride; this has an added advantage of keeping the concentration of Bu3SnH low to 
facilitate cyclisation instead of reduction. One of the attractive alternatives to toxic tin-centred 
radicals are non-toxic triorganosilanes. The most successful tin hydride substitute to date is 
tris(trimethylsilyl)silane.40 
An example of a TTMSS mediated cyclisation has been shown in Equation 1 (Scheme 27). 41 
Moreover, Giese-type reductive addition reactions of alkyl halides onto activated olefins were 
successfully performed with (TMS)3SiH Equation 2 (Scheme 27).42 The ease of separating the 
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silane byproducts ((TMS)3SiX from organic products is an attractive feature of it. Unfortunately, it 
is more air-sensitive and expensive than tributyltin hydride. 
(ii) 
.. ,,,/ 
H 
o-l + ~CN (iii) o-rCN (2) 
67 68 69 
Scheme 27. Reagents and conditions: i, (TMS)3SiH, AIBN, benzene, 16 h; ii, POC13, NaBH3CN, 
NaOMe; iii, (TMS)3SiH, AIBN, 90%. 
Triorganogermanium hydrides can also be used as triorganotin hydride substitutes. The use of 
trialkylgermanium hydrides, including Bu3GeH and (TMS)3GeH, as potential contenders for 
Bu3SnH has also been investigated. These hydrides react less rapidly with carbon-centred radicals 
than tributyltin hydride hence competitive simple reduction is observed to a lesser extent. As an 
example, the addition of 1-iodoundecane to acrylonitrile using (TMS)3GeH is shown in Equation 3 
(Scheme 28).43 Radical cyclisation reactions can also be carried out with tri-2-furylgermane as a 
triorganotin hydride substitute.44 The reactions are generally carried out in THF using E~B and 0 2 
as an initiator. 
(i) 
70 68 
(ii) 
72 
~)­(r) 
73 
(3) 
(4) 
(1) 
Scheme 28. Reagents and conditions: i, (TMS)3GeH, AIBN, 80 °C, 71 %; ii, tri-2-furylgermane, V-
70, H20, 80 °C, 75%. 
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Furthermore, the tri-2-furylgermane reactions can be carried out using catalytic amounts of the 
germane and water is tolerated as a solvent in these reductive radical chain reactions.44 V-70 was 
used as a water soluble radical initiator in these reactions, as shown for a typical5-exo-cyclisation in 
Equation 4 (Scheme 28). 44 Organogermanium hydrides are expensive and another disadvantage is 
that germanium-centred radicals generally react less readily with alkyl halides than Bu3Sn• or 
(TMS)3Si• radicals. 
Metal centred radicals can be prepared by homolysis of weak metal-metal bonds in metal dimers of 
the type ~M-M~. Tin-centred radicals can be generated from hexaalkylditin or hexaarylditin 
compounds as the weakest bond in these compounds is the tin-tin bond and this can be 
homolytically cleaved by heating above 100 °C or by photolysis (Scheme 29). Dimers of other 
group 14 elements also undergo homolysis to give radicals. In hexamethyl compounds of the type 
Me6M2, where M is a group 14 element, the strength of the M-M bond decreases as the size of the 
element increases and so lead-centred radicals are generally more easily formed than silicon-centred 
radicals. 
heat .. 2 x R3sn· 
orhv 
Scheme29 
Bowman has reported a cascade radical synthesis of heteroarenes via iminyl radicals using 
hexamethylditin Equations 5 and 6 (Scheme 30).45 
(i) (5) 
74 
(ii) 
(6) 
77 
Scheme 30. Reagents and conditions: i, (Me3Sn2) 2, t-BuPh, sunlamp irradiation (2 x 150 W), 150 
°C, 48 h, 73%; ii, (Me3SnJ2, t-BuPh, sunlamp irradiation (2 x 150 W),150 °C, 48 h, 60%. 
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Similar reactions can be mediated using polymer-supported distannanes.46 
Other metals have also been used for radical reactions. For example, Parsons has investigated some 
interesting atom transfer radical cyclisations using dimanganese decacarbonyl [MniC0)10].47 The 
photolysis of this dimer using visible light generates the manganese pentacarbonyl radical which 
reacts with organohalides to form carbon-centred radicals (Scheme 31 ). The advantages of the use 
of dimanganese decacarbonyl include mild reaction conditions, clean and efficient cyclisation-
trapping sequences and simple removal of manganese halide by-products (on DBU work-up). The 
use of copper complexes in mediating atom transfer radical cyclisation reactions have also been 
reported.48 
~1)~------;~ OJ;f1 
I I 
PMB PMB 
78 79 
Scheme 31. Reagents and conditions: i, 10% Mn2(C0)10, hv, DCM, 1 h, 78%. 
Non-metal hydrides, bearing a weak non-metal-hydrogen bond can also replace Bu3SnH in radical 
reactions. Suitable non-metal hydrogen bonds include sulfur hydrogen, phosphorus-hydrogen or 
boron-hydrogen. 
Polarity reversal catalysis using thiols as catalysts has been intensively investigated.49 The concept 
has successfully been applied in reductive radical chain reactions using stoichiometric amounts of 
trialkylsilanes in the presence of a thiol as a catalyst. Halogen abstractions with thiyl radicals are 
not favourable. The important H-transfer reactions in these chain processes benefit from favourable 
polar effects in their transition states. The concept is outlined briefly in Scheme 32. 
Thiols can be used in cyclisation reactions. Thiyl radical additionlcyclisation reactions have been 
summarized thoroughly.50 For example, the reaction of the carbamate 80 with thiophenol under 
radical conditions affords the cyclised compound 81 in 85% yield (Scheme 33).51 
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Scheme 32. Polarity reversal catalysis using thiols and trialkylsilanes in radical reductions. 
Scheme 33. Reagents and conditions: i, PhSH, AIBN, 85%, dr = 3: l. 
A variety of organophosphorous compounds bearing weak phosphorus-hydrogen bonds can act as 
effective hydrogen-atom donors. For example, two alternative phosphorous compounds of 
particular significance in radical chemistry are hypophosphorous acid (H3P02) and its N-
ethylpiperidine salt (EPHP). These compounds, which contain weak P-H bonds, can replace Bu3SnH 
in many cyclisation reactions and have the added advantage that they allow us to carry out radical 
reactions in aqueous media. Murphy has reported the use of hypophosphorous acid and it s 
corresponding salt (EPHP) to mediate radical cyclisations in both aqueous and organic media. 52 For 
example, EPHP was used to mediate a key 5-exo-trig cyclisation reaction leading to the synthesis of 
the natural product alboatrin (Scheme 34).53 
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Scheme 34. Reagents and conditions: i, EPHP, AIBN, 77%. 
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Phosphorous based radical reagents are an attractive alternative to organotins because these reagents 
are inexpensive, easily handled, and the phosphorous halide by-products are readily removed. 
Although, in some cases, the phosphonyl radicals can add to double bonds rather than react with the 
alkyl halides. The phosphonyl radicals are also less reactive than tin- or silicon-centred radicals so 
alkyl halides with weak carbon-halogen bonds are required, this can be an advantage because the 
lower reactivity of phosphonyl radicals can ensure that the weakest bond within a polyhalogenated 
precursor is selectively broken. 
Other radical reagents, which can act as hydrogen donors are continually being developed. Roberts 
showed that phosphine ligated boranes can be used as radical reducing reagents.54 New hydrides of 
gallium and indium have been introduced to act as radical reducing reagents in reductive chain 
reactions.55·56 Other transition metal based hydrides such as Schwartz reagent [Cpz.Zr(H)Cl] are 
promising alternatives to the tin hydrides. Another major advance in the area of radical chemistry is 
the use of solid-supports to perform radical reactions. 
1.2.9 Solid-Phase Radical Reactions 
The construction of libraries of compounds using combinatorial and parallel synthesis has witnessed 
a great deal of development in recent years. The need for fast delivery of large number of diverse 
compounds for high throughput screening assays has initiated a huge effort in industry and academia 
aimed at designing and adapting reactions for solid-phase synthesis. As a result many solution-
phase reactions have been adapted to solid-supported substrates.57 The execution of radical 
reactions on solid-supports would be very valuable for combinatorial chemistry. When we started 
our studies, only two applications had been reported. In 1997, Balasubramanian reported the first 
example of solid-supported synthesis of dihydrobenzofurans from aryl halide precursors (Scheme 
35), the first carbon-carbon bond-forming reactions on solid-phase using radical methodology. 58 
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Scheme 3S. Reagents and conditions: i, Bu3SnH (4.7 equiv.), AIBN, t-BuOH, toluene, 100 °C; ii, 
NaOMe, MeOH, rt, 24 h; iii, Bu3SnH (20-25 equiv.), 5 mol% AIBN, toluene, 70-80 °C, 4 examples, 
63-80%. 
Aryl halide cyclisations onto unsaturated bonds have also been investigated by Du and Armstrong 
(Scheme 36).59 
OMe 
Ph 
(i) and (ii) 
c;T'o 
OH 
(iii) and (iv) H02C 
91 
Scheme 36. Reagents and conditions: i, HMPA (40 equiv.), Sml2 (10 equiv.), THF, rt, 1 h; ii, 20% 
TFA/DCM, 63%; iii, (40 equiv.) HMPA, 3-pentanone (20 equiv.), Sml2 (10 equiv.), THF, rt, 2 h; iv, 
20% TFA/DCM, 33%. 
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Successful intramolecular radical cyclisations from aryl iodides precursors on polystyrene-Rink 
resin and TentaGel-Wang resin show that these resins are compatible with radical conditions. 
Furthermore, TentaGe! resin allowed polymer swelling in aqueous solvents. a-Amino esters have 
successfully been synthesised on solid-support (Scheme 37) using a radical protocol.60 
Q-oH 
Scheme 37. Reagents and conditions: i, DEAD, PPh3 , THF, rt; ii, RI, (M~Sn)2, benzene, hv; iii, 1 
M HCI!EtzO, MeOH/DCM; iv, 10% Pd!C, EtOH/AcOH/H20. 
The oxime acid 92 was attached to the Wang resin employing Mitsunobu esterification method to 
give the resin-bound phenylsulfonyl oxime ether 93. The attachment of 92 to the resin proceeded 
well. Treatment of 93 with alkyl iodides and hexamethylditin in benzene and irradiation at 30 nm 
for 24 hat 35 °C afforded 94 as shown in Scheme 37. Compound 94 was cleaved from solid-
support by treatment with HCl/EtzO ( 1-N) in M eO HID CM for 48 h at room temperature to give the 
product 95 in high yield based on the initial loading of the Wang resin. Then the successful 
reduction of compound 95 gave final product 96 in good yields. 
These early results demonstrated that radical reactions on solid-support have great synthetic 
potential as new carbon-carbon bond forming methods for combinatorial chemistry. Solid-phase 
intramolecular reactions58 have indicated that intermolecular reactions are also possible using similar 
approaches. Caddick demonstrated successful examples of addition of toluenesulfonyl radicals to 
isolated alkenes and alkynes on solid-support. Excellent yields of addition to both alkenes and 
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alkynes were observed in certain cases (Scheme 38).61 Success of intermolecular radical reactions 
on solid-support shows its potential applications. 
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Scheme 38. Reagents and conditions: i, 5-Hexynoic acid, DIPEA, HATU, DMF; ii, 5-Hexenoic 
acid, DIPEA, HATU, DMF; iii, TsBr, AIBN, toluene, 65-70 °C; iv, 95% TFA (aq.). 
Synthesis of substituted indolines on solid-support, via radical methodology has also been reported 
(Scheme 39).62 
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~N~e-Q 
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Scheme 39. Reagents and conditions: i, R2NH2 (10 equiv.), E~N (27 equiv.), DCM, 25 °C, 12 h; ii, 
Bu3SnH (4 equiv.), AIBN (1.3 equiv.), toluene, 90 °C, 2-4 h. 
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These results show that solid-phase synthesis of substituted indolines can be achieved and 
tracelessly cleaved giving access to the medicinally important 1-methylindolines. Furthermore, 
radical cyclisation reaction itself results in a cyclizing cleavage from the resin, instead of requiring a 
separate step for target release. 
Solid-phase radical reactions are not only limited to tributyltin hydride which is most widely used as 
the radical mediator. There are reports of supported radical reactions which have demonstrated the 
successful generation of radicals using other radical mediators. Recent studies within our group by 
William Barton have shown that the Quadragel alkylselenides and Quadgragel acyl selenides can 
facilitate a traceless cleavage protocol whereby the radical chain propagating entity is tethered to the 
resin and the newly generated radical centre is released into solution.63 A successful application of 
this protocol is illustrated in Scheme 40.63 The homolytic cleavage of the pyrazole precursor 111 
was carried out using TTMSS/AIBN. The radical cyclisation afforded the withasomnine analogue 
112 in 61% yield. This methodology has been extended to other interesting heterocycles. 
HO-o-Se)2 
108 
(iii) 
Scheme 40. Reagents and conditions: i, NaBH4, I(CH2) 4Cl, EtOH, 38%; ii, Quadragel-Ms, K2C03, 
DMF, 80%; iii, TTMSS, ACCN, toluene, 61%. 
Functionalised pyrrolidines have been synthesised by radical cyclisation of oxime ethers attached to 
a polymer support by use of triethylborane as the radical initiator.64 Stereocontrol in free radical 
mediated reactions is of great significance in organic synthesis. 
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Scheme 41. Reagents and conditions: i, E~B, DCM, -78 °C, K2C03, THF, MeOH, 20 °C. 
In recent years, a high degree of stereocontrol in solution-phase radical reactions has been achieved 
at low temperature by using triethylborane as the radical initiator. A high degree of stereocontrol in 
solid-phase radical reactions has also been achieved by using triethylborane and diethylzinc as the 
radical initiators at low reaction temperature (Scheme 41).65 
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Scheme 42. Reagents and conditions: i, RI, E~B in hexane, toluene, 100 °C; ii, NaOMe, MeOH, 
THF, H20, 20 oc. 
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Tandem radical reactions are an excellent method for the stereoselective construction of multiple 
bonds on solid-support. The Naito group has investigated the simple solid-phase tandem radical 
addition-cyclisation reaction of aldoxime ethers onto a,f3-unsaturated carbonyl groups (Scheme 
42).66 
The synthesis of benzofurans using tetrathiafulvalene (TTF) as an oxidant to generate aryl radicals 
from arenediazonium fluoborates has successfully been carried out in solution-phase. The synthesis 
of benzofurans has also successfully been performed on resin. 67 The polymer-supported 
tetrathiafulvalene approach gives easily isolated products from radical-polar crossover reactions and 
the support is regenerated and hence can be reused. 
The use of solid-supported organotin hydride has been reported by Neumann and others.68 Solid-
supported organotin reagents have a great potential for synthetic organic chemistry as polymer-
supported tin hydride allows easy separation of the supported tin by-products by simple filtration. 
Barton-McCombie deoxygenation of secondary alcohols has successfully been carried 
out using catalytic amounts of supported tin hydride in the presence of trimethoxysilane.69 The 
results show that the catalytic use of supported organotin hydride is non-polluting; the solid-phase 
approach to Barton-McCombie deoxygenation of secondary alcohols seems especially suitable for 
applications in the synthesis of bioactive compounds. The Barton radical decarboxylation on solid-
phase has also been reported by Tadei?0 
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Scheme 43. Reagents and conditions: i, 25% Piperidine in DMF, 25 min followed by succinic 
anhyride, DMF (3 equiv.), 70 oc, 3 h; ii, 1-hydroxy-2-pyridinethione (3 equiv.), DIPEA (4 equiv.), 
DMF, rt, 4 h; iii, hv (200 W lamp), CBrCl3 (50 equiv.), DMF, 20 min; iv, hv (200 W lamp), THF, 20 
min; v, TFAIDCMIE~SiH (1/1/0.1), rt, 1 h. 
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A Wang type resin was loaded with Fmoc-Gly-OH and after deprotection of the nitrogen, reacted 
with succinic anhydride to give product 119 (Scheme 43). The Barton ester 120 was synthesised by 
reaction of 119 with 1-hydroxy-2-pyridinethione using HBTU (2-(lH-benzo-triazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluoro-phosphate) in the presence of DIPEA in DMF. Irradiation of 120 in 
benzene or THF followed by acid cleavage afforded product 121 in 76% isolated yield. The 
irradiation of Barton ester 120 in DMF in the presence of at least 50 equiv. of CBrCl3, gave 
compound 122 exclusively in 72% yield. The reaction was employed to generate peptides 
containing novel amino acids on solid-phase (Scheme 43). The authors have demonstrated that the 
photochemical fragmentation of the Barton ester can be successfully employed to generate radicals 
on solid-phase. 
A new polymer-supported radical source has been developed by Taddef1 for a solid-phase version 
of the Hunsdiecker reaction or to liberate free alkoxy radicals that undergo cyclisations under mild 
conditions (Scheme 44). 
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Scheme 44. Reagents and conditions: i, BrCH2C02H, NaOH, MeOCOCl, E~N, DMAP, DCM, rt, 
12 h; ii, Br2, dry MeOH; iii, EtOCSSK, acetone, 0 °C, 5 h, rt, 12 h, NH20H.HCl, pyridine, MeOH, 0 
°C; iv, ZnCl2 (5 M in E~O), LiOH, MeOHffHF; v, N-Fmoc-Gly-Wang resin, piperidine, DMF, 
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HBTU, DIPEA, NMP, rt, 6 h; vi, KOH, HOCH2CH20H; vii, pyridine, rt, 3 days; viii, benzene, 200 
W lamp, t-BuSH, rt, 4 h. 
A Wang resin carrying N-Fmoc-Gly was deprotected under standard conditions and acid 125 was 
coupled with the supported glycine under classical peptide coupling conditions to afford 126. The 
alkylation procedure is long but provided the desired hydroxamate 128. The radical cyclisation of 
compound 128 was carried out in benzene by irradiating the mixture with a tungsten lamp (200 W) 
in the presence oft-BuSH as radical trap. The reaction gave the expected 5-exo-trig cyclised 
product 129. 
Solid-supported organotin reagents have been shown to mediate efficient radical cyclisation 
reactions but the reductive nature of these cyclisations is a major disadvantage. Therefore, the 
growth of transition-metal mediated radical reactions has gained importance.72 Clark has shown that 
efficient 5-exo and 5-endo atom transfer radical cyclisations can be mediated by solid-supported 
Schiff base copper complexes and these catalysts can be reused (Scheme 45).73 
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Scheme 45. Reagents and conditions: i, CuCl, MeCN; ii, DCM, 80 °C, 1 h, 93%. 
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Reaction of the solid-supported catalyst 131 with N-allyl-N-benzyl-2,2,2-trichloro precursor 132 
proceeded well to give 133 in 93% yield. From the above mentioned solid-supported reactions it 
can be concluded that there are no inherent difficulties in performing radical reactions on solid-
phase. 
In the beginning, there were doubts about benzylic hydrogen abstraction from the polystyrene 
matrix, but success of radical reactions on solid-phase contradicts these unfounded doubts. A 
unique feature of solid-supported reactions is the loading of polymeric resins, typically s 1 mmollg 
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of beads, hence effectively placing an upper limit for the maximum concentration attainable for 
solid-phase reactions. This high dilution facilitated by the solid-support can be useful for radical 
reactions. Another important feature of solid-supported reactions is the introduction of tinkers 
which serve as spacers between the substrate and the matrix. The linker can influence the chain 
mobility to a great extent as well as the polymer microenvironment where the reaction is taking 
place. Solid-phase protocols offer advantages in terms of easy reaction workup. Development of 
efficient and novel radical protocols on solid-support would be very valuable for combinatorial 
chemistry. 
1.3 Aims and Objectives of the project 
The synthesis of interesting heterocyclic compounds using radical protocols continues to grow in 
importance and is finding increasing application in pharmaceutical synthesis?3 The aim of our 
research is to develop radical methodologies to construct heterocycles (benzimidazoles, imidazoles, 
indoles and pyrroles) on solid-support. The solution-phase protocol has already been developed; it 
involves radical ipso substitution as shown in Scheme 46.74 
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Scheme 46. Radical cyclisation via ipso-substitution. 
In translating the radical synthetic methodology onto solid-phase suitable plans are required for 
attachment of radical precursors to the resin. Again the incorporated carboxyl or alcohol 
functionality in radical precursors (136-138 and 141) provide useful handles for attachment as 
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shown in Scheme 47. Carboxylic acid groups are excellent for developing 'lead' optimisation due 
to the wide range of functional group transformations to aldehydes, ketones, ami des and nitriles. 
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Scheme 47. Solid-phase radical cyclisation via ipso-substitution and potential precursors. 
The attachment handle could be placed on the benzo ring 138, the azole ring 134 and 137 or on the 
side chain 141. Two different radical protocols, i.e. radical cyclisations involving ipso-substitution 
(Scheme 47) and radical oxidative cyclisations (Scheme 48), would be investigated and optimised, 
using a variety of radical reagents, for the construction of heterocycles onto solid-support. Another 
objective of the project was to study aryl radical cyclisations to construct novel heterocycles in 
solution-phase and then extend those protocols on solid-phase and build a library of biologically 
active compounds by cleaving the desired targets using a variety of amines to give diversity to the 
desired heterocycles 144 and 146 as depicted in Scheme 48. 
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Scheme 48. Solid-phase radical cyclisations via oxidative methodology. 
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CHAPTER2 
Intramolecular Alkyl Radical Cyclisations by 
"ipso" Substitution at the C-2 Position of Benzimidazoles and Imidazoles in 
Solution-Phase 
2.1 Introduction 
Synthesis of benzimidazole and imidazole analogues is becoming increasingly important. Several 
functionalised benzimidazoles75'76 and imidazoles77 exhibit biological properties. The benzimidazole 
147 is an important heterocyclic nucleus which has seen extensive use in medicinal chemistry. 
Benzimidazole derivatives have shown such a diverse biological activities as inhibition of 
phosphodiesterase IV.78 The benzimidazole ring occurs in vitamin 812 and in many biological 
active compounds. The imidazole ring occurs in many naturally occurring compounds such as 
histidine. 
x-()c)-R2 
147 \ 1 R 
The aim of our research is to synthesise an array of functionalised benzimidazoles and imidazoles 
via radical methodology as described in Chapter 1, Section 1.3. Caddick initially developed a novel 
protocol to [1,2-a]fused indoles based on intramolecular aromatic "ipso" substitution.79 Bowman 
and eo-workers advanced these studies with cyclisations onto imidazoles and benzimidazoles.33 Our 
initial studies set out to copy the previous study in the research group by Aldabbagh and Bowman.33 
We decided to adapt this protocol to provide a facile route to a number of [1,2-a]fused 
benzimidazole and imidazole systems in solution-phase and then translate the synthetic sequence 
onto solid-support. The free radical route selected to synthesise [1,2-a]fused benzimidazoles and 
imidazoles is shown in Scheme 49. 
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Scheme 49. Reagents and conditions: i, N-protection; ii, substitution at C-2; iii, N-deprotection; iv, 
N-alkylation; v, radical cyclisation. 
2.1.1 Preparation of N ·( ro-Phenylselanyl)alkyl-2-(phenylsulfanyl)benzimidazoles 
Radical Precursors 
Prior to introducing the phenylsulfanyl group (a radical leaving group necessary for ipso-
substitution) at the C-2 position of benzimidazole it is necessary to protect N-1, as the use of 
organolithium reagent would deprotonate C-2 as well as N-1 position and generate a dianion which 
would complicate the synthesis. The trityl group was selected for the protection of benzimidazole; it 
is a cheap commercially available reagent. The protection of benzimidazole with trityl chloride 
gave compound 149 in 78% yield. It has long been recognised that the C-2 position on theN-
protected benzimidazole is the most acidic. Hence, the lithiated C-2 anion of 1-(triphenylmethyl)-
1H-benzo[d]imidazole ISO was formed using n-BuLi in dry THF at -78 °C, and this was quenched 
using diphenyl disulfide at 0 °C (Scheme 50). 
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Scheme SO. Reagents and conditions: i, trityl chloride, E~N, DCM, rt, 78%; ii, n-BuLi, THF; iii, 
diphenyl disulfide; iv, cone. HCI, MeOH, reflux, 80%. 
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The trityl group was hydrolytically cleaved by refluxing compound 151 in acidic aqueous methanol 
over 3 h to afford 1H-benzo[d]imidazol-2-yl phenyl sulfide 152 in 80% yield. The phenylselanyl 
alkyl precursors were prepared for subsequent intramolecular alkyl radical cyclisation reactions. 
The phenylselanyl (PhSe) group is an excellent leaving group in radical reactions but a poor leaving 
group in SN2 substitutions. The 1-iodo-ro-(phenylselanyl)alkanes (156-158) were synthesised using 
methodology previously developed by the Bowman group.33·~ The iodine atom in 1-chloro-ro-
iodoalkanes was displaced by phenylselanide anion (Phse·), which was generated by reduction of 
diphenyl diselenide with sodium borohydride as shown in Equation 7 (Scheme 51). 
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Scheme 51. Reagents and conditions: i, diphenyl diselenide, NaBH4, MeOH, rt, 153 (86% ), 154 
( 69% ), 155 (99% ); ii, sodium iodide, acetone, reflux, 156 (82% ), 157 ( 65% ), 158 (89% ). 
The chlorides (153-155) were converted to the iodides as shown in Equation 8 (Scheme 51) by SN2 
displacement using an excess of sodium iodide in acetone. The yields were satisfactory in all cases. 
The1-[(ro-phenylselanyl)alkyl]benzimidazole precursors (159-160) were synthesised in moderate to 
good yields using sodium hydride in dry THF and 1-iodo-ro-(phenylselanyl)alkanes (156-158) as 
shown in Scheme 52. 
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Scheme 52. Reagents and conditions: i, sodium hydride, ICHiCH2)nCH2SePh, THF, reflux, 159 
(77%), 160 (54%). 
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2.1.2 Radical Cyclisations of 1-[(ro-Phenylselanyl)alkyl]-2-(phenylsulfanyl)·1H 
-benzimidazole Radical Precursors (159-160) 
1-[3-(Phenylselanyl)propyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 159 (Scheme 53) was treated 
with B~SnH under standard radical cyclisation conditions (slow addition of tributyltin hydride, 
using syringe pump). The work up procedure involved extraction of the benzimidazole compounds 
into acidic solution, washing with light petroleum in order to remove tributyltin residues and 
subsequent basification of the aqueous layer afforded 2,3-dihydro-1H-benzo[d]pyrrolo[l,2-
a]imidazole 161 in a 29% yield. Analysis of the petroleum layer showed the presence of tin 
residues and unidentifiable material. Decomposition must have occurred which accounts for the low 
yield of the cyclised product 161. The reaction has been previously studied in our group33 and the 
proposed mechanism has been outlined in Chapter 1, Section 1.3, Scheme 46. 
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Scheme 53. Reagents and conditions: i, Bu3SnH, AIBN, toluene, reflux, 29%. 
The earlier studies of 5-membered ring cyclisation onto heteroarenes has been shown to be slow due 
to ring strain.81 In an attempt to overcome the slow rate of cyclisation of precursor 159, a non-
reductive radical reagent was used. In the absence of a H-donating radical source we hoped that a 
better yield would be obtained. 
2.1.3 Use of Hexamethylditin 
Hexamethylditin was used in place of Bu3SnH in a photolysis reaction (Chapter 1, Section 1.2.8, 
Scheme 29) with 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 159 
(Scheme 54). We tried to optimise the yield of 2,3-dihydro-1H-benzo[d]pyrrolo[l,2-a]imidazole 
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161, using hexamethylditin and UV lamp irradiation to generate the alkyl radicals for radical 
cyclisations.82 We only obtained the cyclised product 161 in 26% yield. The rest of the mixture 
contained unidentifiable material. We did not observe the reduced product since hexamethylditin 
was used in place of tributyltin hydride, i.e. there is no source of hydrogen to reduce the 
intermediate alkyl radical. The reaction was repeated twice using exactly the same conditions 
without improvement in the yield. 
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Scheme S4. Reagents and conditions: i, hexamethylditin, t-butylbenzene, hv, 30 h, 85 °C, 26%. 
When the same reaction was repeated in toluene we observed the reduced product and the cyclised 
product in 1:1 ratio. The yield of the cyclised product 161 was more or less the same as it was in the 
two previous attempts. Therefore, we concluded that toluene is a source of hydrogen which is 
capable of reducing the intermediate alkyl radical, therefore, we observed the reduced product. We 
did not observe any reduction when tert-butylbenzene was employed as a solvent as it has a tertiary 
centre adjacent to the benzene ring. Theoretically, the lack of a hydrogen source should encourage 
cyclisation over reduction. The low yields of the cyclised product 161 indicate that some kind of 
decomposition occurs under the conditions employed. 
The radical cyclisations of 1-[4-(phenylselanyl)butyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 
160, to construct 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162, were carried out as 
illustrated in Scheme 55. The reaction was carried out under different experimental conditions and 
the results have been summarised in Table 3. 
When the radical cyclisation was performed in acetonitrile, a high yield of the cyclised product was 
obtained. It can be concluded that the best solvent choice is acetonitrile for the synthesis of 1,2,3,4-
tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162. The 61% yield compares favourably with the 
yield previously obtained (54%) in the research group?3 
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Scheme SS. Reagents and conditions: i, Bu3SnH, radical initiator (AIBN or AMBN), solvent 
(toluene, cyclohexane or acetonitrile), reflux. 
Table 3. Reaction conditions for the synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-
a]pyridine 162. 
Entry Conditions Outcome 
1 B~SnH, AIBN, toluene, reflux, 8 h. 25% 
2 B~SnH, AIBN, cyclohexane, reflux, 8 h. 23% 
3 Bu3SnH, AMBN, acetonitrile, reflux, 8 h. 61% 
Comparison of these radical cyclisation reactions shows that the formation of the six membered ring 
may be more favourable than the formation of the five membered ring. Although the radical 
cyclisation of 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl)-1H-benzo[ d]imidazole 1S9 proceeds 
by way of a 5-exo route, and the cyclisation of 1-[4-(phenylselanyl)butyl]-2-(phenylsulfanyl)-1H-
benzo[d]imidazole 160 proceeds by way of a 6-exo route, the synthesis of a tricyclic 6,5,5-
benzimidazole goes through a very strained transition state. The transition state is much less 
strained in the formation of the six-membered ring in the cyclisation of the intermediate radical 
160a to 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162. This provides evidence that 
cyclohexane ring formation is more favourable than cyclopentane ring formation when cyclising 
onto a 5-membered ring heteroarene. It also suggests that the cyclisation rate of the alkyl radical 
generated from 1-[4-(phenylselanyl)butyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 160 is very 
high. Cyclisation occurs before the alkyl radical can be intercepted and reduced by any source of 
hydrogen. 
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2.1.4 Preparation of 2-Chloro-1-[( ro-Phenylselanyl)alkyl]-1H-benzimidazole 
Radical Precursors (164-166) 
One of the objectives was to optimise the conditions for radical cyclisations in solution-phase before 
translating the reaction sequence onto solid-phase. For that purpose, the benzimidazole precursors 
(164-166) with a chloro substituent at C-2 position were synthesised successfully (Scheme 56). The 
aim was to compare the reactivity of leaving groups as a result of ipso-substitution. 
o=N (i) ~N~ 164, n = 1 N}-CI --~~~~ r-CI 1~,n=2 N~ 166,n= 3 
163 H 
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Scheme 56. Reagents and conditions: i, sodium hydride, ICHiCH2)nCH2SePh, THF, reflux, 3 h, 
164 (61% ), 165 (42% ), 166 (51%). 
2.1.5 Radical Cyclisation of2-Chloro-1-[(3-phenylselanyl)propyl]-1H-benzo[d]imidazole 164 
The radical precursor 164 was treated with BU:3SnH under standard radical cyclisation conditions 
(slow addition of tributyltin hydride, using syringe pump) (Scheme 57). 2,3-Dihydro-1H-
benzo[d]pyrrolo[l,2-a]imidazole 161 was afforded in 10% yield. From our studies with the 2-
phenylsulfanyl analogue, we expected that the synthesis of 2,3-dihydro-IH-benzo[ d]pyrrolo[ 1,2-
a]imidazole 161 would be difficult due to the strain caused by the formation of two five membered 
rings. Again, we suggest that the intermediate alkyl radical is quenched by H-transfer from Bu3SnH. 
We observed the reduced product 167 as the major product and the yield of the cyclised product 161 
was worse than the yield obtained with the corresponding 2-phenylsulfanyl analogue 159. 
From the previous radical cyclisations with the 2-phenylsulfanyl analogues it can be concluded that 
the formation of tricyclic 6,5,6-benzimidazole is less strained and consequently the degree of 
cyclisation is greater. All the above mentioned alkylations and cyclisations were performed using 
the selanide radical precursors. The effect of a different radical precursor was also investigated, 
bromine instead of a phenylselanyl group. 
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Scheme 57. Reagents and conditions: i, Bu3SnH, AIBN, toluene, reflux, 167 (51%), 161 (10%). 
At that stage we started working on the synthesis of tributylgermanium hydride so that we could test 
the efficiency of different radical reagents in radical cyclisation reactions. 
2.2 Synthesis of Tributylgermanium Hydride 
The majority of radical reactions are carried out using tributyltin hydride. The synthesis of complex 
natural products can be handled with ease using key radical transformations. However, it is difficult 
to remove toxic organotin compounds from desired targets in purification procedures. Organotin 
compounds are neurotoxic and any food or medicines containing these compounds are unfit for 
human consumption. For this reason, the use of triorganotin hydrides for the synthesis of medicines, 
drugs, and food additives is avoided, and non-toxic alternatives to tin hydride have been 
investigated. Researchers have investigated trialkylgermanium hydrides, including Bu3GeH and 
(Me3Si)3GeH as potential replacements for tributyltin hydride. Several advantages of Bu3GeH over 
Bu3SnH have been well documented,83 tributylgermanium hydride is quite stable. These hydrides 
generally react less readily with carbon-centred radicals and so have the advantage that simple 
reduction is less of a problem than for Bu3SnH cyclisations. Studies of the use of 
triorganogermanium hydrides as alternatives to Bu3SnH had also been initiated in the research group 
by Sussie Krintel.84 Hence we decided to use tributylgerinanium hydride; the synthesis and the 
proposed mechanism for the Cp2TiC12 catalyzed reaction of GeC14 with n-BuMgCl to produce 
Bu3GeH is shown in Scheme 58.85 The synthesis was very successful and we isolated Bu3GeH in 
95% yield. 
47 
GeCI4 + 5 n-BuMgCI-C__,_.P? .... :r_iC_,I?"-l...,._ n-Bu3GeH + n-Bu4Ge 
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Scheme 58. Synthesis of tributylgermanium hydride. 
The experiment was repeated with an excess of germanium tetrachloride and the rest of the 
conditions were kept identical. This led to incomplete butylation of the GeCl4 and the reaction 
afforded a mixture of products which were non-separable. LC-MS analysis of the mixture 
confirmed the products as shown in Scheme 59. The product mixture was reduced using an excess 
of LiAlH4 in dry ether. The reduction step proceeded very efficiently and resulted in the formation 
of Bu3GeH and Bu2GeH2• Distillation under reduced pressure yielded Bu3GeH (21%) and Bu2GeH2 
(28%). 
GeCI4 + BuMgCI (i) Bu2GeH2 + Bu3GeH + Bu2GeCI2 + Bu2GeCIH 
(ii) 
_ ___:.....;...._--!._ Bu2GeH2 + Bu3GeH 
Scheme 59. Reagents and conditions: i, cat. Cp2TiCl2, ether; ii, LiAlH4, ether, 0 °C, 20 h. 
The efficient separation of B~GeH2 and Bu3GeH by distillation under reduced pressure was an 
interesting improvement of the published protocol in which the mixture of Bu3GeH and Bu4Ge had 
to be distilled two or three times to get clean separation. This different set of conditions needs to be 
optimised and will possibly lead to an improved synthesis. Bu2GeH2 may also prove a useful 
reagent. Direct reduction of commercially available Bu3GeCl with LiAlH4 in dry ether is another 
option which involves less synthetic steps and relatively less expensive route to the desired radical 
reagent. 
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2.2.1 Radical Cyclisation of 1-(4-Bromobutyl)-2-cbloro-lH-benzo[d]imidazole 168 
1-(4-Bromobutyl)-2-chloro-1H-benzo[d]imidazole 168 was successfully prepared by alkylation of 
2-chlorobenzimidazole 163 with 1,4-dibromobutane and the radical cyclisation was carried out 
using tributylgermanium hydride (one pot addition) as shown in Scheme 60. 
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Scheme 60. Reagents and conditions: i, sodium hydride, 1,4-dibromobutane, DMF, 20 h, 168 
(95%); ii, Bu3GeH, AIBN, toluene, reflux, 12 h, 162 (54%). 
The work up procedure involved extraction of the cyclised adduct 162 into acidic solution and 
washing with light petroleum in order to remove tributylgermanium residues. Subsequent 
basification of the aqueous layer gave 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162 in a 
yield of 54%. Tributylgermanium hydride was used as an alternative to tributyltin hydride to 
increase and optimise the yield of the cyclised material. The advantages of germanium hydride 
include an easy work up procedure and it also eliminates the use of syringe pump (slow addition of a 
radical reagent). 
2.3 Preparation of Imidazole Radical Precursors 
A large number of imidazole derivatives show biological activity, e.g. nitroimidazoles, which are 
used as antibiotics and anticancer agents.86 The radical cyclisation onto imidazoles has been 
documented by Bowman et aC3•81 ·fl1 These cyclisations involved an intramolecular ipso-substitution 
protocol. One of the objectives of our project was to synthesise imidazole moieties using radical 
methodology on solid-support to avoid purification problems and to test various radical reagents to 
promote cyclisation onto imidazoles tethered to the resin. For that purpose, we decided to construct 
a solution-phase model to determine the efficiency of radical cyclisation and then translate it onto 
resin. 
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Earlier studies in the group had shown that ipso-substitution could be carried out on 2-
(phenylsulfonyl)imidazoles (Scheme 61 ).33 
[~ (i) N~z --~~--~ 
~Se Ph 
169, Z = Ts: a, n = 1; b, n = 2; c, n = 3 
170, Z = SPh: n = 1 
171, Z = PhS02: n = 1 
radical precursor 
169a, Z = Ts, n = 1 
169b, Z=Ts, n =2 
169c, Z = Ts, n =3 
170, Z = SPh, n = 1 
171, Z = PhS02, n = 1 
Scheme 61. Reagents and conditions: i, B~SnH, AIBN, toluene, reflux. 
product (% yield) 
172a, 52% 
172b,48% 
172c, 63% 
172a, 16% 
172a, 51% 
This work reported that the yields of cyclisation were moderate to good when PhS02 was the 
leaving group but when phenylsulfanyl (PhS) was used as the leaving group the yield of cyclisation 
was low with a slightly higher yield of reduced product ( 18% ). The authors suggested that the 
stronger electron withdrawing group (PhS02) was required to facilitate the cyclisation step. PhS02 
makes the ring more electron deficient and accelerates attack by the nucleophilic alkyl radical. 
Therefore, when imidazoles are used a more electron withdrawing group (or better leaving group) is 
required. The imidazole ring in benzimidazole is less aromatic and hence, addition of the 
intermediate radical in cyclisation is more facile and the more weakly electron withdrawing 2-
(phenylsulfanyl) group is sufficient to facilitate cyclisation over reduction. Caddick et af9 in their 
studies on 2-substituted indoles had shown that PhS02 was best but that PhSO and PhS also worked 
but the yields of the desired cyclised adducts were less satisfactory than those obtained with the 
corresponding sulfones. 
We therefore considered that a more electron withdrawing arylsulfanyl group may prove useful. We 
also sought an easier route to introduce the Z-leaving group. In order to test this hypothesis lH-
imidazole-2-yl pyridin-2-yl sulfide 174 was synthesised by substitution of 2-chloropyridine with 
commercially available 2-mercaptoimidazole 173 and subsequent alkylation reaction afforded 1-[4-
(phenylselanyl)butyl]-lH-imidazole-2-yl pyridin-2-yl sulfide 175 in excellent yield (99%) (Scheme 
62). Thiopyridine was chosen as a possible radical leaving group for ipso substitution because of its 
electron withdrawing nature. 
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N [ }-sH 
N 
H 
173 
~ N ~ 
(i) • r(N~S~_.J -"'-"(ii)_.• [ }-s~ .. J 
ll_N;- N N N 
H ~SePh 
174 175 
Scheme 62. Reagents and conditions: i, potassium carbonate, 2-chloropyridine, DMF, reflux, 174 
(95%); ii, sodium hydride, ICHiCH2) 2CH2SePh, THF, reflux, 175 (99%). 
The thiopyridine moiety should be a good radical leaving group due to its electron withdrawing 
nature and we assumed that it would result in higher cyclisation yields to give the desired bi-cyclic 
imidazole adducts. Furthermore, for solid-phase radical reactions, pyridine could be used as a linker 
with a handle which could either be hydroxy or carboxy functionality to be attached to the solid-
support. We also synthesised 1H-benzo[d]imidazole-2-yl pyridin-2-yl sulfide 177 (Scheme 63) to 
investigate the radical cyclisations on benzimidazole moiety with a more electron withdrawing 
radical leaving group. The yield was not optimised. 
(i) • (XI N}-s_() 
~ N N 
177 H 
Scheme 63. Reagents and conditions: i, potassium carbonate, 2-chloropyridine, DMF, reflux, 40%. 
2.3.1 Radical Cyclisations of 1-(4-(Phenylselanyl)butyl}-lH-imidazole-2-yl 
pyridin-2-yl sulfide 175 
The radical methodology was applied to 1-[4-(phenylselanyl)butyl]-lH-imidazole-2-yl pyridin-2-yl 
sulfide 175 as shown in Scheme 64. Radical cyclisations were attempted under various 
experimental conditions as summarized in Table 4. In most attempts the cyclised product was not 
observed except when we performed reaction at room temperature using triethylborane as an 
initiator and tris-(trimethylsilyl)silane as a radical generating reagent (Entry 4). The reaction 
resulted in the formation of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 180 in 9% yield. We also 
observed the formation of l-butyl-1H-imidazol-2-yl pyridin-2-yl sufide 179 in 16% yield. Entries 1 
and 2 show the formation of 1-[but-3-enyl]-lH-imidazole-2-yl pyridin-2-yl sulfide 178. The reason 
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for the formation of 1-[but-3-enyl]-18-imidazole-2-yl pyridin-2-yl sulfide 178 is unknown but this 
kind of alkene by-product has also been observed in other radical cyclisation reactions in our group 
which involve cyclisations onto azoles. 
"\-s--0 l!_N N _ _.. riN}--s--0 lL..N N + (N}--s--0 lL..N N + 175 
~Se Ph 
175 
··~ 
178 
~ 
179 180 
Scheme 64. Radical cyclisation of 1-[4-(phenylselanyl)butyl]-1H-imidazole-2-yl pyridin-2-yl 
sulfide 175. 
Table 4. Reaction conditions for the synthesis of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 180. 
Entry Conditions Outcome 
1 B11:3SnH (slow addition), AIBN, toluene, Alkene by-product 178 (60%) and 
reflux, 10 h. starting material175 (20%) 
2 B11:3GeH, AIBN, toluene, reflux, 14 h. Alkene by-product 178 (12%) and 
starting material175 (30%) 
3 TTMSS, BE~, acetonitrile/cyclohexane, All starting material175 
24h. 
4 TTMSS, BE~. benzene, 24 h. Reduced product 179 (16%) and cyclised 
product 180 (9%) 
The results of these radical cyclisations indicate that it is not feasible to translate the synthetic 
sequence onto solid-support as thiopyridine is apparently not an efficient radical leaving group or 
facilitator of the cyclisation step. Therefore, we decided to adopt other strategies, i.e. to find other 
suitable linkers which can serve as an efficient leaving group during ipso-substitution processes. 
In the next chapter we describe our studies of solid-supported benzimidazole precursors and 
corresponding radical cyclisations. 
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CHAPTER3 
Intramolecular Radical Cyclisations, by "ipso" Substitution, 
of Solid-Supported Benzimidazoles 
3.1 Synthesis of Solid-Supported Benzimidazole Derivatives 
In adapting our solution-phase ipso-substitution methodology to solid-phase, suitable precursors 
were required for attachment to the resin. There were several approaches under consideration for 
solid-supported radical reactions as shown in Chapter 1, Section 1.3, Scheme 47. We decided to 
study several different benzimidazole derivatives having a carboxyl functionality to provide the 
useful handle for attachment to solid-phase. Initially we investigated benzimidazole derivatives 
with the carboxylic acid on the leaving group. Methyl2-(1H-benzo[d]imidazol-2-
ylsulfanyl)ethanoate 181 was selected as a solution-phase mimic for potential solid-phase work, as it 
has the handle to be attached to the resin. A putative synthesis for radical precursors and radical 
cyclisation is shown in Scheme 65. 
o I Q)-s_}-o 
181 H 
o 1 o 
_ __;(,_,_i) -~ Q)--s_}-o -~<H>_~ Q)-s_}-oH 
182 l .. - 183 l .. -
0 p 
----'< ...... m>'---~ Q)--s_)--o (W) 
184 l .. ~ 
'i1n"'SePh 
<J'01('sH 
0 
186 
~'SePh ~'SePh 
Scheme 65. Reagents and conditions: i, NaH, ICH2(CH2)nCH2SePh, THF, reflux; ii, 2 M NaOH, 
methanol, reflux; iii, Wang resin, DMAP, DIC, DCM; iv, Bu3SnH, AIBN, toluene, reflux. 
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This route does leave both the product and the Bu3Sn-moieties in solution, therefore requiring 
separation after the solid-phase reaction. The advantages would be the ability to recycle the thiol 
and that unreacted starting material and uncyclised reduced material would be left attached to the 
resin. The latter should greatly assist purification of cyclised products. In the benzimidazole studies 
the cyclised products are easily separated from Bu3Sn-residues by extraction in acidic solution. 
As a first stage in our synthetic endeavours, we decided to perform the esterification of 2-
benzimidazolylsulfanyl)acetic acid. The esterification of (2-benzimidazolylsulfanyl)acetic acid 187 
gave the desired methyl2-(1H-benzo[d]imidazol-2-ylsulfanyl)ethanoate 181 in 89% yield as 
illustrated in Scheme 66.88 
~N}-s o 
~N "-_/( 
187 H OH 
(i) ~N}-s o ~N "-_/( 
181 H o-
Scheme 66. Reagents and conditions: i, acetyl chloride, MeOH, reflux, 89%. 
The alkylation of methyl 2-(lH-benzo[d]imidazol-2-ylsulfanyl)ethanoate 181 was investigated. 
Simple methylation was attempted to synthesise methyl2-[(1-methyl-1H-benzo[d]imidazol-2-
yl)sulfanyl]ethanoate 188 (Scheme 67). The reaction resulted in the formation of a complex product 
mixture. Further alkylation attempts were also not fruitful, probably due to the molecule having 
more than one reactive site for deprotonation. Hence, due to complexities that arose as a result of 
alkylation, we considered that another route had to be investigated. 
~N}-s o ----7~t-~ _,..., ~N~s o ~N y ~Nr- \__jJ 
181 H 0- 188 \ b-
Scheme 67. Reagents and conditions: i, sodium hydride, Mel, THF, reflux. 
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3.1.1 Studies Using Mercaptobenzoic Acid as a Linker and a Leaving Group 
We decided to look at other alternative approaches such as developing a synthetic sequence which 
involved less synthetic steps towards the synthesis of solid-supported benzimidazole precursors 
(Scheme 68). It is highly desirable to minimise demanding synthetic steps when planning a solid-
phase synthesis and therefore it is easier to adapt established solution-phase precedents to polymer 
supported reaction. We also needed compounds which contained less reactive sites. The use of 
cheap and readily available 2-chlorobenzimidazole 163 appeared a good route to test the homolytic 
aromatic substitution protocol on solid-phase. Possible routes to the required radical precursors 
attached to solid-support are shown in Scheme 68. 
OC
N 4-r:nercaptobenzoic OCN -o-
'}--cl acid 189 I '}--s C02H 
N base ~ N ~ /; 
163 H 190 H 
PhSe(CH2)nl. 
base 
n=1,2,3 
PhSe(CHvnl. 
base 
n=1,2,3 
Resin, DIG, OCN -o--~-~-:--• Nrs ~ . 1; co2-Q 
191 H 
PhSe(CHvnl. 
base 
n=1,2,3 
OC
N 4-mercaptobenzoic OCN -o- Resin, DIG, OCN -o-~CI _a_ci_d~--- ~ . DMAP ,..... I ~ - -Q Nr- base N}-S ~ /; C02H _D_C_M __ _. ~ N}-S ~ /; C02 . 
I I I 
(CH2)nSePh (CH2)nSePh I (CH2)nSePh 
~.-___________________ _. ]Radical reagent, 
AIBN, toluene 
Hs-Q-co2-c:) 
base 
Scheme 68. Putative syntheses of solid-supported benzimidazole precursors and radical 
cyclisations. 
The solid-supports which we employed for radical reactions are shown in Scheme 69. 
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OMe 
Q-o 
Rink resin 
~0_/\_ ~Wang resin OH 
Amino Merrifleld resin 
Scheme 69. Common solid-supports for organic reactions. 
Primarily, we decided to synthesise simple precursors to check the feasibility of further application 
and S~r reactions at the C-2 position of 2-chlorobenzimidazole 163 with thiolates (Scheme 70). 
The synthesis of 2-chloro-1-(triphenylmethyl)-1H-benzo[d]imidazole 193 and 2-chloro-1-methyl-
1H-benzo[d]imidazole 195 proceeded well (Scheme 70). Therefore C-2 substitutions on 2-chloro-1-
(triphenylmethyl)-1H-benzo[d]imidazole 193 and 2-chloro-1-methyl-1H-benzo[d]imidazole 195 
were performed under different experimental conditions. The initial attempts were not successful, 
but after a few attempts, the difficulties were overcome and we managed to get satisfactory 
substitutions. The results are summarized in Table 5. 
(X)-c1 _ _:,(i..;_) _._ (X)-c1 
163 H 193 CPh3 
(iii) (XN 
X .. I rsPh 
~ N 
194 CPh3 
(ii) 
(X)-c1 (iii) ., (X)-SPh 
195 \ 196 \ 
Scheme 70. Reagents and conditions: i, trityl chloride, E~N, DCM, 193 (30% ); ii, NaH, Mel, THF, 
reflux 195 (64%); iii, PhSH, bases (NaH or KOH), solvents (THF or ethanol) 196 (85%). 
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Table 5. Reaction conditions for the synthesis of benzimidazole derivatives 194 and 196. 
Entry Conditions Outcome 
1 Compound 193, NaH, PhSH, THF, reflux Unsuccessful 
overnight. 
2 Compound 193, PhSH, EtOH, KOH, 16 h Unsuccessful 
reflux. 
3 Compound 195, NaH, PhSH, THF, reflux 70% 
overnight. 
4 Compound 195, PhSH, EtOH, KOH, 16 h 85% 
reflux. 
The failure of C-2 substitution, in the case of 2-chloro-1-(triphenylmethyl)-1H-benzo[d]imidazole 
193, is associated with the steric hindrance of bulky trityl group. Substitution with the less sterically 
hindered 2-chloro-1-methyl-1H-benzo[d]imidazole 195 proceeded without difficulty. The next 
substitution we studied was between 2-chlorobenzimidazole 163 and benzenethiol prior to 
protection or alkylation reactions (Scheme 71). The substitution reaction was carried out under 
different experimental conditions (Table 6). The substitution reaction afforded 1H-
benzo[d]imidazol-2-yl phenyl sulfide 152 in 66% yield (Entry 4). 
cr:~CI _---:...(i):....-___.. cr:~SPh 
163 \ 152 \ H H 
Scheme 71. Reagents and conditions: i, PhSH, EtOH, KOH, reflux, 66%. 
Table 6. Reaction conditions for the synthesis of 1H-benzo[d]imidazol-2-yl phenyl sulfide 152. 
Entry Conditions Outcome 
1 K2C03, PhSH, acetone, rt. Unsuccessful 
2 E(3N, PhSH, DCM, rt. Unsuccessful 
3 NaH, PhSH, THF, reflux, overnight. Unsuccessful 
4 PhSH, EtOH, KOH, reflux, 6 h. 66% 
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Mter establishing the correct conditions for the substitution at the C-2 position of 2-
chlorobenzimidazole 163, the next step was the introduction of 4-mercaptobenzoic acid 189 (a 
linker) via ipso-substitution as shown in Scheme 72. The ipso-substitution of chlorine at the C-2 
position of 2-chlorobenzimidazole 163 with 4-mercaptobenzoic acid 189 was successful and 4-(1H-
benzo[d]imidazol-2-ylsulfanyl)benzene-1-carboxylic acid 190 was afforded in a 68% yield. To 
optimise the yield, varying equivalents of potassium hydroxide were used and the rest of the 
parameters were kept identical. No significant change was observed. An excess of potassium 
hydroxide could result in substitution to yield 2-hydroxybenzimidazole and then tautomerism to 1,3-
dihydrobenzimidazole-2-one. Further hydrolysis could open the 5-membered ring. 
(X)-c1 
163 \ H 
(i) (X)-s-0-cooH 
190 \ H 
Scheme 72. Reagents and conditions: i, 4-mercaptobenzoic acid 189, EtOH, KOH, reflux, 68%. 
Alkylation of 4-[(lH-benzo[d]imidazol-2-yl)sulfanyl]benzene-1-carboxylic acid 190 to synthesise 4-
( { 1-[3-(phenylselanyl)propyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 197 
was also attempted, but under the conditions employed, the lack of protection of carboxy proton 
resulted in complications (Scheme 73). 
(X)-s-Q-cooH 
190 H 
(i) N 
-""*X--.... (XN}-s-Q-cooH 
197 I 
~Se Ph 
Scheme 73. Reagents and conditions: i, sodium hydride, 1-iodo-3-(phenylselanyl)propane, THF, 
reflux. 
Mter considering the difficulties involved in the alkylation of 4-(lH-benzo[d]imidazol-2-
ylsulfanyl)benzene-1-carboxylic acid 190, we decided that the best choice was to perform 
substitution reactions on previously alkylated 2-chlorobenzimidazole precursors (164-166) (Chapter 
2, Section 2.1.4, Scheme 56). The S,vAr reactions on these alkylated 2-chlorobenzimidazoles were 
very successful (Scheme 74). 
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(X)-c1 _ _;..<i.:..-) __.. (X)-s-Q-cooH 
~Se Ph ~SePh 
197, n = 1 
198, n =2 
199, n =3 
Scheme 74. Reagents and conditions: i, 4-mercaptobenzoic acid 189, potassium tert-butoxide, 
ethanol, reflux, 18 h, 197 (90%), 198 (quantitative), 199 (quantitative). 
3.1.2 Synthesis of 4-Mercapto-N-(4-methylbenzyl)-benzamide 200 
for SNAr Substitution Reactions 
The other alternative approach under investigation towards the solid-supported benzimidazole 
precursors was the attachment of the linker to the desired solid-support (resin) followed by 
subsequent S~r substitution. First of all, we decided to develop a solution-phase protocol as a 
guide for solid-phase procedures. The carboxyl group on the linker can be attached either as an 
ester (Wang, Merrifield) or by an amide (Rink, Amino Merrifield). We decided to initially 
investigate the possibility of amide attachment. 
Our initial work involved a sample coupling reaction between 4-mercaptobenzoic acid 189 and 4-
methylbenzylamine to synthesise 4-mercapto-N-( 4-methyl-benzyl)-benzamide 200 as a mimic of the 
solid-phase system (Scheme 75). The conditions would subsequently be employed for the 
substitution of 2-chlorobenzimidazole163 on solid-phase. Unfortunately all the attempts to 
synthesise 4-mercapto-N-(4-methylbenzyl)-benzamide 200 failed (Table 7). 
Hs-Q-cooH 
189 
(i) -cMO X .,. HS 
NH 
200 
Scheme 7S. Reagents and conditions: i, 4-methylbenzylamine, DIC, DMAP, DCM, rt. 
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Table 7. Reaction conditions for the synthesis of 4-mercapto-N-(4-methylbenzyl)-benzamide 200. 
Entry Conditions Outcome 
1 DIC, DMAP (cat.), 4-methylbenzylamine, DCM, rt, 18 h. Unsuccessful 
2 EDCI, NMM, 4-methylbenzylamine, DCM, -15 °C, 3 h. Unsuccessful 
3 EDCI, E~N, 4-methylbenzylamine, DCM, rt, 18 h. Unsuccessful 
4 DIC, DMAP (cat.), 4-methylbenzylamine, DCM, reflux, 18 h. Unsuccessful 
References in the literature89 provided an insight into the failure of desired coupling, i.e. the 
unprotected thiol functionality of 4-mercaptobenzoic acid 189 is very reactive towards the 
intermediate carbodiimide complexes and hence, resulted in the formation of thioester. Therefore, it 
was decided to investigate other methods for solution-phase reactions, e.g. to form mixed 
anhydrides using chlorosulfonyl isocyanate90 or isobutyl chloroformate91 and then react it with 4-
methylbenzylamine to form an amide linkage. We decided to protect the 4-mercaptobenzoic acid 
189 with a triphenylmethyl group prior to performing coupling reaction with 4-methylbenzylamine. 
The subsequent cleavage of the trityl group would result in the formation of the 4-mercapto-N-( 4-
methylbenzyl)-benzamide 200 and allow substitution reactions to be carried out on 2-
chlorobenzimidazole derivatives. The protection of the 4-mercaptobenzoic acid 189 with a trityl 
group was performed as shown in Scheme 76. The reaction was carried out under two different sets 
of experimental conditions (Table 8). The use of triphenylmethanol proved more successful than the 
use of triphenylmethyl chloride. 
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Table 8. Reaction conditions for the synthesis of 4-(tritylsulfanyl)-benzoic acid 201. 
Entry 
I 
2 
Conditions Outcome 
4-mercaptobenzoic acid 189, trityl chloride, E~N. DCM. 12% 
4-mercaptobenzoic acid 189, triphenylmethanol, TFA, E~N. 100% 
DCM.92 
HS-o-COOH 
189 
(i) -o--~:..__.... Ph3C-S ~ /; COOH 
201 
Scheme 76. Reagents and conditions: i, triphenylmethanol, TFA, reflux, 100%. 
4-(Tritylsulfanyl)-benzoic acid 201 was coupled with 4-methylbenzylamine as illustrated in Scheme 
77. However the reaction afforded two products that eo-eluted on column chromatography which 
made the purification difficult and furthermore cleavage of S-trityl under different experimental 
conditions also failed (Table 9). As the deprotection of S-trityl protected 202 proved difficult so we 
decided to look at another protecting group. 4-(Acetylsulfanyl)-benzoic acid 20393 was synthesised 
in excellent yield (Scheme 78). 
(ii) ~0 
X • Hs--0---J, 200 HNq 
Scheme 77. Reagents and conditions: i, ClS02NCO, E~N, 4-methylbenzylamine, DCM; ii, acidic 
conditions. 
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Table 9. Attempted synthesis of 4-mercapto-N-(4-methylbenzyl)-benzamide 200. 
Entry 
1 
2 
3 
Conditions Outcome 
TFA, DCM, reflux. Unsuccessful 
1 M HCl, MeOH, reflux. Unsuccessful 
HBr/acetic acid 30 % wt. Unsuccessful 
0 
HS-o-COOH 
189 
__...:..(i~) --{ -o-
s ~ ;/ COOH 
203 
Scheme 78. Reagents and conditions: i, acetic anhydride, pyridine, rt, 100%. 
Coupling reactions using 203 were performed to afford 4-mercapto-N-(4-methylbenzyl)-benzamide 
200 under different experimental conditions (Scheme 79). The results are summarised in Table 10. 
The major product of the coupling reactions was an undesired by-product 204 as shown in Scheme 
79. The undesired reaction pathway led to in-situ transfer of the acetyl group from sulfur to 
nitrogen. The S-acetyl group is very labile under the reaction conditions employed and therefore we 
decided to abandon this methodology and continue work on S-trityl precursor 201. 
s~o 
--{~-OH .. 
HS~O + O'LN~ \ ~ ~-H·Nq· I 204 0 203 200 f ~ 
Scheme 79. Attempted synthesis of 4-mercapto-N-( 4-methylbenzyl)-benzamide 200. 
Table 10. Synthesis of 4-mercapto-N-(4-methylbenzyl)-benzamide 200. 
Entry Conditions Outcome 
1 4-methylbenzylamine, NMM, EDCI, DCM.94 15% 
2 4-methylbenzylamine, ClS02NCO, E(3N, DCM.90 Poor yield 
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Further study of the coupling reaction between 4-(tritylsulfanyl)-benzoic acid 201 and 4-
methylbenzylamine gave better yields and when HOAT was employed as the coupling agent with 
EDCI, a high yield (86%) of amide 202 was obtained. Cleavage of the S-trityl group was also 
accomplished by a literature procedure.95 
'j-s ~ ~ COOH--~~• ~S ~ ~ Ph Ph -Q-'' (i) Ph Ph --Q-i" 0 
Ph - I 
201 Ph 202 HNQ 
~ ~ 
(ii) ~0 HS\_JJ, 
200 HNQ 
Scheme 80. Reagents and conditions: i, 4-methylbenzylamine, HOAT, EDCI, DCM, 86%; ii, 
TFA/DCMIE~SiH (9:10:1), rt, 17%. 
3.1.3 Coupling Reactions 
Our first solid-phase studies were conducted with Wang resin (Section 3.1.1, Scheme 69). The 
efficient preparation of benzimidazole derivatives on solid-support in high yield and purity is 
illustrated in Scheme 81. The coupling reactions of benzimidazole acid derivatives (197-199) were 
carried out using corresponding diisopropylcarbodiimide (DIC), with DMAP added to catalyse the 
esterification of Wang resin. The results of the coupling reactions showed that for complete 
immobilisation (loading) of the benzimidazole acid precursors (197-199) onto Wang resin, it was 
necessary to perform double coupling (to attain a high loading of 205-207). 
In order to monitor the outcome of a reaction carried out on the solid-support we found that FT -IR 
spectroscopy using samples of the resin prepared as a KBr disk to be a suitable and informative 
method for identification of polymer-supported organic compounds. IR spectra for the 
benzimidazole precursors (205-207) show the formation of ester band and (MAS) 1H NMR spectra 
show complete immobilisation (attachment) of benzimidazole precursors onto resin. The loadings 
were assessed by cleavage and analysis of a portion of the resin-bound precursors (205-207) prior to 
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performing the cyclisation reactions. 
erN -o-(ii) - - )lr N.,_S ~ b COOH 
(iii) ~N -o-
)lr ~N-,_s ~ J co2-Q 
~SePh 
205, n = 1 Wang (0.96 mmol) 
206, n = 2 Wang (0.95 mmol) 
207, n = 3 Wang (0.94 mmol) 
(iv) 
~Se Ph 
197, n = 1 
198, n = 2 
199, n = 3 
~NtJ ~N 
135 )n 
Scheme 81. Reagents and conditions: i, NaH, THF, ICHz(CH2)nCH2SePh, reflux; ii, 4-
mercaptobenzoic acid, potassium tert-butoxide, ethanol, reflux; iii, Wang resin, DIC, DMAP, DCM, 
DMF; iv, radical mediators (tributyltin hydride, TTMSS, tributylgermanium hydride), radical 
initiators (AIBN, AMBN) and common solvents as described in tables 11, 12, 13, 14. 
We also used Rink resin and amino Merrifield resin (Section 3.1.1, Scheme 69) for coupling 
reactions (Scheme 82). The objective was to compare the compatibility of these resins with radical 
cyclisation conditions. 
~N -o-Vl--N}-S ~ tJ COOH 
~Se Ph 
(i) ~N -o-
)lr Vl--N}-s ~ tJ CONH-Q (ii) 
~SePh 
208, n = 1 Amino (0. 78 m mol) 
209, n = 2 Rink (0.63 mmol) 
~N~ Vl--N 
135 )n 
Scheme 82. Reagents and conditions: i, amino Merrifield resin or Rink resin, DIC, DMAP or 
HOAT, DCM, DMF; ii, radical mediators (tributyltin hydride, TTMSS, tributylgermanium hydride), 
radical initiators (AIBN, AMBN) and common solvents as described in tables 11 and 12. 
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We continued our efforts to develop different routes towards solid-supported benzimidazole 
precursors. One of the routes involved the attachment of 4-tritylsulfanyl-benzoic acid 201 to the 
resin. The coupling reaction was carried out using amino Merrifield resin (Scheme 83). TheIR 
spectrum of the resin-bound moiety 210 showed the amide band at 1718 cm-1 and 1654 cm-1, and 
thereby confirmed the successful attachment of the 4-(tritylsulfanyl)-benzoic acid 201 to the resin. 
Elemental analysis was not conclusive hence quantitative loading was not determined. 
~NH2 (i) 
Scheme 83. Reagents and conditions: i, 4-(tritylsulfanyl)-benzoic acid 201, DIC, HOAT, DCM. 
This alternative putative synthesis of solid-supported benzimidazole precursors is illustrated in 
Scheme 84. The idea was to develop a traceless linker for radical ipso-substitution reactions on 
resin and regenerate the tinker at the end of the reaction and re-use it. This protocol could allow the 
same resin-tinker to be used for a variety of different heterocycles to be loaded via S~r reaction. 
Due to lack of time this protocol was not further studied but provides another potential route for 
radical synthesis on solid-phase. 
(JCN --Q--10 C'' (ii) ___ 'L-s -------~~~!. ...• ·--------------- /" ~ j 
N HN 
4r,;-sePh Q 
Scheme 84. Reagents and conditions: i, TFNDCM/Et3Si, rt; ii, 2-chlorobenzimidazole derivatives 
(164-166), KOH, a suitable solvent for solid-phase reaction; iii, Bu3SnH, AIBN, toluene, reflux. 
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3.1.4 Radical Cyclisations of Solid-Supported Benzimidazole Precursors 
The solid-supported benzimidazole precursors (205-207) were subjected to radical cyclisations 
under various experimental conditions. The idea was to optimise the conditions required for radical 
reactions, e.g. the use of several radical reagents, amounts of initiators, reaction times, temperature, 
loading levels on the resins and attachment and cleavage conditions. Success of these solid-
supported radical cyclisations would enable us to extend the study to more complicated and novel 
reactions to show that solid phase synthesis can be applied to new radical syntheses as a common 
synthetic tool. 
Synthesis of2,3-Dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole 161 on Solid-Phase 
We performed the radical cyclisations on Wang resin-bound benzimidazole 205 as shown in Scheme 
85. The results are summarised in Table 11. In all these radical cyclisation reactions the product 
was easily separated by filtration from the resin and the Bu3Sn-residues separated by extraction of 
cyclised product 161 into dilute acid. Unreacted starting material and reduced product were cleaved 
off the resin using TFA/DCM (9:1). The LC/MS analysis of the cleaved material confirmed the 
presence of reduced product and starting material (Entries 4 and 6). We did not detennine the yields 
of the reduced product 212 and starting material 197 in all these instances as the cleaved sample was 
contaminated with tin residues and other by-products hence we submitted the crude sample for 
purification (using automated Flex HPLC, reversed phase column chromatography). We managed 
to get pure reduced product 212 but loss of material occurs during this automated purification 
process. 
(XN -o-N}-s ~ J co2-Q 
2os I 
~SePh 
Radical 
reactions (X)-s-Q-cooH 
212 ~ + 
ex:~ 
161 ~ 
+ Q-oH 
(11 %) 
Scheme 85. Synthesis of 2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole 161 on solid-phase. 
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Table 11. Reaction conditions for the synthesis of2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole 
161. 
Entry Conditions Outcome 
Resin 208, B~SnH, AIBN, benzene, reflux, 18 h, one pot addition. 161 (trace) 
1 
Resin 205, B~SnH, AIBN, benzene, reflux, 24 h, one pot addition. 161 (trace), 
2 212 also 
observed 
3 Resin 205, B~SnH, AIBN, benzene, reflux, 48 h, one pot addition. 161 (trace), 212 also 
observed 
4 Resin 205, Bu3SnH, AIBN, benzene, slow addition over 7 h. 161 (3 % ), 212 Overall reflux 8 h. (1 0%) and 197 
(41%) 
Resin 205, B~SnH, AIBN, benzene, slow addition over 5 h. The 161 (5 %), 
5 addition of reagents was repeated over 5 h. Overall reflux 10 h. 212 also 
observed 
Resin 205, B~SnH, AIBN, toluene, slow addition over 26 min, 161 (11 %), 
6 reflux. Further B~SnH/AIBN was added after 3 h. Overall reflux 212 and 197 
5h. also observed 
Resin 205, Bu3SnH, AIBN, benzene, slow addition over 2 h, reflux. 161 (5% ), 
7 Further Bu3SnH/AIBN was added after 3 h. Overall reflux 5 h. 212 also 
observed 
We obtained all the spectroscopic data to confirm the structure of the reduced product 212. None of 
the above mentioned reaction conditions led to a significant improvement in the yield of 2,3-
dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole 161 and this poor yield could be associated with the 
ring strain which in turn favours reduced product 212 over cyclised product 161. Synthesis of 2,3-
dihydro-1H-benzo[d]pyrrolo[l,2-a]imidazole 161 in solution-phase also gave poor yields. These 
results indicate that solid-phase synthesis provides similar results to solution-phase, i.e. no real 
advantage. 
Therefore, we decided to work on other resin-bound benzimidazole moieties to construct tricyclic 
6,5,6-fused and 6,5,7-fused benzimidazole derivatives. The first studies were on the Wang resin-
bound precursor 206 as shown in Scheme 86 and Table 12. The analogous reaction in solution-
phase proceeded in high yield. The synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 
162 on solid-phase was performed under different experimental conditions. Entries 4 and 8 showed 
the best results achieved so far and in both instances the yields were comparable with solution-phase 
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reactions. In all these radical cyclisation reactions unreacted starting material198, reduced product 
213 and alkene-by product 214 were cleaved off the resin using TFAIDCM (9: 1). The LC/MS 
analysis was carried out on cleaved material to confirm the products. We did not determine the 
yields of the reduced product 213, alkene by-product 214 and unreacted starting material198 in all 
these instances as the cleaved samples were contaminated with tin residues and other by-products. 
Hence we submitted the crude sample for purification using automated Flex HPLC, reversed phase 
column chromatography. 
We managed to get pure reduced product 213, alkene by-product 214 and unreacted starting material 
198 but loss of material occurs during this automated purification process. We obtained all the 
spectroscopic data to confirm the structure of the reduced product 213 and the alkene by-product 
214. Also, as expected, slow addition of Bu3SnH gave better yields of cyclisation and less of 
uncyclised reduced product 213. The dilution effect of the sites on the resin does not overcome one-
pot addition and dilution of Bu3SnH is still required by using syringe pump addition. 
reactions 
er:~+ Q-oH 
162(60 %) 
~N -o-~N}--s ~ J co2-Q 
206 ~SePh 
Radical 
+ 
0r-N -o-~N}--8 ~ ;} COOH 
214 ~ 
Scheme 86. Synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 on solid-phase. 
The results also show that both Rink resin.209 (Entry 7) and Wang resin 206 are quite compatible 
for radical reactions. When TTMSS (Entries 9 and 10) and tributylgermanium hydride (Entry 13) 
were used as radical mediators, the yields of the cyclised product 162 are not as good as with 
tributyltin hydride. 
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Table 12. Reaction conditions for the synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-
a]pyridine 162. 
Entry Conditions Outcome 
1 Resin 206, B~SnH, AIBN, benzene, slow addition over 12 162 (14 %), 213, 
h, reflux. 198 and214 
were also 
isolated 
2 Resin 206, B~SnH, AIBN, benzene, slow addition over 12 162 (trace), 198 
h, overall reflux 48 h. and214 were 
also isolated 
3 Resin 206, Bu3SnH, AIBN, benzene, one pot addition, 162 (3 % ), 198 
overall reflux 48 h. and 214 were 
also isolated 
4 Resin 206, Bu3SnH, AIBN, benzene, slow addition over 7 h, 162 (60 %), 213 
then filtration followed by washing, addition of equimolar and 214 were 
reagents over 7 h, reflux. also isolated 
5 
Resin 206, Bu3SnH, AIBN, benzene, slow addition over 7 h, 162(49%) 
reflux. 
6 Resin 206, Bu3SnH, AIBN, DMF/benzene (6/5 mL), slow 162 (9 % ), 198 
addition over 4.5 h, overall reflux 7 h. and 214 were 
also isolated 
7 Rink resin 209, Bu3SnH, AIBN, benzene, slow addition over 162 (44 %), 213 
6 h, overall reflux 7 h. and 198 were 
also isolated 
8 Resin 206, B~SnH, AIBN, benzene, slow addition over 7 h, 162 (57%), 213 
overall reflux 8 h. was also isolated 
9 
Resin 206, TTMSS, AIBN, benzene, one pot addition, reflux 162 (20 % ), 213 
lOh. was also isolated 
Resin 206, TTMSS, AIBN, benzene, slow addition over 5 h, 162 (16 % ), 213 
10 overall reflux 8 h. was also isolated 
11 Resin 206, Bu3SnH, AIBN, toluene, slow addition over 2 h, 162 (49 %), 213 
then 3 h further reflux. Another addition of Bu3SnH/AIBN. and 214 were 
A further 1.5 h reflux. also isolated 
12 Resin 206, B~SnH, AIBN, benzene, slow addition over 2 h, 162 (58 % ), 213 
then 3 h further reflux. Another addition of B~SnHIAIBN. and 214 were 
A further 1.5 h reflux. also isolated 
13 Resin 206, Bu3GeH, AIBN, toluene, one pot addition, 162 (22 % ), 198 
overall reflux 8 h. was also isolated 
Tributylgermanium hydride did not work efficiently with the phenylselenyl system. Bu3GeH has a 
stronger Ge-H bond than the Sn-H bond in B~SnH and reacts ea. 20 x slower. Therefore, to 
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achieve higher yields with Bu3GeH longer reaction times will be required. Another reason could be 
associated with phenylselanyll formation which can inhibit radical reactions. A lot of unreacted 
material was observed which may suggest that inhibition is a problem. However, the results still 
prove that TIMSS and tributylgermanium hydride can be used as an alternative to tributyltin 
hydride for solid-phase radical reactions, but obviously the conditions have to be optimised for these 
radical mediators. 
Synthesis of 7 ,8,9,10-Tetrahydro-6H-benzo[ 4,5]imidazo[1,2-a ]azepine 215 on Solid-Phase 
In order to complete our studies on solid-phase we needed to carry out 5-, 6- and 7-membered ring 
cyclisations. The 5-membered ring cyclisations were as disappointing as the solution-phase whereas 
6-membered ring cyclisations were optimised to similar yields as solution-phase. 7-Membered ring 
cyclisations suffer from an unfavourable entropy barrier, and very low yield of7,8,9,10-tetrahydro-
6H-benzo[4,5]imidazo[l,2-a]azepine 215 was achieved in solution-phase (17%).33 We performed 7-
membered ring radical cyclisations on Wang resin-bound benzimidazole 207 as shown in Scheme 
87. The results are summarised in Table 13. The yield of the seven membered [1,2-a]fused 
benzimidazole 215 was poor in both instances; more work needs to be carried out to maximise the 
yield. The factor behind the poor yield could be the entropy barrier which disfavours the radical 
cyclisation which results from a large ring size. 
~N -o-~N.,_S ~ J co2-Q 
201 I ~SePh 
Radical 
reactions o=:b+Q-oH 
215 
Scheme 87. Synthesis of7,8,9,10-tetrahydro-6H-benzo[4,5]imidazo[l,2-a]azepine 215 on solid-
phase. 
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Table 13. Reaction conditions for the synthesis of 7,8,9,10-tetrahydro-6H-benzo[4,5]imidazo[l,2-
a]azepine 215. 
Entry Conditions Outcome 
Bu3SnH, AIBN, benzene, slow addition over 5 h, then 5 h 215 (2 % ), 216 also 
1 further reflux. isolated 
2 
Bu3SnH, AIBN, tert-butylbenzene, slow addition over 2.5 h, 215 (4 %), 216 
then 9 h further heating at 130 oc. (72%) 
3.1.5 Radical Cyclisation Reactions Using Microwave Irradiation 
Radical reactions were performed on Wang resin-bound benzimidazole derivatives (205-207) using 
"Smiths Personnel Chemistry synthesiser" a source of microwave irradiation. This synthesiser has 
an integrated liquid handler which allows automated microwave reactions of up to 96 separate 
reaction vessels. The conditions for each reaction can be individually programmed. The reactions 
are carried out in sealed tubes with working volumes of up to ,.., 3 mL. The results of these reactions 
are summarised in Table 14. The yields were determined by 1H NMR spectroscopy using the 
internal standard. 
~N -o-~N~S ~ 11 co2-Q 
206 ~SePh 
Radical cx:b+ 
162 
(}-oH 
reactions 
+ ():)---s-0-cooH 
213 ~ 
Scheme 88. Synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 on solid-phase 
using microwave irradiation. 
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Table 14. Radical cyclisations ofWang resin-bound benzimidazole precursor 206 for the synthesis 
of 1 ,2,3,4-tetrahydrobenzo[ 4,5]imidazo[l ,2-a ]pyridine 162. 
Entry Conditions Outcome 
1 
Time: 10 + 10 min (double addition); Temp.: 100 °C; Solvents: 162 (14 %), 213 
DMF/benzene (1.25/1.25 mL); Conditions: B~SnH, AMBN. was observed 
2 Time: 10 + 10 min (double addition); Temp.: 100 °C; Solvents: 162 (52 % ), 213 Propan-1-ol/benzene (1/lmL); Conditions: B~SnH, AMBN. was observed 
3 Time: 10 min; Temp.: 130 °C; Solvents: Propan-1-ol (2.5 mL); 162 (20 % ), 213 Conditions: Bu3SnH, AMBN. was observed 
4 Time: 10 + 10 min (double addition); Temp.: 100 °C; Solvents: t- 162 (36 % ), 213 Butanol/benzene (1.25/1.25 mL); Conditions: Bu3SnH, AMBN. was observed 
5 Time: 10 min; Temp.: 135 °C; Solvents: Propan-1-ol/benzene 162 (44 %), 213 (1.25/1.25 mL); Conditions: Bu3SnH, AMBN. was observed 
6 Time: 10 + 10 min (double addition); Temp.: 100 °C; Solvents: 162 (17 %), 213 CH3CN/benzene (1.25/1.25 mL); Conditions: Bu3SnH, AMBN. was observed 
Time: 10 + 10 min (double addition); Temp.: 135 °C; Solvents: 162 (44 %), 213 
6 Propan-1-ol/benzene (1.25/1.25 mL); Conditions: B~SnH, was observed 
AMBN. 
7 
Time: 20 min; Temp.: 135 °C; Solvents: Propan-1-ol/benzene 162 (38 % ), 213 
(1.25/1.25 mL); Conditions: B~SnH, AMBN. was observed 
The cyclised product 162 was obtained by filtration of resin followed by washing of resin with 
appropriate set of solvents. As all these experiments were conducted on a small portion of resin 206 
(20 ,..., 25 mgs ) hence, we only conducted LC/MS analysis of the filtrate containing cyclised product 
162 and tin residues to confirm the structures. We determined the yields of cyclised product 162 by 
1 H NMR spectroscopy using the internal standard. Unreacted starting material and reduced product 
were cleaved off the resin using TFAIDCM (9: 1). The LC/MS analysis of the cleaved material 
confirmed the benzimidazole products. 
We did not determine the yields of the reduced product 213 and unreacted starting material 198 in 
all these instances. We believe the results to be very novel. To our knowledge, these results are the 
first report of radical reactions on solid-phase using microwave irradiation. The cost of the 
apparatus will be a limiting factor, but where available, provide a new method for dramatically 
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cutting the time of reactions. The main advantage of this technique is the short reaction time. In the 
case of the tricyclic 6,5,6-fused benzimidazole 162, the highest yield is 52 % (Entry 7) and the 
reaction is complete within 20 min. This time is short for radical reactions but considerably longer 
than the normal time of 1-5 min required for most reactions using this technique of focussed 
microwave irradiation. The optimum yield is similar to that of solution-phase and that of solid-
phase without irradiation but with shorter reaction times. Propan-1-ol was found to be the most 
suitable solvent for microwave radical reactions as it is quite polar and generally, for reactions 
carried out using microwave, polar solvents give best results. The solvent optimisation indicates the 
importance of the correct solvent for use of combined solid-phase and microwave irradiation 
together. 
With the success of the cyclisation of resin-bound benzimidazole precursor 206 to 162, we 
investigated the 5-membered ring cyclisation using the same optimal conditions (Scheme 89). 
Unfortunately, the results of microwave irradiation parallel those for solution-phase and solid-phase. 
Again the yield was determined by 1H NMR spectroscopy using the internal standard. 
~N -o-~N~S ~ ;/ CONH-Q 
2os I ~SePh 
Radical 
reaction er:~ 
161 0 
Scheme 89. Reagents and conditions: i, Bu3SnH, AMBN, 20 min, 135 °C, propan-1-ol/benzene 
(1.25/1.25 mL), 3%. 
Solution-phase radical reactions to synthesise 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 
162 using the microwave methodology were also performed (Scheme 90) but the yields are not 
impressive. The results of these reactions have been summarised in Table 15. These solution-phase 
reactions were not optimised due to time constraints but results conclusively provide evidence that 
microwave radical reactions are feasible and take a lot less time then under normal conditions. 
Again the yields were determined by 1H NMR spectroscopy using the internal standard. 
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Scheme 90. Synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 in solution-phase 
using microwave irradiation. 
Table 15. Reaction conditions for the synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-
a]pyridine 162 using microwave irradiation. 
Entry Conditions Outcome 
1 Time: 10 min; Temp.; 135 °C; Solvents: Propan-1-ol/benzene 
(1.25/1.25 mL); Conditions: B~SnH, AIBN. 
162 (11 %) 
2 Time: 10 min; Temp.: 100 °C; Solvents: Propan-1-ol/benzene 
(1.25/1.25 mL); Conditions: B~SnH, AMBN. 
162 (20 %) 
Further studies are required to fully determine the conditions for radical reactions on solid-phase 
using 'focussed' microwave irradiation. In conclusion, we have demonstrated that intramolecular 
alkyl radical cyclisations, by ipso-substitution, onto solid-supported benzimidazole precursors are 
facile processes. 
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3.2 Attachment to Solid-Phase Using a Handle on the Benzo Ring of Benzimidazole Moieties 
As discussed at the beginning of this chapter, there are several possibilities for attaching the 
benzimidazoles to solid-supports. The advantage of attachment via the benzene ring of the 
benzimidazole is that the radical cyclisation via ipso-substitution results in the formation of the 
cyclised product which remains tethered to the resin. After the completion of radical reaction, the 
resin would be washed with appropriate set of solvents to remove all the excess of reagents which 
would eliminate traces of toxic tin-residues. The products could subsequently be cleaved off the 
resin using 95% TFNDCM. Obviously the disadvantages of this route would be the separation of 
the cyclised product from other by-products. Purification would need to be achieved using 
conventional chromatographic methods. A putative synthesis of the solid-supported benzimidazole 
precursors is shown in Scheme 91. 
0 
HO~N 1 rsPh 
~ N 
(ii) 
.. 
217 l ~ X" se Ph 
(i) 
0 
f'""'Y"'0~N v 1 rsPh 
~ N 
218 l -
~"SePh 
Scheme 91. Reagents and conditions: i, Wang resin, DMAP, DIC, DCM; ii, Bu3SnH, AIBN, 
toluene, reflux; iii, TFNDCM. 
The construction of a solution-phase model to mimic the solid-phase system was proposed. Both 
the acid and 1-NH need to be protected to facilitate phenylsulfanylation at C-2. Synthesis of the 
methyl lH-benzo[d]imidazole-5-carboxylate 222 was successful and the pure product was obtained 
at the end of the reaction (Scheme 92). We also prepared the benzyl ester, phenylmethyl lH-
benzo[d]imidazole-5-carboxylate 223, for comparative studies (Scheme 92). Tritylation of the 
methyllH-benzo[d]imidazole-5-carboxylate 222 was almost quantitative (Scheme 93). 
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221 H 
0 
_<:...:-.i> _.'o~N~ lJN 
222 H 
Scheme 92. Reagents and conditions: i, acetyl chloride, MeOH, reflux, 222 92%; ii, DEAD, PPh3, 
benzyl alcohol, THF, rt, 223 8%. 
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Scheme 93. Reagents and conditions: i, trityl chloride, E~N, DCM, rt, 93%; ii, n-BuLi, diphenyl 
disu:fide, THF; iii, Hydrolysis under acidic conditions. 
Protection of N-1 of precursor 222 with the trityl group was carried out to avoid the problems as 
described earlier. Unfortunately, tritylation gave the 5- and 6- isomers as protection can occur onto 
N-3 as well as onto N-1. The separation of these regioisomers was attempted using conventional 
flash chromatographic methods but the mixture of regioisomers proved to be inseparable. 
Therefore, we attempted the synthesis of the 2-(phenylsulfanyl)-1-(triphenylmethyl)benzimidazole 
ester 226 on a mixture of non-separable regioisomers 224 and 225 (Scheme 93). Attempts all failed, 
possibly due to steric hindrance from the trityl group. We came to the conclusion that it was best to 
reduce the methyl1-(triphenylmethyl)-1H-benzo[d]imidazole-5-carboxylate 224 and methyl1-
(triphenylmethyl)-1H-benzo[d]imidazole-6-carboxylate 225 to corresponding alcohols. 
The advantage of the hydroxy analogue is that the zwitterionic character is removed making 
subsequent (solution-phase) reactions easy. Methyl1-(triphenylmethyl)-1H-benzo[d]imidazole-5-
carboxylate 224 and methyl 1-(triphenylmethyl)-1H-benzo[d]imidazole-6-carboxylate 225 were 
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reduced to two regio-isomers [1-(triphenylmethyl)-1H-benzo[d]imidazol-6-yl]-methanol227 and [l-
(triphenylmethyl)-1H-benzo[d]imidazol-5-yl]-methanol228 (Scheme 94) in good yield. The 
protection of the benzimidazole alcohol precursors 227 and 228 was carried out using tert-
butyldimethylsilyl chloride, which proceeded satisfactorily. 
0 
'o~l N~ + RN~ 
UN/ ,........o N 
2 ' 0 c' Ph3 2 4 CPh3 
(i) 
(ii) 
TBDMS,...O~N { 
~N~ + 
229 CPh3 
Scheme 94. Reagents and conditions: i, LiAlH4 , Et:zO, 68%; ii, TBDMSCl, imidazole, DMF, 50%. 
Considerable difficulty was encountered with the Zwitterionic nature of the benzimidazole 
carboxylic acid. The formation of regioisomers was also a major problem in most of the synthetic 
steps. Separation of these regioisomers proved more difficult than expected due to eo-elution in 
column chromatography. Attempts to separate the regioisomers have so far not proved successful 
which hampers further research into continuation of SPOS. At this point we decided to concentrate 
our studies on the ipso-substitution route and no further work was carried out. 
The next chapter describes the intramolecular aryl radical cyclisations onto benzimidazole moieties 
in solution-phase and on solid-phase. 
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CHAPTER4 
Intramolecular Aryl Radical Cyclisations, by "ipso" Substitution, at the C-2 
Position of Benzimidazoles and Imidazoles 
4.1 Introduction 
Aryl radical cyclisations are now widely used in organic synthesis for the construction of fused 
aromatic systems.96 The intramolecular addition of aryl radicals to multiple bonds is well 
documented in the literature.97 The number of aryl radical cyclisations onto arenes and heteroarenes 
is less well investigated. Some examples are detailed here. Harrowven et af8 has reported a total 
synthesis of the alkaloid toddaquinoline in which an intramolecular addition of an aryl radical to a 
pyridine ring featured as the key step. Caddick et af'9 has shown that ipso-substitution by vinyl and 
aryl radical cyclisations onto indole moiety are viable processes but are moderate yielding (Scheme 
95). 
()C)-so.Tol (i) 
231 ~Br 
u 
Scheme 95. Reagents and conditions: i, Bu3SnH, AIBN, toluene, reflux, 31%. 
Aryl radical cyclisations have been used for the syntheses of the Amaryllidaceae alkaloids, 
vasconine, assoanine, oxoassinine and pratosine.99 The Jones group has also investigated the 
intramolecular cyclisation of aryl radicals onto pyrrole.100'101 One of the these successful additions of 
aryl radicals onto heteroarenes is shown in Scheme 96. Radical cyclisation of the N-(2-
iodophenyl)pyrrole-3-carboxamide 233 gave the tricyclic pyrrolo[3,2-c]quinolone 234, the ring 
system found in the recently isolated alkaloid martinelline. 
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233 Me 0 234 Me 
Scheme 96. Reagents and conditions: i, Bu3SnH, AIBN, toluene, reflux, 52%. 
4.1.1 Intramolecular Aryl Radical Cyclisations onto Benzimidazoles in Solution-Phase 
The examples in the literature suggested that cyclisation of aryl radicals onto pendant 
arenes/heteroarenes provides a useful method of constructing biologically interesting fused 
heterocycles as outlined in the introductory section. The objective of our research was to study the 
reactions of benzimidazoles with alkyl and aryl radicals. Our studies of the cyclisation of alkyl 
radicals onto benzimidazoles is reported in Chapter 2 and 3. Our aim was to develop a simple 
protocol for aryl radical cyclisation onto heteroarene using o-(halogenophenyl)alkyl building blocks. 
For instance, aryl radical cyclisations onto benzimidazoles would result in the formation of 
tetracycles (Scheme 97). There has been considerable interest in tetracycles of this kind as they 
exhibit biological activity.102 
R (XN')-Cl (i) R (X}-cl (ii) 
235 ~ ~[I, OMs] ~6 Lx 
Vx U 
X= Br,J 
(iii) 
Scheme 97. Reagents and conditions: i, KOH, DMF, rt; ii, 4-mercaptobenzoic acid, potassium tert-
butoxide, ethanol, reflux; iii, acetyl chloride, methanol, reflux; iv, radical reagents (i.e. TTMSS, 
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Bu3SnH or Bu3GeH), radical initiators (AIBN or AMBN) and common solvents (toluene, benzene, 
hexane or acetonitrile). 
4.1.2 Preparation of Aryl Radical Precursors 
After the successful synthesis of tricyclic benzimidazole derivatives on solid-phase we decided to 
investigate tetracyclic systems first in solution-phase and then translate these synthetic sequences 
onto solid-phase. To construct 6,5,5,6-fused benzimidazole derivatives via aryl radical cyclisation 
methodology we synthesised versatile aryl precursors to meet the requirements necessary for the 
system. 1-Iodo-2-(iodomethyl)benzene 241 was prepared as shown in Scheme 98. The chloride 
240 was stirred under reflux with sodium iodide in a Fink:elstein reaction to afford the 1-iodo-2-
(iodomethyl)benzene 241 quantitatively. It is imperative that Finkelstein reaction is carried out in 
the dark environment as decomposition of the benzylic iodide occurs in the light. We also prepared 
another aryl precursor which involved activation of commercially available 2-iodobenzyl alcohol 
242 with methanesulfonyl chloride to form a mesylate derivative 243. The mesyl group is a good 
leaving group in SN2 reactions and can be easily displaced by nucleophiles. We synthesised (2-
iodophenyl)methyl methanesulfonate 243 in a 60% yield (Scheme 99). 
I I ()Cl (i) .. (y-1 
240 241 
Scheme 98. Reagents and conditions: i, sodium iodide, acetonitrile, reflux, 100%. 
I 
(i) .. (Joso2Me 
242 243 
Scheme 99. Reagents and conditions: i, methanesulfonyl chloride, triethylamine, DCM, rt, 60%. 
In order to construct 6,5,6,6-fused benzimidazole derivatives via our proposed aryl radical 
cyclisation methodology, we also synthesised corresponding aryl precursors to meet the 
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requirements necessary for the system. We decided to use identical strategy as applied to 2-
iodobenzyl alcohol 242. The treatment of 2-bromophenylethyl alcohol 244 with methanesulfonyl 
chloride afforded 2-(2-bromophenyl)ethyl methanesulfonate 24S in a yield of 99% (Scheme 100). 
The synthesis of 1-bromo-2-(2-chloroethyl)benzene 246 also proceeded successfully in a moderate 
yield (66 %); the aim was to carry out the displacement reaction with sodium iodide because iodide 
is a good leaving group in SN2 reactions (Scheme 101). 
Br Br ~OH_(.:..:...i)_..~OMs 
244 245 
Scheme 100. Reagents and conditions: i, methanesulfonyl chloride, triethylamine, toluene, rt, 18 h, 
99%. 
Br Br ~OH _ _...(i.._) ~ ~0 
244 246 
Scheme 101. Reagents and conditions: i, cone. HCl, 115 °C, 18 h, 66%. 
4.1.3 Synthesis of Methy14-( { 1-[(2-iodophenyl)methyl]-1H-benzo[ d]imidazol-2-yl}sulfanyl) 
benzene-1-carboxylate 249 
The alkylation of 2-chlorobenzimidazole 163 was readily achieved using the KOH/DMF conditions. 
The substitution of 2-chloro-1-[(2-iodophenyl)methyl]-1H-benzo[d]imidazole 247 resulted in the 
quantitative formation of 4-( { 1-[(2-iodophenyl)methyl]-1H-benzo[d]imidazol-2-
yl}sulfanyl)benzene-1-carboxylic acid 248 (Scheme 102). Esterification of 4-( {1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 248 gave methyl 
4-( { 1-[(2-iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-carboxylate 249 in a 
78% yield. We synthesised the ester with the aim of solution-phase studies of aryl radical 
cyclisation as a model for later studies on solid-phase. 
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Scheme 102. Reagents and conditions: i, potassium hydroxide, 1-iodo-2-(iodomethyl)benzene 241, 
DMF, rt, 95%; ii, 4-mercaptobenzoic acid, potassium tert-butoxide, ethanol, reflux, 18 h, 100%; iii, 
acetyl chloride, methanol, reflux, 18 h, 78%. 
4.1.4 Radical Cyclisation Reactions ofMethy14-({1-[(2-iodophenyl)methyl]-
1H-benzo[ d]imidazol-2-yl}sulfanyl)benzene-1-carboxylate 249 
Methyl4-( { 1-[(2-iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylate 
249 was subjected to free radical conditions (TIMSS, slow syringe pump addition) and afforded 
11H-benzo[4,5]imidazo[l,2-a]isoindole 250 (20%) as the minor product (Scheme 103). The 
reduced product methyl 4-{[ 1-(phenylmethyl)-1H-benzo[ d]imidazole-2-yl]sulfanyl }benzene-1-
carboxylate 251 was unfortunately the major product, obtained in a 40% yield. When the radical 
cyclisation of precursor 249 was repeated using tributylgermanium hydride (one pot addition), the 
reduced compound 251 was afforded as the sole product (60%). The results suggest that the 
formation of 5-membered ring is hindered due to the strain in the transition state, hence, we 
observed the reduced 251 as the predominant product in both instances. The result with Bl1:3GeH is 
unusual in that the slower rate of H-abstraction from Bl1:3GeH should allow more time for cyclisation 
to take place, as had been observed for alkyl radical cyclisations. 
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(i) • (XI N~t=o 
~ N I + 
250 ,9 
Scheme 103. Reagents and conditions: i, TIMSS, AIBN, toluene, reflux, 5 h, 250 (20%), 251 
(40%). 
The precursor 248 was also coupled with Wang resin to give a resin-bound benzimidazole moiety 
252 as shown in Scheme 104. The loading of the resin was found to be 0.60 mmollg by cleaving a 
portion of resin with TFA/DCM (9/1). 
(i) 
(0.60 mmoVg) 
Scheme 104. Reagents and conditions: i, Wang resin, DMAP, DIC, DCM/DMF, rt. 
4.2 Synthesis of 1-[2·(2-Bromophenyl)ethyl]-2-chloro-1H-benzo[d]imidazole 253 
We extended our work to include the synthesis of 6,5,6,6-fused benzimidazole derivatives. From 
our previous studies it was apparent that the formation of 6-membered ring is a more facile reaction. 
The first step of the synthesis of radical precursor involved alkylation of 2-chlorobenzimidazole 163 
(Scheme 105). We synthesised 1-[2-(2-bromophenyl)ethyl]-2-chloro-1H-benzo[d]imidazole 253 
using Mitsonobu conditions. The reaction gave a mixture of the product 253 and a non-isolable 
DEAD by-product (1:1). Therefore, this route was not deemed suitable for the synthesis of 1-[2-(2-
bromophenyl)ethyl]-2-chloro-18-benzo[d]imidazole 253 due to the problems associated with 
purification. Therefore, an alternative route was employed and 1-[2-(2-bromophenyl)ethyl]-2-
chloro-1H-benzo[d]imidazole 253 was prepared in 98% yield by alkylation of2-
chlorobenzimidazole 163 using sodium hydride in dry THF, and 2-(2-bromophenyl)ethyl 
methanesulfonate 245, as shown in Scheme 105. 
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(X)-c1 (i) (X)-c1 + by-product 
163 H 253 (1 :1) 
!(11) Br 
(X)-c1 
253 
Br 
Scheme 105. Reagents and conditions: i, triphenylphosphine, DEAD, 2-bromophenylethyl alcohol, 
DCM, rt, 24 h; ii, sodium hydride, THF, 2-(2-bromophenyl)ethyl methanesulfonate 245, reflux, 3 h, 
98%. 
4.2.1 Synthesis ofMethyl4-({1-[2-(2-bromophenyl)ethyl]-1H-benzo[d]imidazol-2-yl)sulfanyl) 
benzene-1-carboxylate 255 
The substitution of 1-[2-(2-bromophenyl)ethyl]-2-chloro-18-benzo[d]imidazole 253 with 4-
mercaptobenzoic acid 189 resulted in the quantitative formation of 4-( {1-[2-(2-bromophenyl)ethyl]-
1H-benzo[d]imidazole-2-yl}sulfanyl)benzene-1-carboxylic acid 254 (Scheme 106). Esterification 
of the benzimidazole acid precursor 254 gave methyl4-( { 1-[2-(2-bromophenyl)ethyl]-J H-
benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylate 255 in a 76% yield. 
OCNN}-cl ___;_:(i)_.. (XN}-s_/\______j;o (ii) N ~OH 
253 254 
Br Br 
Scheme 106. Reagents and conditions: i, 4-mercaptobenzoic acid, potassium tert-butoxide, ethanol, 
reflux, 18 h, 99%; ii, acetyl chloride, methanol, reflux, 18 h, 76%. 
84 
4.2.2 Radical Cyclisation Reactions to Synthesise 5,6-Dihydrobenzo[4,5]imidazo 
[2,1-a]isoqoinoline 256 
The radical cyclisation reaction was carried out using tributyltin hydride (slow addition over 5 h 
using a syringe pump). 4-( { 1-[2-(2-Bromophenyl)ethyl]-lH-benzo[ d]imidazole-2-
yl}sulfanyl)benzene-1-carboxylic acid 254 was treated with Bu3SnH, prior to performing the radical 
reaction on precursor 255. The radical cyclisation reaction gave 5,6-dihydrobenzo[4,5]imidazo[2,1-
a]isoquinoline 256 (11 %, determined by 1H NMR spectroscopy using an internal standard). 
GC/MS analysis also confirmed the formation of 5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 
256. The poor yield of the cyclised product 256, in this instance, is due to poor solubility of 
precursor 254 in toluene. No solubility problems were encountered with the methyl ester and 
radical cyclisation of methyl 4-( { 1-[2-(2-bromophenyl)ethyl]-J H-benzo[d]imidazol-2-
yl)sulfanyl)benzene-1-carboxylate 255 afforded cyclised product 256 (60%). 
(i) (X)-D 
256 l_}--ff 
Scheme 107. Reagents and conditions: i, tributyltin hydride, AIBN, toluene, reflux, 8 h, 60%. 
The results indicate that in the radical cyclisation of 255 which proceeds via a 6-exo route, the 
transition state is much less strained in the formation of 6-membered ring in 256. These results are 
in good agreement with our previous alkyl radical cyclisations onto benzimidazole to construct the 
6,5,6-fused benzimidazole adduct 162. As a part of our continuing efforts to adapt radical 
cyclisation methodology to polymer supported reactions we also investigated a solid-phase synthesis 
of 5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256. 
4.2.3 Synthesis of Solid-Supported Benzimidazole Precursor 257 
The preparation of the benzimidazole derivative 257 on solid-support was achieved in high yield as 
illustrated in Scheme 108. The coupling reaction of 4-({1-[2-(2-bromophenyl)ethyl]-1H-
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benzo[d]imidazole-2-yl}sulfanyl)benzene-1-carboxylic acid 254 was performed using 
corresponding diisopropylcarbodiimide (DIC), with DMAP added to catalyse the esterification of 
the Wang resin. The results of the coupling reactions showed that for complete immobilisation of 
benzimidazole acid precursor 254 onto Wang resin, it is necessary to perform double coupling to 
attain a high loading of 257. TheIR spectrum of the solid-supported benzimidazole precursor 257 
shows the formation of ester band at 1713 cm-1 and the (MAS) 1H NMR spectrum shows complete 
immobilisation (attachment) of benzimidazole precursor onto resin. The loading was assessed by 
cleavage and analysis of a portion of the resin-bound precursor 257 prior to performing the 
cyclisation reactions. 
Scheme 108. Reagents and conditions: i, Wang resin, DMAP, DIC, DCM/DMF, rt. 
4.2.4 Radical Cyclisations of Solid-Supported Benzimidazole Precursor 257 
Previously established solution-phase radical methodology was applied to the solid-supported 
benzimidazole derivative 257 (Scheme 109). The results of radical cyclisation reactions of resin-
bound benzimidazole adduct 257 are outlined in Table 16. 
~N -o-~N~S ~ !J co2-Q 
257 
~NtP~ + ~N ~ # 
256 
~N -o-~N.,_S ~ !J COOH 
258 
Br + 
(254) 
Scheme 109. Synthesis of 5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256. 
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Table 16. Reaction conditions for the synthesis of 5,6-dihydrobenzo[4,S]imidazo[2,1-
a ]isoquinoline 256. 
Entry Conditions Outcome 
1 BU;,SnH, AIBN, benzene, reflux, 8 h. 256 (44%), 254 and 258 were 
also observed 
2 Bu3GeH, AIBN, toluene, reflux, 8 h. 256 (71 %), 254 and 258 were 
also observed 
At the end of the radical reactions, the resin was filtered and the filtrate collected. The filtrate was 
analysed by MS, HPLC and 1H NMR spectroscopy. The analysis indicated that the cyclised product 
256 was formed predominantly in both instances. The optimum result was attained when the solid-
supported precursor 257 was reacted with tributylgermanium hydride (a non-toxic radical mediator). 
The yield of cyclised product 256 is very impressive (71%) especially as the reaction has not yet 
been optimised. The use of tributylgermanium hydride also eliminated the use of slow syringe 
pump addition. The cyclised product 256 was contaminated with tributylgermanium residues and 
was purified using flash chromatography to obtain pure cyclised adduct 256. Purification proved to 
be much easier when tributylgermanium hydride was employed in radical reactions. The by-
products were cleaved from the resin using standard cleavage conditions. GC-MS analysis of 
cleaved sample shows the presence of the reduced product and the starting material. The % yield 
was not determined because the attempts to separate the reduced product and the starting material 
failed due to eo-elution in column chromatography. Interestingly, tributylgermanium hydride did 
not work as efficiently with the phenylselenyl system in our previous studies (Chapter 2 and 3) as 
with the aromatic bromide. 
In summary, we have demonstrated the successful cyclisation of aryl radicals by ipso-substitution 
onto benzimidazole in solution-phase and on solid-phase. In order to create chemical diversity in 
the cyclised product 256, we plan to utilise commercially available substituted benzimidazole 
derivatives. 
4.3 Preparation of Imidazole Radical Precursors 
One of the objectives of our project was to extend the aryl radical cyclisation methodology to 
imidazoles with the aim of constructing interesting biologically active imidazole moieties. We 
began our model studies to determine the efficiency of intramolecular aryl radical cyclisation onto 
C-2 position of imidazole in solution-phase. Solid-phase approaches have been widely used in the 
generation of libraries for lead discovery; the ultimate aim is to examine the solid-phase synthesis of 
imidazole analogues using radical ipso-substitution strategy. 
The first step towards the synthesis of an imidazole radical precursor involved reaction between 
commercially available 2-mercaptoimidazole 259 and commercially available 6-chloronicotinic acid 
ethyl ester. This moiety behaves as a traceless linker as a result of radical ipso-substitution reaction. 
It is also strongly electron withdrawing and should favour intramolecular radical ipso-substitution 
process (Scheme 110). Preparation of the desired intermediate ethyl 6-(lH-imidazol-2-
ylsulfanyl)pyridine-3-carboxylate 260 was achieved in a reasonable yield (50%). The treatment of 
precursor 257 with 2-(2-bromophenyl)ethyl methanesulfonate 245 under NaH/DMF conditions 
afforded ethyl 6-( { 1-[2-(2-bromophenyl)ethyl]-lH-imidazol-2-yl }sulfanyl)pyridine-3-carboxylate 
261 in a 75% yield. 
(:lsH 
H 
259 
261 
Scheme 110. Reagents and conditions: i, sodium hydride, 6-chloronicotinic acid ethyl ester, DMF, 
80 oc, 12 h, 50%; ii, sodium hydride, 2-(2-bromophenyl)ethyl methanesulfonate 245, DMF, rt, 25 h, 
75%. 
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4.3.1 Radical Cyclisations ofEthyl6-({1-[2-(2-bromophenyl)ethyi]-1H-imidazol-
2-yl}sulfanyl)pyridine-3-carboxylate 261 
The radical methodology was applied to ethyl6-( {1-[2-(2-bromophenyl)ethyl]-1H-imidazol-2-
yl }sulfanyl)pyridine-3-carboxylate 261 as depicted in Scheme 111 and Table 17. 
/[())~ ~
N \ 
# 
![)\__ fJC02Et 
+ N S + (261) 
262 
261 263 
Scheme 111. Synthesis of 5,6-dihydroimidazo[2,1-a]isoquinoline 262. 
Table 17. Reaction conditions for the synthesis of 5,6-dihydroimidazo[2,1-a]isoquinoline 262. 
Entry Conditions Outcome 
1 Bu3SnH (slow addition), AIBN, toluene, 262 (37%), 261 (19%) and 
reflux, 10 h. 263 (32%) 
2 TTMSS, AIBN, toluene, reflux, 12 h. 262 ( 45%) and 263 ( 45%) 
3 Bu3GeH, AIBN, toluene, reflux, 8 h. 262 (20%) and 263 (56%) 
The intramolecular aryl radical cyclisations onto imidazole were successful. All these experimental 
conditions led to the formation of the cyclised product 262 in moderate yield as well as the reduced 
uncyclised product 263. However, the reaction conditions have not yet been optimised and higher 
yields of cyclisation could possibly be achieved. Due to time restraints we decided to investigate 
aryl radical cyclisations via 'oxidative' methodology to construct heterocycles on solid-support as a 
priority, and if time permitted we would explore this area further. 
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CHAPTERS 
Synthesis of Novel Heterocycles by Oxidative Radical Cyclisation Methodology 
5.1 Introduction 
Radical oxidative cyclisation reactions have extensively been reviewed in Chapter 1, Section 1.2.5. 
Imidazole, indole and pyrrole subunits are widely distributed in nature. The oxidative radical 
cyclisations have been reported for several nitrogen containing heteroarenes,26·27•28 and several 
literature precedents show that imidazoles, indoles, pyrroles and pyrazoles with an electron 
withdrawing groups can be successfully employed to synthesise a range of polycyclic nitrogen 
heterocycles that may exhibit biological activity. 
Moody104 has successfully investigated alkyl radical cyclisations onto substituted indoles as depicted 
in Scheme 112. Indole cyclisation studies by Muchowski 105 are quite similar to those of Moody .104 
Muchowski106 also investigated aryl radical cyclisations onto a substituted pyrrole core (Scheme 
113). Kraus107 carried out aryl radical conditions onto substituted indoles with a carbonyl link 
between the indole and aryl groups. 6-0xo-6H-isoindolo[2,1-a]indole-11-carbaldehyde 269 was 
obtained as a sole product (Scheme 114). It is notable that Moody/04 Muchowski105 and Kraus107 all 
observe only the oxidized products after radical cyclisation, and that the presence of an electron 
withdrawing group is required on the radical accepting ring system. 
CHO CHO 
~ (i) OCb ~N/~ N) 
'-Cl n 
n 2M 
Scheme 112. Reagents and conditions: i, B~SnH, AIBN, toluene, reflux, 3 h, 264 n = 1 (64%), n = 
2 (75%), n = 3 (43%). 
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~ 
CHO + ()\-CHO 
d 
265 267 
Scheme 113. Reagents and conditions: i, B~SnH, AIBN, benzene, reflux, hv, 24 h, 266 ( 43% ), 267 
(<10%). 
CHO COBr 0~ 
268 
CHO 
(i) 
Scheme 114. Reagents and conditions: i, Bu3SnH, AIBN, benzene, reflux, hv, 4 h, 35%. 
Our aim in these studies was to develop aryl radical cyclisations, via 'oxidative' methodology, onto 
imidazole, indole, pyrrole and pyrazole rings to get access to novel heterocycles. The presence of 
electron withdrawing functionality on these templates is known to assist cyclisation. We decided to 
utilise commercially available ester containing imidazole, indole, pyrrole and pyrazole moieties. 
The ultimate aim was to construct heterocycles on solid-support using the radical 'oxidative' 
methodology. For that purpose we needed a template heterocycle with a functionality (e.g. 
ester/carboxylic acid) which could be coupled to the resin (Wang, Rink or Tentagel) followed by 
radical cyclisation to attain our targets. In this way we could build a library of biologically active 
compounds. We planned to cleave the desired targets from the resins using a variety of amines to 
give diversity to the desired heterocycles. 
5.1.1 Synthesis of Imidazole Analogues Using the 'Oxidative' Radical Methodology 
Our initial work involved synthesis of imidazole moieties via oxidative radical methodology. 
The alkylation of substituted imidazoles can be problematic because there are two reactive nitrogen 
atoms, hence it is possible for alkylation to occur on either nitrogen and give two regioisomers. 
Alkylation can also occur on both nitrogen atoms resulting in salt formation. Therefore, the control 
of the regiochemistry of the alkylation is very important. The imidazole-4(5)-carboxylate exists as a 
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mixture of tautomers with the 4-tautomer being predominant. The anion generated is ambident and 
has two canonical forms with negative charge, either on N-1 or N-3. Under basic conditions the 
alkylation occurs at N-1 as the base deprotonates the imidazole ring and the most nucleophilic of the 
ambident nitrogen anion centre reacts. The N-1 anion of methyl4-imidazole-carboxy1ate 270 is the 
most nucleophilic because it is the least affected by the electron withdrawing properties of the ester 
group, e.g. Scheme 115. In neutral conditions, alkylation will occur on N-3. The lone pair of 
electrons on N-3 makes it the more nucleophilic of the two nitrogen atoms. Alkylation followed by 
loss of a proton from N-1 would form the isomeric product. 
Alkylation of methyl4-imidazole-carboxylate 270 afforded methyl 1-[(2-iodophenyl)methyl]-1H-
imidazole-4-carboxylate 271 in a modest yield ( 43% ). The other regioisomer 272 was not observed. 
The result suggest that dialkylation may have occurred and the imidazole is lost as the salt at 
filtration (Scheme 115). 
(i) 
l 271 
272 
Scheme 115. Reagents and conditions: i, sodium hydride, 1-iodo-2-(iodomethyl)benzene, DMF, 80 
°C, 13 h, 271 (43%), 272 (0%). 
Radical cyclisation reactions of precursor 271 gave methyl 1-(phenylmethyl)-1H-imidazole-4-
carboxylate 274 as a sole product. The cyclised product 273 was not obtained at all. Formation of 
the 5-membered ring in 273 is more difficult because the 5,5,6-fused system is more strained 
(Scheme 116). The results of these cyclisations are identical to our previous findings (Chapter 4, 
Section 4.1.4). 
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Me02C Me02C 
t~ (i) + tJ )\ N diN N I N 
u 273 )) 
271 274 
Scheme 116. Attempted synthesis of the cyclised product 273. 
Table 18. Reaction conditions for the synthesis of the cyclised product 273. 
Entry Conditions Outcome 
1 B11:3SnH, AIBN, toluene, reflux, 13 h. 274(33%) 
2 B11:3GeH, AIBN, toluene, reflux, 10 h. 274(56%) 
Alkylation of methyl4-imidazole-carboxylate 270 with 2-(2-bromophenyl)ethyl methanesulfonate 
245 gave two regioisomers methyll-[2-(2-bromophenyl)ethyl]-IH-imidazole-4-carboxylate 275 and 
methyll-[2-(2-bromophenyl)ethyl]-IH-imidazole-5-carboxylate 276. The two regioisomers were 
easily separated by column chromatography and were identified by 1H NMR spectroscopy. The 
yields of these regioisomers are comparable. The reason for the lack of regioselectivity towards the 
4-isomer is not clear. 
Me02C Me02C t~ tJ _![N (i) + Me02C N)\ 
N N 
H 
270 
Br Br 
275 276 
Scheme 117. Reagents and conditions: i, sodium hydride, 2-(2-bromophenyl)ethyl 
methanesulfonate 245, DMF, 80 °C,13 h, 275 (50%), 276 (48%). 
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Radical cyclisation reactions of methyl 1-[2-(2-bromophenyl)ethyl]-1H-imidazole-4-carboxylate 
275 were carried out under different experimental conditions (Scheme 118). The results have been 
summarised (Table 19). When the radical cyclisation reaction was performed using Bu3SnH, low 
yields of the methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 (16%) and methyl 
5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 (4%) were observed (Entry 1). The 
formation of methyl5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 was unexpected, but 
upon careful consideration it appeared that both modes of cyclisation are viable processes. The 
electron withdrawing effect of ester group at C-4 position can induce cyclisation onto C-2 position 
(by making it more electrophilic) as well as C-5 position of imidazole. We did not observe the 
reduced product or the starting material. The structure of methyl5,6-dihydroimidazo[5,1-
a]isoquinoline-1-carboxylate 277 was confirmed using X-ray crystallography, as shown in Figure 6. 
A 90° rotation of the molecule is also shown, which illustrated the planarity of the molecule. 
_--:..:..(i)_,._ 06) 
277 
Br 
275 
Scheme 118. Synthesis of methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 and 
methyl5,6-dihydroimidazo[2, 1-a ]isoquinoline-2-carboxylate 278. 
Table 19. Reaction conditions for the synthesis of methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-
carboxylate 277 and methyl5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278. 
Entry Conditions Outcome 
1 Bu3SnH, AIBN, toluene, reflux, 10 h. 277 (16%) and 278 (4%) 
2 Bu3GeH, PhSH, AIBN, toluene, reflux, 10 h. 277 (44%) 
3 Bu3GeH, AIBN, toluene, reflux, 10 h. 277 (38%) and 278 (19%) 
4 TTMSS, AIBN, toluene, reflux, 12 h. 277 (30%) and 278 (30%) 
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Figure 6. X -ray crystal structures of methyl 5,6-dihydroimidazo[S,l-a ]isoquinoline-1-carboxylate 
277. 
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The amount of cyclisation was much greater when Bu3GeH, was employed (Entry 2). Methyl 5,6-
dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 was obtained in a moderate yield of 44% as a 
sole product. The results demonstrate that some kind of decomposition also occurred which 
prevented the efficiency of radical cyclisation reaction. The radical cyclisation of methyl 1-[2-(2-
bromophenyl)ethyl]-1H-imidazole-4-carboxylate 275 was repeated with Bu3GeH but without 
addition of catalytic amount of thiol to assist cyclisation. The cyclisation reaction was successful 
and afforded methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 in a38% yield and 
methyl5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 in a 19% yield (Entry 3). It is 
noteworthy that in all the above results, the uncyclised compounds are not observed at all. The 
reaction of methyl 1-[2-(2-bromophenyl)ethyl]-1H-imidazole-4-carboxylate 275 with TTMSS and 
AIBN gave the methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 in a 30% yield and 
methyl5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 in a 30% yield. The separation of 
these cyclised products 277 and 278 was readily achieved by column chromatography in all these 
instances. There are not obvious reasons for the different regioselectivities between the formation of 
the 2-isomer 278 and the 5-isomer 277. 
The analysis of the results show that aryl radical cyclisation onto imidazole can be best attained by 
using B~GeH. We have already listed the advantages of using Bu3GeH in radical reactions over 
triorganotin radical mediators. The results also suggest that B~GeH is an efficient reagent in 
radical cyclisation reactions and provided first successful example of intramolecular aryl radical 
cyclisations onto imidazole. Success of TTMSS mediated intramolecular aryl radical cyclisation 
onto imidazole shows that it is also an attractive non-toxic alternative to toxic triorganotin hydride. 
In all these radical cyclisation reactions we used AIBN in excess because the evidence suggests that 
AIBN is the oxidising agent and plays a part in oxidation step.23-27 The postulated mechanisms are 
outlined in Scheme 119. The intermediate re-radical280 is stable and reacts slowly if at all with 
radical mediator Bu3SnH or B~GeH, otherwise the reduced product would be formed. It is clear 
that in all of the above results, the reduced product is not afforded at all. Only the cyclisation 
products are obtained. Disproportionation would involve the aryl radical 279 abstracting hydrogen 
from the intermediate cyclised radical 280 to give a molecule of cyclised product and a molecule of 
the reduced product 281 (Scheme 120) in a chain inhibition step. The formation of the re-radical 280 
inhibits the reduction of the aryl radical 280. Therefore, we assume that the re-radical 280 must have 
been intercepted by AIBN or a break down product from AIBN. 
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The assumption that AIBN acts as the oxidant needs further investigation. Routes A and B (Scheme 
119) result in the formation of 2-cyanopropane which was not detected in our studies. 2-
Cyanopropane is very volatile compound and could be lost either from the reaction vessel during 
reflux or during evaporation of solvent in work up. There is no concrete evidence of what is 
involved in rearomatisation step. 
275 
Route C 
------Cf!;) 
279 
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280 
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+ 2n 
280(n- radical) 280(n- radical) 
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CN CN • CN CN 
2n 2n 
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Bu3GeH 
Scheme 119. Possible role of AIBN in the oxidative step of the radical cyclisation. 
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281 
Scheme 120. Putative disproportionation between the aryl radical and the intermediate cyclised 
radical. 
The unusual formation of the regioisomer 278 via cyclisation onto the 2-position of the imidazole 
275 suggested that better cyclisation might be obtained using the imidazole 5-ester 276. The other 
regioisomer, methyll-[2-(2-bromophenyl)ethyl]-lH-imidazole-5-carboxylate 276 was subjected to 
the radical conditions as detailed in Table 20. Our surmise proved to be correct and methyl 5,6-
dihydroimidazo[2,1-a]isoquinoline-3-carboxylate 282 was obtained in 71% yield (Entry 1). No 
unreacted material was recovered. Repeating the reaction using Bu3GeH also afforded cyclised 
product 282 in a yield of 54%. We expected a higher yield of cyclised product 282 in the case of 
Bu3GeH. No other by-products were observed in either of these reactions. We conclude that 
cyclisation occurs before the aryl radical can be intercepted and reduced by any source of hydrogen. 
The structure of methyl 5,6-dihydroimidazo[2,1-a]isoquinoline-3-carboxylate 282 was confirmed 
using X-ray crystallography as shown in Figure 7. 
98 
(i) 
Br 
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Scheme 121. Synthesis of methyl 5,6-dihydroimidazo[2, 1-a ]isoquinoline-3-carboxylate 282. 
Table 20. Reaction conditions for the synthesis of methyl 5,6-dihydroimidazo[2, 1-a ]isoquinoline-3-
carboxylate 282. 
Entry Conditions Outcome 
1 B~SnH, AIBN, toluene, reflux, 13 h. 282 (71%) 
2 B~GeH, AIBN, toluene, reflux, 12 h. 282 (54%) 
Figure 7. X -ray crystal structure of methyl 5,6-dihydroimidazo[2, l-a ]isoquinoline-3-carboxylate 
282. 
99 
5.1.2 Synthesis of Methyl5,6-dihydroindolo[2, 1-a ]isoquinoline-12-carboxylate 285 
by Oxidative Radical Cyclisation 
The first step in the synthesis involved the alkylation of methyl indole-3-carboxylate 283 (Scheme 
122). Alkylation under basic conditions gave methyl 1-[2-(2-bromophenyl)ethyl]-1H-indole-3-
carboxylate in a moderate yield of 40%. The synthesis required improvement but was not further 
optimised. 
~O.Me (i) 
283 H 
Scheme 122. Reagents and conditions: i, sodium hydride, 2-(2-bromophenyl)ethyl 
methanesulfonate 245, DMF, 21 h, 40%. 
Treatment of methyl1-[2-(2-bromophenyl)ethyl]-1H-indole-3-carboxylate 284 with Bu3GeH (one 
pot addition) led to the isolation of methyl 5,6-dihydroindolo[2, 1-a ]isoquinoline-12-carboxylate 285 
in 68% yield as shown in Scheme 123. The intramolecular radical cyclisation onto the substituted 
indole ring was achieved successfully. No unreacted starting material, other by-products or reduced 
products were recovered. 
285 
Scheme 123. Reagents and conditions: i, Bu3GeH, AIBN, toluene, reflux, 12 h, 68%. 
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We have shown that aryl radical cyclisation onto indole substituted with an electron withdrawing 
group occurs readily. When the electron withdrawing group is at the C-3 position of the indole ring, 
cyclisation occurs onto C-2 position. This is due to the fact that the cyclisation is occurring onto an 
a,~-unsaturated position and the intermediate radical is extensively delocalised and therefore has 
increased stability. 
5.1.3 Synthesis of Ethyl 5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate 288 by 
Oxidative Radical Cyclisation 
The same alkylation procedure as that used for the alkylation of methyl4-imidazole-carboxylate 271 
was followed utilising 2-(2-bromophenyl)ethyl methanesulfonate 245. Since the radical cyclisation 
of the six-membered ring was proven to be the most successful in all the previous examples, then 
ethyl 1-[2-(2-bromophenyl)ethyl]-1H-pyrrole-2-carboxylate 287 was synthesised by alkylation of 
ethyl pyrrolo-2-carboxylate 286 (Scheme 124). 
(i) 
Br 
287 
Scheme 124. Reagents and conditions: i, sodium hydride, 2-(2-bromophenyl)ethyl 
methanesulfonate 245, DMF, 80 °C, 97%. 
The radical cyclisation of ethyl l-[2-(2-bromophenyl)ethyl]-1H-pyrrole-2-carboxylate 287 was 
performed using Bu3GeH (one pot addition) as illustrated in Scheme 125. The only compound 
isolated from the reaction under these conditions was the desired cyclisation to yield ethyl 5,6-
dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate 288 in 82% yield. The successful intramolecular 
radical cyclisation onto substituted pyrrole at C-5 position provides evidence that 6-exo mode of 
cyclisation is very favourable though it is very unusual not to observe any reduced product. 
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287 
Scheme 125. Reagents and conditions: i, Bu3GeH, AIBN, toluene, reflux, 12 h, 82%. 
5.1.4 Synthesis of Ethyl 2-( trifluoromethyl)-5,6-dihydropyrazolo[ 5,1-a ]isoquinoline-
1-carboxylate 293 by Oxidative Radical Cyclisation 
There are very few natural products containing pyrazole rings compared to other nitrogen containing 
heteroarenes. Withasomnine 289 (Figure 8) was first isolated from Withania somnifera 26 years 
ago. Withasomnine 289 and analogues contain a [1,2-b]-fused bicyclic pyrazole structural motif.1<Xl 
Will Barton, one of our group members has successfully employed a radical protocol to construct 
withasomnine 289 analogues as shown in Chapter 1, Section 1.2.5, Scheme 18. 
289 
Figure 8. Withasomnine. 
We also wanted to utilize the aryl radical cyclisation protocol to synthesise pyrazole analogues. The 
commercially available ethyl3-(trifluoromethyl)pyrazole-4-carboxylate 290 was considered as a 
potential substrate for intramolecular aryl radical cyclisations to be studied in detail. The 
regioselective alkylation of ethyl 3-(trifluoromethyl)pyrazole-4-carboxylate 290 proved difficult and 
afforded two regioisomers (Scheme 126). The desired regioisomer 291 was formed predominantly. 
The separation of these regioisomers was not very efficient because the ethyl 1-[2-(2-
bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 291, at the end of the 
purification, was still found to be contaminated with compound 292. 
102 
Br 
~OMs 
245 
291 
Scheme 126. Reagents and conditions: i, sodium hydride, DMF, 80 °C, 291 (85% ). 
Intramolecular aryl oxidative radical cyclisation of ethyl1-[2-(2-bromophenyl)ethyl]-3-
(trifluoromethyl)-1H-pyrazole-4-carboxylate 291 at the C-5 position was achieved in moderate yield 
using Bll:JGeH (one pot addition) and AIBN in excess (Scheme 127). The ethyl2-(trifluoromethyl)-
5,6-dihydropyrazolo[5,1-a]isoquinoline-1-carboxylate 293 was identified as the main reaction 
product. No unreacted starting material was recovered. The putative rearomatisation mechanism 
has already been described. 
293 
291 
Scheme 127. Reagents and conditions: i, Bu3GeH, AIBN, toluene, reflux, 12 h, 57%. 
5.1.5 Synthesis of Solid-Supported Pyrrole 295 and Pyrazole 297 
Success of intramolecular aryl radical cyclisations via 'oxidative' methodology in solution-phase 
enabled us to adapt the protocol for solid-supported synthesis of these interesting heteroarenes. The 
first step towards the synthesis of solid-supported pyrrole precursor 295 involved the hydrolysis of 
previously synthesised ethyl 1-[2-(2-bromophenyl)ethyl]-lH-pyrrole-2-carboxylate 287 as depicted 
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in Scheme 128. The hydrolysis of the pyrrole precursor 287 furnished the desired acid precursor 
294 under standard conditions in excellent yield. Our past experience has shown that the Wang 
resin is highly compatible with the radical reaction conditions. Hence, 1-[2-(2-bromophenyl)ethyl]-
1H-pyrrole-2-carboxylic acid 294 was tethered to the Wang resin using DIC and catalytic DMAP. 
The IR spectrum of the solid-supported pyrrole precursor 295 showed the formation of an ester band 
at 1702 cm-•. Attempts to cleave the material from a portion of resin proved futile. Therefore, we 
did not attempt the radical cyclisation reaction on pyrrole 295 as the cleavage of cyclised material 
would suffer the same fate so we decided to look for alternative approaches to solve the problem. 
Br 
287 295 
Scheme 128. Reagents and conditions: i, 2 M sodium hydroxide, ethanol, reflux, 8 h, 98%; ii, 
Wang resin, DMAP, DIC, DCM/DMF, rt. 
At the same time we started working on solid-supported pyrazole derivative 297. The hydrolysis of 
ethyl 1-[2-(2-bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 291 afforded 
pyrazole acid precursor 296 in a yield of 97% as shown in Scheme 129. The coupling reaction of 
pyrazole acid derivative 296 was carried out using the corresponding diisopropylcarbodiimide 
(DIC), with DMAP added to catalyse the esterification of Wang resin. 
291 296 297 
Scheme 129. Reagents and conditions: i, 2 M sodium hydroxide, ethanol, reflux, 8 h, 97%; ii, 
Wang resin, DMAP, DIC, DCM/DMF, rt. 
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The results of the coupling reactions showed that for complete immobilisation of pyrazole acid 
precursor 296 onto Wang resin, it was necessary to perform double coupling to attain a high loading 
of 297. TheIR spectrum for the resin-bound pyrazole 297 showed the formation of an ester band 
at17'23 cm·1• The loading was assessed by cleavage and analysis of a portion of the resin-bound 
precursor 297 (TFAIDCM 9: 1) prior to performing the cyclisation reactions. 
5.2 Radical Cyclisation Reactions of Solid-Supported Pyrazole 297 
Radical cyclisation reactions were performed on resin-bound pyrazole 297 under various 
experimental conditions to test the efficiency of intramolecular aryl cyclisations (Scheme 130). The 
results have been summarized in Table 21. 
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Scheme 130. Synthesis of 2-( trifluoromethyl)-5,6-dihydropyrazolo[S, 1-a ]isoquinoline-1-carboxylic 
acid 298. 
Table 21. Reaction conditions for the synthesis of 2-(trifluoromethyl)-5,6-dihydropyrazolo[S, l-
a ]isoquinoline-1-carboxylic acid 298. 
Entry Conditions Outcome 
1 B~GeH, AIBN, toluene, reflux, 30 h. 298 (20% ), 296 (70%) 
2 TTMSS, AIBN, toluene, reflux, 24 h. 298 (53%), 299 (27%) 
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The treatment of resin-bound pyrazole 297 with Bu3GeH was carried out (Entry 1). After the radical 
cyclisation reaction, the resin was filtered and washed with an appropriate set of solvents to 
eliminate the traces of the excess of reagents. The tethered products on the resin were cleaved using 
TFA/DCM (9/1) and a crystalline material was recovered. The LC-MS analysis of the cleaved 
sample from the resin confirmed the presence of cyclised adduct 2-(trifluoromethyl)-5,6-
dihydropyrazolo[5,1-a]isoquinoline-1-carboxylic acid 298, unaltered starting material296 and 
reduced product 299. The 1H NMR spectrum of the cleaved sample was very clean and also showed 
the cyclised product 298 and the starting material 296 ( 1: 1 ). The separation of these compounds by 
column chromatography was unsuccessful due to eo-elution. The radical cyclisation reaction of 
resin-bound pyrazole 297 was repeated using ITMSS (Entry 2). Again we observed the 2-
( trifluoromethyl)-5,6-dihydropyrazolo[S, 1-a]isoquinoline-1-carboxylic acid 298 and the reduced 
product 299. The % yield has been determined by the weight of the material recovered at the end of 
these reactions. Careful manipulation of radical mediator resulted in the higher ratio of cyclised 
product 298. Time constraints did not permit us to examine the synthesis in more detail and extend 
it to other interesting heteroarenes. The results of the solid-supported aryl cyclisations onto pyrazole 
show its future potential. Separation of resulting polar compounds can be resolved by derivatising 
the products. Modification in cleavage conditions could lead us to synthesise a small library of 
novel compounds which may have pharmacological activities. 
5.2.1 Conclusions 
• Tributylgermanium hydride and ITMSS have shown great potential for solid-phase radical 
reactions. 
• The mercaptobenzoic acid tinker which we introduced at C-2 position of 2-chloro 
benzimidazole derivatives is a novel traceless linker and can be used for combinatorial 
synthesis. 
• Other interesting heterocyclic analogues have been synthesised in solution-phase via the 
oxidative radical approach. Successful synthesis of the pyrazole 298 via the oxidative 
methodology using the solid-phase shows its potential for combinatorial synthesis. 
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EXPERIMENTAL 
General 
IR spectra were recorded on a Perkin-Elmer Ff-IR Paragon 1000 spectrometer. TheIR spectra 
were carried out on neat samples unless otherwise stated. 1H NMR spectra were recorded using a 
Bruker AC 250 spectrometer at 250 MHz unless otherwise stated and J values are given in Hz. 13C 
NMR spectra were recorded using Bruker DPX 400 MHz spectrometer at 100.6 MHz unless 
otherwise stated. NMR spectra were recorded with CDC13 as solvent and tetramethylsilane (TMS) 
as an internal reference unless otherwise stated. 1,4-Dimethoxybenzene was used as an internal 
standard where indicated. Chemical shifts are reported in 6 units. Elemental analysis was carried 
out on a Perkin Elmer 2400 CHN Elemental Analyser. Mass spectra were recorded using a Kratos 
MS 80 instrument. The GC-MS used was the Fisons GC 8000 series (AS 800) spectrometer. 
TLC using silica gel as the absorbent was performed with aluminium backed plates with silica gel 
(Merck Kieselgel 60 F254) and TLC using alumina as absorbent was carried out with aluminium 
backed plates coated with neutral aluminium oxide (Merck 60 F254). TLC plates were viewed under 
UV, with iodine or by immersing the plate in either of the solutions of KMn04 or phosphomolybdic 
acid. Column chromatography using silica gel was carried out with Merck Kieselgel 60 H silica and 
column chromatography using alumina was carried out with Aldrich aluminium oxide, activated 
neutral, Brockmann 1, STD Grade, 150 mesh size. 
All the alkylations, substitutions and radical reactions were carried out under an atmosphere of 
nitrogen, using dry glassware. Anhydrous solvents such as THF, DMF, acetonitrile, benzene and 
toluene were obtained commercially. Other solvents such as DCM, ethyl acetate, light petroleum 
and methanol were distilled before use. Sodium hydride was obtained as a 60 % dispersion in 
mineral oil and was washed with light petroleum. Analytical grade diethyl ether and acetone were 
obtained commercially. 
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EXPERIMENTAL FOR CHAPTER TWO 
1-(Triphenylmethyl)-lH-benzo[d]imidazole 149 
(X) 
\ 
149 CPh3 
Benzimidazole 148 (9.48 g, 80.2 mmol) was dissolved in DCM (500 mL). Triphenylmethyl 
chloride (30.0 g, 107.5 mmol) was added over 20 min and the mixture stirred until the solution was 
complete. Triethylamine (34 mL, 243.9 mmol) was added slowly to the stirred solution and the 
stirring was continued overnight at ambient temperature. The solution was evaporated to dryness 
and the residue was recrystallised from absolute ethanol and dried to give 1-(triphenylmethyl)-1H-
benzo[d]imidazole 149 as cream coloured needles (22.53 g, 62.6 mmol, 78 % ); mp 180-182 oc 
(lit}® mp 180-181 °C); (Found: M+, 360.1624. C26H2oN2 requires 360.1626); ()H 6.50 (1 H, ddd, 1 = 
8.3, 0.9, 0.9, 7-H), 6.88 (1 H, ddd, 1 = 8.9, 7.2, 1.2, 5-H), 7.15-7.32 (16 H, m, ArH), 7.77 (1 H, ddd, 
1 = 8.3, 0.9, 0.9, 4-H) and 7.87 (1 H, s, 2'-H); be 75.41 (Cq), 115.38 (benzimidazole ArCH), 120.28 
(benzimidazole ArCH), 122.02 (benzimidazole ArCH), 122.30 (benzimidazole ArCH), 128.00 (3 x 
ArCH), 128.13 (6 x ArCH), 130.16 (6 x ArCH), 134.78 (ArC), 141.35 (3 x ArC), 144.13 (ArC) and 
144.65 (2-C); mlz El 360 (M+, 2 %), 243 (100) and 165 (100). 
1-[ (3-Chloropropyl)selanyl]benzene 15333 
PhSe~CI 
153 
Diphenyl diselenide (5.0 g, 16.0 mmol) was dissolved in absolute ethanol (810 mL) at ambient 
temperature. Sodium borohydride (1.34 g, 35.5 mmol) was added slowly to the stirred solution at 0 
°C. After 30 min, 1-chloro-3-iodopropane (3.43 g, 31.9 mmol) was added dropwise and the mixture 
was stirred at ambient temperature overnight. The solution was evaporated to dryness and 2 M 
hydrochloric acid (75 mL) was added and the solution extracted with diethyl ether (8 x 50 mL). The 
combined organic extracts were washed with sodium carbonate (3 x 50 mL) and brine (2 x 50 mL) 
and dried (MgS04). The crude product was purified by column chromatography using silica gel as 
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absorbent with light petroleum/DCM (4:1) as eluents to yield 1-[(3-chloropropyl)selanyl]benzene 
153 as a pale yellow oil (6.42 g, 27.4 mmol, 86 %); (Found: M+, 233.9714. C9H11SeCl requires 
233.9715); vmax (neat)/cm-1 3071,2954, 1578, 1477, 1437, 1262, 1072, 1022,735 and 691; ()H 2.10 
(2 H, quintet, J = 7.0, 2-H), 3.00 (2 H, t, J = 7.0, CH2SePh), 3.62 (2 H, t, J = 7.0, ClCH2), 7.23-7.28 
(3 H, m, ArH) and 7.47-7.51 (2 H, m, ArH); ~c 24.42 (2-C), 32.52 (1-C), 44.22 (3-C), 126.97 
(ArCH), 129.06 (ArCH), 131.00 (ArC) and 132.67 (ArCH); mlz El 234 (M+, 90 %), 171 (17), 158 
(100), 91 (35), 78 (65), 51 (25) and 41 (22). 
1-[ ( 4-Chlorobutyl)selanyl]benzene 15433 
CI~SePh 
154 
Diphenyl diselenide (10.0 g, 32.0 mmol) was dissolved in methanol (1 L) at room temperature. 
Sodium borohydride (3.05 g, 80.0 mmol) was added slowly to the stirred solution at 0 °C. After 30 
rnin, 4-bromo-1-chlorobutane (8.11 rnL, 70.4 mrnol) was added dropwise and the mixture was 
stirred at ambient temperature overnight. The solution was evaporated to dryness and 2 M 
hydrochloric acid (75 mL) was added and the solution extracted with diethyl ether (8 x 50 rnL). The 
combined organic extracts were washed with sodium carbonate (3 x 50 mL) and brine (3 x 50 mL) 
and dried (MgS04). The crude product was purified by column chromatography using silica gel as 
absorbent and light petroleum/DCM (9:1) as eluents to yield 1-[(4-chlorobutyl)selanyl]benzene 154 
as a colourless oil (12.0 g, 48.39 rnmol, 69 %); (Found: M+, 247.9873. C1JI13ClSe requires 
247.9871); vmax (neat)/cm-1 3070, 2935, 1578, 1477, 1437, 1312, 1299, 1280, 1073, 1022 and 736; 
6H (1.83-1.94 (4 H, m, 2-H, 3-H), 2.92 (2 H, t, J = 7.0, CH2SePh), 3.53 (2 H, t, J = 6.0, ClCH2), 7.22-
7.28 (3 H, m, ArH) and 7.48-7.50 (2 H, m, ArH); ~c 26.66 (3-C), 26.97 (2-C), 32.40 (CH2SePh), 
44.33 (ClCH2), 126.91 (ArCH), 129.07 (ArCH), 130.04 (ArC) and 132.71 (ArCH); m/z El 248 (M+, 
44 %), 158 (45), 91 (100), 78 (43) and 55 (55). 
1-[ (5-Chloropentyl)selanyl]benzene 15533 
PhSe~CI 
155 
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Diphenyl diselenide (9.48 g, 30.4 mmol) was dissolved in absolute ethanol (600 mL) at ambient 
temperature. Sodium borohydride (2.30 g, 60.8 mmol) was added slowly to stirred solution at 0 °C. 
After 30 min, 1-bromo-5-chloropentane (8.0 mL, 60.7 mmol) was added dropwise and the mixture 
was stirred at ambient temperature overnight. The solution was evaporated to dryness and 2 M 
hydrochloric acid (75 mL) was added and the solution extracted with diethyl ether (8 x 50 mL). The 
combined organic extracts were washed with sodium carbonate (3 x 50 mL) and brine (2 x 50 mL) 
and dried (MgS04). The crude product was purified by column chromatography using silica gel as 
absorbent with light petroleurn!DCM (4:1) as eluents to yield 1-[(5-chloropentyl)selanyl]benzene 
155 as a clear oil (15.90 g, 60.68 mmol, 99 %); (Found: M+, 262.0029. C11H15SeCl requires 
262.0028); vmax (neat)/cm-1 3050, 1578, 1477, 1437, 1300, 1283, 1234, 1073, 1022, 736 and 699; OH 
1.51-1.59 (2 H, m, 3-H), 1.69-1.80 (4 H, m, 4-H, 2-H), 2.90 (2 H, t, J = 7.3, 1-H), 3.51 (2 H, t, J = 
6.6, 5-H), 7.21-7.28 (3 H, m, ArH) and 7.45-7.50 (2 H, m, ArH); be 27.05 (3-C), 27.58 (2-C), 29.43 
( 4-C), 32.05 (1-C), 44.79 (5-C), 126.80 (ArCH), 129.04 (2 x ArCH), 130.31 (ArC) and 132.61 (2 x 
ArCH); mlz El (262 (M+, 50%), 181 (14), 158 (65), 77 (88), and 69 (100). 
1-[ (3-Iodopropyl)selanyl]benzene 15633 
PhSe~l 
156 
1-[(3-Chloropropyl)selanyl]benzene 153 (2.88 g, 12.3 mmol) and sodium iodide (24.0 g, 160.1 
mmol) were added to dry acetone (250 mL) and stirred in the dark under reflux for 18 h. The 
precipitated sodium chloride was removed by filtration on a celite bed and the solution was 
evaporated to dryness. The solid residue was triturated with diethyl ether and the solution filtered a 
second time. The ether solution was evaporated to dryness to afford 1-[(3-
iodopropyl)selanyl]benzene 156 as a yellow oil (3.3 g, 10.1 mmol, 82 %); (Found: M+, 325.9070. 
C9H11Sel requires 325.9071); vmax (neat)/cm-1 3054, 2969, 1578, 1477, 1436, 1203, 1022, 735 and 
691; bH 2.15 (2 H, quintet, J = 7.0, 2-H), 2.98 (2 H, t, J = 7.0, CH2SePh), 3.28 (2 H, t, J = 7.0, 
ICH2), 7.25-7.28 (3 H, m, ArH) and 7.49-7.52 (2 H, m, ArH); be (6.50 (CH2SePh), 28.54 (CH2), 
33.66 (ICH2), 127.55 (ArCH), 129.57 (ArCH), 129.85 (ArC) and 133.35 (ArCH); mlz FAB 326 
(M+, 100 %), 199 (60) and 169 (25). 
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1-[ ( 4-Iodobutyl)selanyl]benzene 15733 
PhSe~1 
157 
1-[(4-Chlorobutyl)selanyl]benzene 154 (3.60 g, 14.6 mmol) and sodium iodide (26.98 g, 180.0 
mmol) were added to dry acetone (250 mL) and heated under reflux for 18 h. The precipitated 
sodium chloride was removed by filtration on a celite bed and the solution was evaporated to 
dryness. The solid residue was triturated with diethyl ether and the solution filtered a second time. 
The ether solution was evaporated to dryness to afford 1-[(4-iodobutyl)selanyl]benzene 157 as 
yellow-orange oil (3.2 g, 9.5 mmol, 65% ); (Found: M+, 339.9227. C1Jl131Se requires 247.9227); 
()H 1.77-1.82 (2 H, m, 2-H), 1.90-1.95 (2 H, m, 3-H), 2.89 (2 H, t, J = 7.1, CH2SePh), 3.18 (2 H, t, J 
= 6.7, ClCH2), 7.25-7.27 (3 H, m, ArH) and 7.45-7.52 (2 H, m, ArH); mlz El 339 (M+, 11 %), 213 
(100), 183 (57), 157 (50) 91 (28) 77 (36) and 55 (81). The oil darkened on standing at ambient 
temperature. 
1-[ (5-lodopentyl)selanyl]benzene 15833 
PhSe~l 
158 
1-[(5-Chloropentyl)selanyl]benzene 155 (5.00 g, 19.1 mmol) and sodium iodide (17.17 g, 114.5 
mmol) were added to dry acetone (250 mL) and heated under reflux for 18 h. The precipitated 
sodium chloride was removed by filtration on a celite bed and the solution was evaporated to 
dryness. The solid residue was triturated with diethyl ether and the solution filtered a second time. 
The ether solution was evaporated to dryness to afford 1-[(5-iodopentyl)selanyl]benzene 158 as a 
brown oil (6.01 g, 17.0 mmol, 89 %); (Found: M+, 353.9388. C11H1sSel requires 353.9384); Vmax 
(neat)/cm-1 3069,2930, 1578, 1477, 1436, 1296, 1266, 1196, 1072, 1022,874,735 and 690; ()H 
1.50-1.56 (2 H, m, 3-H), 1.70-1.87 (4 H, m, 4-H, 2-H), 2.90 (2 H, t, J = 7.36, 1-H), 3.16 (2 H, t, J = 
6.96, 5-H), 7.23-7.28 (3 H, m, ArH) and 7.46-7.50 (2 H, m, ArH); m/z El 354 (M+, 14% ), 323 (20), 
227 (27), 197 (66), 155 (42), and 69 (100). 
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1H-Benzo[d]imidazol-2-yl phenyl sulfide 152110 
(le)-sPh 
H 
152 
1-(Triphenylmethyl)-1H-benzo[d]imidazole 149 (6.00 g, 16.7 mmol) was dissolved in THF (185 
mL) and the mixture was stirred at ambient temperature. The temperature of the stirred solution was 
lowered to -78 oc and a solution of n-butyllithium added dropwise (15.0 mL, 24.0 mmol). The 
solution turned pink and was stirred at 0 oc for a further 20 min. A solution of diphenyl disulfide 
(5.45 g, 25.0 mmol) in THF (15.0 mL) was added dropwise and the stirring was continued 
overnight. The solution was evaporated to give the crude product as a yellow oil which was 
dissolved in methanol (100 mL) and concentrated hydrochloric acid (10.0 mL, 31-34% w/w 
solution) was added. The reaction mixture was heated under reflux for 4 h. The reaction mixture 
was reduced to approximately 20 mL in vacuuo and extracted with light petroleum to remove by-
products. The aqueous layer, containing the protonated benzimidazole compounds, was basified to 
pH 14 with sodium carbonate and 1 M sodium hydroxide (few drops). The basic solution was 
extracted with DCM (3 x 20 mL). The combined organic extracts were dried (MgS04) and 
evaporated to dryness to yield a crude solid. The residue was purified by column chromatography 
using neutral alumina as absorbent with DCM and diethyl ether (1:1) as eluents to afford 1H-
benzo[d]imidazol-2-yl phenyl sulfide 152 as white crystals (3.00 g, 13.3 mmol, 80 %), mp 202-205 
oc (lit.110 mp 201.5-202.5 °C); (Found: M+, 226.0559. Cl3HION2S requires 226.0565); vmax 
(nujol)/cm-1 1617, 1510, 1412, 1348, 1265, 1233, 977,739 and 686; bH 7.15-7.51 (9 H, m, ArH); 
m/z El 226 (M+ 60 %), 225 (100), 192 (10), 167 (5), 77 (8). 
1-[3-(Phenylselanyl)propyl]· 2-(phenylsulfanyl)-1H-benzo[ d) imidazole 15~3 
0)--SPh 
~Se Ph 
159 
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1H-Benzo[d]imidazol-2-yl phenyl sulfide 152 (0.65 g, 3.0 mmol) was added slowly to NaH (90 mg, 
3.8 mmol) in dry THF (200 mL). The mixture was stirred and heated under reflux for 1 hand 1-[(3-
iodopropyl)selanyl]benzene 156 (0.73 g, 2.2 mmol) in THF (10 mL) was added dropwise to the 
reaction mixture. The mixture was heated under reflux for a further 2 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan solid, 
which was purified by column chromatography using neutral alumina as absorbent with light 
petroleum and DCM followed by diethyl ether as eluent to afford 1-[3-(phenylselanyl)propyl]-2-
(phenylsulfanyl)-1H-benzo[d]imidazole 159 as a pale yellow oil (0.99 g, 2.3 mmol, 77 % ); (Found: 
M+, 424.0504. c22H20N2SSe requires 424.0512); Ymax (neat)/cm-1 3056, 2930, 1579, 1478, 1423, 
1354, 1248, 1023,908,740 and 690; 6H 2.02-2.15 (2 H, m, 2-H), 2.81 (2 H, t, J = 7.0, 3-H), 4.31 (2 
H, t,J =7.0, 1-H), 7.19-7.28 (9 H, m, ArH), 7.37-7.46 (4 H, m, ArH) and 7.71-7.75 (1 H, m, ArH); 
be 24.80 (2-C), 30.10 (3-C), 44.60 (1-C), 110.05 (ArCH), 120.32 (ArCH), 122.85 (ArCH), 123.68 
(ArCH), 127.65 (ArCH), 128.32 (ArCH), 129.76 (2 X ArCH), 129.87 (2 X ArCH), 131.07 (2 X 
ArCH), 133.37 (2 x ArCH), 129.81 (ArC), 132.27 (ArC), 136.18 (ArC), 143.75 (ArC) and 148.03 
(ArC); mlz El 424 (M+, 10 %), 356 (35), 225 (43), 199 (100). 
1-[ 4-(Phenylselanyl)butyl]-2-(phenylsulfanyl)-1H-benzo[ d]imidazole 16033 
(X)-sPh 
~SePh 
160 
1H-benzo[d]imidazol-2-yl phenyl sulfide 152 (0.96 g, 4.3 mmol) was added slowly to a suspension 
ofNaH (0.12 g, 5.0 mmol) in dry THF (190 mL). The mixture was stirred and heated under reflux 
for 1 hand 1-[(4-iodobutyl)selanyl]benzene 157 (1.44 g, 4.3 mmol) in THF (10 mL) was added 
dropwise to the reaction mixture. The mixture was heated under reflux for a further 2 h. The salts 
formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a brown oil, which was purified by column chromatography using neutral alumina as 
absorbent and light petroleum/ethyl acetate (4:1) as eluents to afford 1-[4-(phenylselanyl)butyl]-2-
(phenylsulfanyl)-IH-benzo[d]imidazole 160 as a pale yellow oil (1.0 g, 2.3 mmol, 54%); (Found: 
M+, 438.0664. C23H22N2SSerequires 438.0669); vmax (neat)/cm-1 3056,2934, 1579, 1477, 1461, 
1437, 1422, 1355, 1278, 1023, 1023,909 and 739; bH 1.66-1.69 (2 H, m, 3-H), 1.81-1.84 (2 H, m, 
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2-H), 2.84 (2 H, t, J = 7.0, 4-H), 4.23 (2 H, t, J = 7.0, 1-H), 7.22-7.26 (9 H, m, ArH), 7.27-7.43 (4 H, 
m, ArH) and 7.70-7.80 (1 H, m, ArH); be 27.16 (3-C), 27.23 (2-C), 29.51 (4-C), 44.19 (1-C), 
109.66 (benzimidazole 4-C), 120.04 (benzimidazole 7-C), 122.38 (benzimidazole 6-C), 123.24 
(benzimidazole 5-C), 127.08 (ArCH), 127.80 (ArCH), 129.09 (2 x ArCH), 129.45 (2 x ArCH), 
129.71 (ArC), 130.49 (2 X ArCH), 132.18 (ArC), 133.01 (2 X ArCH),135.73 (ArC), 143.41 (ArC) 
and 147.40 (benzimidazole 2-C); m/z El 438 (M+, 80 %), 281 (100), 239 (25), 172 (22), 109 (13) 
and 77 (27). 
2,3-Dihydro-1H -benzo[ d]pyrrolo[1,2-a ]imidazole 161111 
5 4 ~ai N~~a ~SaN 
8 9 2 1 
161 
Method A (thermal method, using tributyltin hydride and toluene) 
A solution of tri-n-butyltin hydride (0.83 mL, 3.1 mmol) in toluene (50 mL) was added to 1-[3-
(phenylselanyl)propyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 159 (0.60 g, 1.4 mmol) in toluene 
(150 mL) at reflux over 5 h using a syringe pump. AIBN (0.16 g, 1.4 mmol) was added to the 
refluxing reaction mixture at equal intervals. The solution was stirred and heated under reflux for a 
further 1 h. Dilute hydrochloric acid was added to the cooled reaction mixture to extract the 
protonated benzimidazole compounds into the aqueous layer and washed with light petroleum to 
remove Bu3Sn-residues. The acidic aqueous layer was basified with sodium carbonate and then 
aqueous sodium hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 
20 mL). The combined organic extracts were dried (MgS04) and evaporated to dryness to give a 
pale yellow oil crude product (0.20 g). The crude product was purified by column chromatography 
using silica gel as absorbent with light petroleum and ethyl acetate as eluents to give 2,3-dihydro-
1H-benzo[d]pyrrolo[1,2-a]imidazole 161 as white crystals (57 mg, 0.36 mmol, 25 %), mp 105-107 
°C (lit. Ill mp 114-115 °C); 6H 2.70 (2 H, quintet, J = 7.4, 2-H), 3.05 (2 H, t, J = 7.6, 3-C), 4.1 (2 H, 
t, J = 7.2, 1-C), 7.25-7.40 (3 H, m, ArH) and 7.67-7.73 (1 H, m, ArH). 
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Method B (uv irradiation, hexamethylditin and terl-butylbenzene) 
The reaction mixture of 1-[3-(phenylselanyl)propyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 159 
(89 mg, 0.21 mmol) and hexamethylditin (114 mg, 0.35 mmol) in tert-butylbenzene (10.0 mL) was 
irradiated with UV lamp at 85 °C for 30 h. Dil. hydrochloric acid was added to the cooled reaction 
mixture to extract the protonated benzimidazole compounds into the aqueous layer and washed with 
light petroleum to remove Bu3Sn-residues. The acidic aqueous layer was basified with sodium 
carbonate and aqueous sodium hydroxide (few drops) to pH 14. The basic solution was extracted 
with DCM (3 x 20 mL). The combined organic extracts were dried (MgS04) and evaporated to 
dryness. The crude product was purified by column chromatography using silica gel as absorbent 
with light petroleum and ethyl acetate as eluents to give 2,3-dihydro-1H-benzo[d]pyrrolo[1,2-
a ]imidazole 161 as white crystals (9 mg, 0.06 mmol, 26% ). The spectral data were identical to those 
of an authentic material. 
1,2,3,4-Tetrahydrobenzo[ 4,S]imidazo[1,2-a ]pyridine 162111 
6 Sa 5 7~NU4a4 8~N 3 9 1 
1 2 
162 
A solution of tri-n-butyltin hydride (0.68 mL, 2.5 mmol) in acetonitrile (50 mL) was added to 1-[4-
(phenylselanyl)butyl]-2-(phenylsulfanyl)-1H-benzo[d]imidazole 160 (0.50 g, 1.2 mmol) in 
acetonitrile (500 mL) at reflux over 5 h using a syringe pump. AMBN (0.24 g, 1.3 mmol) was 
added to refluxing reaction mixture at equal intervals. The solution was stirred and heated under 
reflux for a further 1 h. Dilute hydrochloric acid was added to the cooled reaction mixture to extract 
the protonated benzimidazole compounds into the aqueous layer and washed with light petroleum to 
remove Bu3Sn-residues. The acidic aqueous layer was basified with sodium carbonate and aqueous 
sodium hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). 
The combined organic extracts were dried (MgS04) and evaporated to dryness to yield white 
crystalline solid. The 1H NMR spectrum of the crude product showed the presence of cyclised 
product and traces of other impurities. The crude product was purified by column chromatography 
using neutral alumina as absorbent with light petroleum and ethyl acetate as eluents to give 1,2,3,4-
tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 as white crystals (121 mg, 0.70 mmol, 61%), mp 
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%-100 oc (lit.111 mp 99.8-100.1 °C); (Found: M+, 172.1003. CllH12N2 requires 172.1001); Vmax 
(KBr)/cm-1 1610, 1505, 1425, 1397, 1328, 1278, and 745; ()H 1.98-2.09 (2 H, m, 3-H), 2.10-2.13 (2 
H, m, 2-H), 3.09 (2 H, t, J = 7.0, 4-H), 4.06 (2 H, t, J = 7.0, 1-H), 7.21-7.30 (3 H,m, ArH) and 7.66-
7.69 (1 H, m, ArH); ~c 20.73 (3-C), 22.65 (2-C), 25.39 (4-C), 42.43 (1-C), 108.71 (6/9-C), 118.82 
(6/9-C), 121.67 (7/8-C), 122.10 (7/8-C), 134.51 (ArC, 7a), 142.65 (ArC, 3a) and 151.71 (4a-C); mlz 
El 172(M+, 100%), 144(28), 117(10)and77(8). 
2-Chloro-1-[ (3-phenylselanyl)propyl]-1H-benzo[ d) imidazole 164 
0)---cJ 
~Se Ph 
164 
2-Chlorobenzimidazole 163 (2.00 g, 13.1 mmol) was added slowly to NaH (0.33 g, 15.7 mmol) in 
dry THF (240 mL). The mixture was stirred and heated under reflux for 1 hand 1-[(3-
iodopropyl)selanyl]benzene (4.28 g, 13.1 mmol) in THF (10.0 mL) was added dropwise to the 
reaction mixture. The mixture was heated under reflux for a further 2 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan solid. 
The residue was purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (9: 1) as eluents to afford 2-chloro-1-[(3-phenylselanyl)propyl]-1H-
benzo[d]imidazole 164 as a pale yellow oil (2.79 g, 8.0 mmol, 61% ); (Found: M+, 350.0091. 
C16H15ClN2Se requires 350.0089); (Found: C, 55.38; H, 4.40; N, 7.94. requires C, 54.95; H, 4.32; N, 
8.01 %); vmax (neat)/cm-1 2930, 1615, 1578, 1469, 1450, 1375, 1329, 1247, 1154, 1022,761,740 
and 691; oH 2.12-2.33 (2 H, m, 2-H), 2.88 (2 H, t, J = 6.9, 3-H), 4.28 (2 H, t, J = 7.1, 1-H), 7.20-
7.23 (6 H, m, ArH), 7.43-7.45 (2 H, m, ArH) and 7.65-7.68 (1 H, m, ArH); oc 24.10 (2-C), 29.30 
(3-C), 43.81 (1-C), 109.36 (benzimidazole 417-C), 119.46 (benzimidazole 4/7-C), 122.67 
(benzimidazole 5/6-C), 123.17 (benzimidazole 5/6-C), 127.32 (ArCH), 129.09 (ArC), 129.22 (2 x 
ArCH), 132.97 (2 x ArCH), 134.99 (ArC), 140.35 (ArC) and 141.71 (benzimidazole 2-C); mlz El 
350 (M+, 43 %), 315 (55), 165 (62), 91 (100) and 77 (29). 
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2-Chloro-1-[(4-phenylselanyl)butyl]-lH-benzo[d]imidazole 165 
():)-c1 
~SePh 
165 
2-Chlorobenzimidazole 163 (2.50 g, 16.4 mmol) was added slowly to NaH (0.47 g, 19.7 mmol) in 
dry THF (240 mL). The mixture was stirred and heated under reflux for 1 h, and 1-[(4-
iodobutyl)selanyl]benzene (6.22 g, 13.1 mmol) in THF (10.0 mL) was added dropwise to the 
reaction mixture. The mixture was heated under reflux for a further 2 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan solid. 
The solid was purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (9:1) as eluents to afford 2-chloro-1-[(4-phenylselanyl)butyl]-1H-
benzo[d]imidazole 165 as a pale yellow oil (2.5 g, 6.87 mmol, 42 %); (Found: M+, 364.0250. 
C17H17ClN2Se requires 364.0246); vmax (neat)/cm-1 3033, 2936, 2860, 1615, 1579, 1469, 1446, 1379, 
1279, 1242, 1154, 1073, 1022, 911 and 739; oH 1.70-1.76 (2 H, m, 3-H), 1.94-2.00 (2 H, m, 2-H), 
2.90 (2 H, t, J = 7.1, 4-H), 4.18 (2 H, t, J = 7.1, 1-H), 7.23-7.28 (6 H, m, ArH), 7.41-7.46 (2 H, m, 
ArH) and 7.67-7.71 (1 H, m, ArH); f>c 27.01 (3-C), 27.20 (2-C), 29.16 (4-C), 43.94 (1-C), 109.38 
(benzimidazole 4/7-C), 119.55 (benzimidazole 417-C), 122.66 (benzimidazole 5/6-C), 123.14 
(benzimidazole 5/6-C), 127.16 (ArCH), 129.11 (2 x ArCH), 129.53 (ArC), 133.05 (2 x ArCH), 
134.94 (ArC, 3a), 140.43 (ArC, 7a) and 141.79 (benzimidazole 2-C); mlz El 364 (M+, 50%), 205 
(100), 165 (90), 129 (30) and 77 (28). 
2-Chloro-1-[ 5-(phenylselanyl)pentyl]-1H-benzo[ d]imidazole 166 
()c)-c1 
~SePh 
166 
2-Chlorobenzimidazole 163 (2.77 g, 18.2 mmol) was added slowly to a suspension of NaH (0.87 g, 
36.4 mmol) in dry THF (250 mL). The mixture was stirred and heated under reflux for 1 h and 1-
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[(5-iodopentyl)selanyl]benzene 158 (6.42 g, 18.2 mmol) in THF (10 mL) was added dropwise to the 
reaction mixture. The mixture was heated under reflux for a further 2 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan solid. 
The solid was purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (9:1) as eluents to afford 2-chloro-1-[5-(phenylselanyl)pentyl]-lH-
benzo[d]imidazole 166 as a pale yellow oil (3.53 g, 9.3 mmol, 51%); (Found: M+, 378.0405. 
C18H19ClN2Se requires 378.0402); vmax (neat)/cm·1 3054, 2934, 1615, 1578, 1469, 1447, 1379, 1352, 
1272, 1235, 1022 and 741; ()H 1.35-1.42 (2 H, m, 3-H), 1.62-1.78 (4 H, m, 2-H and 4-H), 2.91 (2 H, 
t, J = 7.4, 5-H), 4.23 (2 H, t, J = 7.0, 1-H), 7.23-7.30 (6 H, m, ArH and 6-H), 7.41-7.44 (2 H, m, 5-H 
and 7-H) and 7.58-7.60 (1 H, m, 4-H); be 26.77 (4-C), 27.43 (3-C), 28.83 (2-C), 29.75 (5-C), 44.29 
(1-C), 109.37 (benzimidazole 4/7-C), 119.54 (benzimidazole 417-C), 122.63 (benzimidazole 5/6-C), 
123.10 (benzimidazole 5/6-C), 126.91 (ArCH), 129.08 (2 x ArCH), 130.13 (ArC), 132.70 (2 x 
ArCH), 134.99 (7a-C), 140.50 (3a-C) and 141.80 (benzimidazole 2-C); mlz El 378 (M+, 20 %), 343 
(8), 262 (48), 158 (68), 77 (48) and 69 (100). 
Radical cyclisation of 2-chloro-1-[(3-phenylselanyl)propyl]-1H-benzo[d]imidazole 164 
5 ~ 4 6a1 N~~a 7'::::::-... N 
8 Sa 9 
1 2 
161 
167 
A solution of tributyltin hydride (0.74 mL, 2.8 mmol) in toluene (50 mL) was added to 2-chloro-1-
[(3-phenylselanyl)propyl]-lH-benzo[d]imidazole 164 (0.64 g, 1.8 mmol) in toluene (150 mL) at 
reflux over 7 h using a syringe pump. AIBN (149 mg, 0.92 mmol) was added to refluxing reaction 
mixture at equal intervals. The solution was stirred and heated under reflux for a further 1 h. Dil. 
hydrochloric acid was added to the cooled reaction mixture to extract the protonated benzimidazole 
compounds into the aqueous layer and washed with light petroleum to remove B11:3Sn-residues. The 
acidic aqueous layer was basified with sodium carbonate and aqueous sodium hydroxide (few drops) 
to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The combined organic extracts 
were dried (MgS04) and evaporated to dryness to give a pale yellow oil. The 1H NMR spectrum of 
the crude product showed the presence of reduced and the cyclised products (8: 1) ratio. The crude 
mixture was purified by column chromatography using neutral alumina as absorbent and light 
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petroleurn/EtOAc (9:1) as eluents to yield 2,3-dihydro-1H-benzo[d]pyrrolo[l,2-a]imidazole 161 as 
pure white crystals (28 mg, 0.18 mmol, 10 %); ()H 2.70 (2 H, quintet, J = 7.4, 2-H), 3.05 (2 H, t, J = 
7.6, 3-H), 4.1 (2 H, t, J = 7.2, 1-C), 7.25-7.40 (3 H, m, ArH) and 7.67-7.73 (1 H, m, ArH). And 2-
chloro-1-propyl-1H-benzo[d]imidazole 167 was obtained as a pale yellow oil (0.18 g, 0.93 mmol, 51 
%); (Found: M+, 194.0611. C,JI11N2Cl requires 194.0607); vmax (neat)/cm·' 3057,2967,2879, 
1616, 1469, 1445, 1375, 1330, 1281, 1244, 1216, 1131, 1008, 762 and 742; ~ 0.96 (3 H, t, J = 7.5, 
CH3), 1.85 (2 H, septet, J = 7.4, 2-H), 4.12 (2 H, t, J = 7.2, 1-H), 7.23-7.30 (3 H, m, ArH) and 7.66-
7.70 (1 H, m, ArH); ()c 1.21 (CH3), 22.66 (CH2), 45.95 (NCH2), 109.49 (ArCH), 119.41 (ArCH), 
122.51 (ArCH), 123.19 (ArCH), 135.04(ArC, 7a/3a), 140.58 (ArC, 3a/7a) and 141.70 (ArC, 2-C); 
mlz El 194 (M+, 67 %), 165 (100), 152 (24), 129 (22), 90 (10) and 77 (9). 
Tributylgermanium hydride85 
Tetrachlorogermanium (5.00 g, 23.3 mmol) and butylmagnesium chloride (2 M solution in diethyl 
ether, 57 mL) were dropwise added to a solution of Cp2TiC12 (0.43 g, 1.7 mmol) in freshly distilled 
diethyl ether ( 140 mL) at -78 °C over 45 min. The mixture was allowed to warm up to rt over 45 
min during which period a colour change from milky red to green was observed and thereafter 
refluxed for 15 h. After cooling to 0 °C aqueous hydrochloric acid (2 M, 57 mL) was added over 1 
h and a colour change to red was observed. The organic layer was separated and the aqueous phase 
was extracted with ether. The combined organic layer was dried (MgS04) and evaporated to 
dryness to give a liquid which was filtered through celite to remove a red solid. Distillation under 
reduced pressure gave tributylgermanium hydride as a colourless oil (5.41 g, 22.1 mmol, 95 %). 
The spectral data corresponds to that stated in literature.82 ()H 0.82-0.92 (15 H, m, 1-H and 4-H), 
1.34-1.43 (12 H, m, 2-H and 3-H) and 3.68 (1 H, sep, J = 2.8, GeH). 
1-(4-Bromobutyl)-2-chloro-1H-benzo[d]imidazole 168 
(X)-c1 
~Br 
168 
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2-Chlorobenzimidazole 163 (2.00 g, 13.1 mmol) was added slowly to a suspension of sodium 
hydride (0.47 g, 19.6 mol) in dry DMF (20 mL). The mixture was stirred for 1 hand 1,4-
dibromobutane (3.57 mL, 26.2 mmol) in DMF (10 mL) was added dropwise to the reaction mixture 
and it was stirred for 20 h. The reaction mixture was evaporated to dryness. The solid was purified 
by column chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate 
(9:1) as eluents to afford 1-(4-bromobutyl)-2-chloro-1H-benzo[d]imidazole 168 as a pale yellow oil 
(3.60 g, 12.5 mmol, 95% ); (Found: MH+, 286.9946. C11H12BrClN2 requires 286.9950); vmax 
(neat)/cm-1 2950, 2369, 1705, 1614, 1469, 1446, 1376, 1279, 1243, 1152, 1143, 1008 and 743; bH 
1.90-1.95 (2 H, m, CH2), 2.01-2.05 (2 H, m, CH2), 3.42 (2 H, t, J = 8.0, BrCHz), 4.24 (2 H, t, J = 8.0, 
NCH2), 7.27-7.32 (3 H, m, ArH) and 7.70-7.71 (1 H, m, ArH); be 27.92 (CH2), 29.54 (CH2), 32.55 
(BrCH2), 43.63 (NCH2), 109.35 (benzimidazole 417-C), 119.60 (benzimidazole 417-C), 122.79 
(benzimidazole 5/6-C), 123.28 (benzimidazole 5/6-C), 134.86 (ArC), 140.38 (ArC) and 141.73 
(ArC); mlz El 286 (M+, 35 %), 209 (18), 165 (100), 129 (54), 102 (48), 90 (52), 77 (34) and 55 (45). 
Radical cyclisation of 1-(4-bromobutyl)-2-chloro-1H-benzo[d]imidazole 168 
6 5a 5 7~NU4a4 8~N 3 9 1 
1 2 
162 
Tributylgermanium hydride (0.56 mL, 2.16 mmol) was added to 1-(4-bromobutyl)-2-chloro-1H-
benzo[d]imidazole 168 (0.31 g, 1.1 mmol) in toluene (100 mL), followed by portion wise addition 
of AIBN (0.35 g, 2.2 mmol) to the refluxing reaction mixture at equal intervals. The solution was 
stirred and heated under reflux for 12 h. The reaction mixture was evaporated to dryness. The 
crude product was purified by column chromatography using neutral alumina as absorbent with light 
petroleum and ethyl acetate as eluents to give 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 
162 as white crystals (0.10 g, 0.58 mmol, 54%); vmax (KBr)/cm-1 1610, 1505, 1425, 1397, 1328, 
1278, and 745; ()H 1.98-2.09 (2 H, m, 3-H), 2.10-2.13 (2 H, m, 2-H), 3.09 (2 H, t, J = 7.0, 4-H), 4.06 
(2 H, t, J = 7.0, 1-H), 7.21-7.30 (3 H,m, ArH) and 7.66-7.69 (1 H, m, ArH). 
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1H-Imidazole-2-yl pyridin-2-yl sulfide 174 
3 3 4 
4r(N _:d\ 
gL ~s~.Js 
N1 N 6 H 1 
174 
A mixture of 2-mercaptoimidazole 173 (2.00g, 20.0 mmol), 2-chloropyridine (1.89 mL, 20.0 mmol) 
and anhydrous K2C03 (7.00 g, 50.7 mmol) in DMF (70 mL) was heated at reflux for 12 h. The 
reaction mixture was evaporated to dryness and the crude product was purified by column 
chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate (1: 1) as 
eluents to afford 1H-imidazole-2-yl pyridin-2-yl sulfide 174 as white crystals (3.36 g ,19.0 mmol, 
95%), mp 97.8-99.5 oc; (Found: M+, 177.0361. C8H7N3S requires 177.0361); vmax (KBr)/cm1 3000, 
2994, 2624, 2374, 1849, 1560, 1448, 1419, 1330, 1122, 966,756 and 720; ()H 6.78 (1 H, d, J = 7.8, 
3-H), 6.93 (1 H, dd, J = 7.8 and 7.8, 5-H), 7.11 (2 H, s, imidazole 5-H and 4-H), 7.38 (1 H, ddd, J = 
7.8, 7.8 and 1.6, 4-H) and 8.29 (1 H, d, J = 4.8, 6-H); be 120.48 (3-C), 121.41 (5-C), 125.05 (4-C), 
134.46 (imidazole 2-C), 137.13 (imidazole 4-C), 137.23 (imidazole 5-C), 148.94 (imidazole 6-C) 
and 159.06 (2-C); mlz El 177 (M+, 100 %), 167 (8), 145 (9), 133 (13), 119 (42), 110 (25), 84 (25) 
and 78(57). 
1-[4-(Phenylselanyl)butyl]-1H-imidazole-2-yl pyridin-2-yl sulfide 175 
3 3 4 J:N~s-Qs 
N1 N 6 ~SePh 
175 
1H-Imidazole-2-yl pyridin-2-yl sulfide 174 (0.45 g, 2.5 mmol) was added slowly to NaH (0.12 g, 
5.1 mmol) in dry THF (90 mL). The mixture was stirred and heated under reflux for 1 hand 1-[(4-
iodobutyl)selanyl]benzene 157 (0.86 g, 2.5 mmol) in THF (10.0 mL) was added dropwise to the 
reaction mixture. The mixture was heated under reflux for a further 24 h. The salts formed were 
removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan solid. 
The residue was purified by column chromatography using neutral alumina as absorbent and light 
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petroleum/ethyl acetate (3:1) and (1:1) as eluents to afford 1-[4-(phenylselanyl)butyl]-1H-imidazole-
2-yl pyridin-2-yl sulfide 175 as a dark brown oil (0.98 g, 2.51 mmol, 99 %); (Found: M+, 389.0465. 
C18H1~3SSe requires 389.0455); vmax (neat)/cm-1 2934, 2101, 1606, 1574, 1477, 1449, 1418, 1277, 
1120, 916, 760, 738 and 692; bH 1.57-1.64 (2 H, m, CH2), 1.78-1.86 (2 H, m, CH2), 2.79 (2 H, t, J = 
7.2, PhSeCH2), 4.02 (2 H, t, J = 7.2, NCH2), 6.84 (1 H, d, J = 8.4, 3-H), 6.99 (1 H,ddd, J = 7.5, 7.5 
and 0.8, 5-H), 7.12 (1 H, d, J = 1.2, imidazole 4-H or 5-H), 7.22-7.25 (4 H, m, ArH), 7.39-7.47 (3 H, 
. m, ArH) and 8.36 (1 H, dd, J = 4.8 and 1.2, 6-H); l)c 26.80 (CH2), 27.01 (PhSe CHJ, 30.70 (CH2), 
46.57 (NCH2), 120.55 (pyridine 3-C), 121.12 (pyridine 5-C), 122.78 (imidazole 4-C), 126.% 
(ArCH), 128.98 (ArCH), 129.06 (ArCH), 129.78 (ArC), 130.95 (imidazole 5-C), 133.47 (2 x 
ArCH), 135.45 (imidazole 2-C), 137.03 (pyridine 4-C), 149.66 (pyridine 6-C) and 159.12 (pyridine 
2-C); mlz El 389 (M+, 3 %), 370 (5), 312 (12), 279 (65), 254 (15), 232 (32), 213 (28), 177 (45), 157 
(32), 122 (85), 91 (45) and 73 (100). 
1H-Benzo[d]imidazole-2-yl pyridin-2-yl sulfide 177 
:a4 1 ~~s_2{-=)s ~?a N1 ~---{ 
7 H 1 
177 
A mixture of2-mercaptobenzimidazole 176 (2.0 g, 13.3 mmol), 2-chloropyridine (1.26 mL, 13.3 
mmol) and anhydrous K2C03 (10.0 g, 72.4 mmol) in DMF (70 mL) was heated at reflux for 12 h. 
The reaction mixture was evaporated to dryness and the crude product was purified by column 
chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate (1:1) as 
eluents to afford 1H-benzo[d]imidazole-2-yl pyridin-2-yl sulfide 177 as white crystals (1.21 g, 5.3 
mmol, 40 %), mp 145-147 oc; (Found: M+, 227.0519. C12H9N3S requires 227.0517); vmax (KBr)/cm-
1 3057, 2951, 2773, 2593, 2372, 1847, 1567, 1413, 1274, 1117, 984 and 748; ~ 7.07 (1 H, dd, J = 
6.7 and 6.7, pyridine 5-H), 7.20-7.26 (3 H, m, ArH), 7.52 (1H, dd, J = 6.7 and 6.7, pyridine 4-H), 
7.58-7.60 (2 H, m, ArH) and 8.46 (1 H, d, J = 4.15, pyridine 6-H); be 114.75 (pyridine 3-C), 121.46 
(417-C), 122.51 (pyridine 5-C), 123.33 (5/6-C), 137.32 (pyridine 4-C), 138.50 (3a-C and 7a-C), 
146.20 (2-C), 149.17 (pyridine 6-C) and 155.47 (pyridine 2-C); m/z El 227 (M+, 100 %), 194 (6), 
169 (94), 149 (11), 122 (24), 91 (13) and 78 (42). 
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1-But-3-enyl-1H-imidazole-2-yl pyridin-2-yl sulfide 178 
A solution of tributyltin hydride (0.12 mL, 0.45 mmol) in toluene (50 mL) was added to 1-[4-
(phenylselanyl)butyl]-1H-imidazole-2-yl pyridin-2-yl sulfide 175 ( 116 mg, 0.29 mmol) in toluene 
(200 mL) at reflux over 10 h using a syringe pump. AIBN ( 48 mg, 0.3 mmol) was added to 
refluxing reaction mixture at equal intervals. The solution was stirred and heated under reflux for a 
further 1 h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the 
protonated imidazole compounds into the aqueous layer and washed with light petroleum to remove 
BU:3Sn-residues. The acidic aqueous layer was basified with sodium carbonate and then sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness to afford 1-[4-
(phenylselanyl)butyl]-1H-imidazole-2-yl pyridin-2-yl sulfide 175 as a dark brown oil (23 mg, 0.06 
mmol, 20 %) and 1-(but-3-enyl)-1H-imidazole-2-yl pyridin-2-yl sulfide 178 as a dark brown oil (39 
mg, 0.17 mmol, 60 %); (Found: M+, 231.0835. C12H13N3S requires 231.0830); vmax (neat)/cm-1 
3468,3106,2977,2932, 1682, 1574, 1561, 1449, 1418, 1278, 1119,978,917,761,721 and 618; ba 
2.44 (2 H, q, J = 7.1, CH2), 4.13 (2 H, t, J = 7.1, NCH2}, 4.99 (2 H, m, 4-H), 5.68 (1 H, m, 3-H), 6.86 
(1 H, d, J = 8.1, pyridine 3-H}, 7.03 (1 H, dd, J = 6.82 and 6.82, pyridine 5-H), 7.17 (1 H, s, 
imidazole 4-H), 7.26 (1 H, s, imidazole 5-H), 7.45 (1 H, ddd, J = 7.8, 7,8 and 2.1, pyridine 4-H) and 
8.39 (1 H, d, J = 4.6, pyridine 6-H); be 35.21 (CH2), 46.73 (NCHz}, 118.20 (4-C), 120.77 (imidazole 
4-C), 121.22 (imidazole 5-C), 123.23 (pyridine 3-C}, 130.95 (pyridine 5-C), 133.48 (3-C), 135.52 
(imidazole 2-C), 137.07 (pyridine 4-C), 149.71 (pyridine 6-C) and 159.10 (pyridine 2-C); mlz El 
231 (M+, 32 %), 198 (16), 177 (100), 153 (25), 121 (82), 78 (88) and 59 (57). 
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5,6, 7,8-Tetrahydroimidazo[ 1,2-a ]pyridine 18W3 
2 ~ 3(l)aa 
4N 8 
5 7 
6 
180 
To a solution of 1-[4-(phenylselanyl)butyl]-1H-imidazole-2-yl pyridin-2-yl sulfide 175 (59 mg, 0.15 
mmol) in anhydrous benzene (25 mL), TTMSS (0.06 mL, 0.2 mmol) and E~B (1.0 M in 
cyclohexane, 0.3 mmol) were added dropwise. The flask was fitted with a rubber septum and air 
was introduced through a needle during stirring at rt for 5 h. Further addition of TTMSS (0.06 mL, 
0.2 mmol) and E~B (1.0 M in hexane, 0.3 mmol) were carried out and the reaction mixture was 
stirred for another 10 h. Dilute hydrochloric acid was added to the cooled reaction mixture to 
extract the protonated imidazole compounds into the aqueous layer and washed with light petroleum 
to remove Bu3Sn-residues. The acidic aqueous layer was basified with sodium carbonate and 
aqueous sodium hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 
20 mL). The combined organic extracts were dried (MgS04) and evaporated to dryness to afford 
5,6,7,8-tetrahydroimidazo[l,2-a]pyridine 180 (0.014 mmol, 9 %). The yield was determined by 1H 
NMR spectroscopy using the internal standard. 
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EXPERIMENTAL FOR CHAPTER THREE 
Methyi2-(1H-benzo[d]imidazol-2-ylsulfanyl)ethanoate 181 
~N~s o ~~ y 
181 0-
Acetyl chloride (12.0 mL, 168.8 mmol) was added dropwise over 10 min to MeOH (50 mL) cooled 
in ice. The solution was stirred for 5 min, (2-benzimidazolylsulfanyl)acetic acid 187 (2.0 g, 9.6 
mmol) was added in one portion and the solution slowly heated to reflux. Heating under reflux was 
continued overnight. The reaction mixture was cooled and evaporated to dryness to give the crude 
methyl ester. Distilled water (50 mL) was added to the crude methyl ester hydrochloride and the 
acidic solution was washed with DCM (2 x 50 mL). The aqueous layer contained benzimidazole 
compounds and was basified to pH 14 with sodium carbonate and 1 M sodium hydroxide (few 
drops). The basic solution was extracted with DCM (3 x 50 mL). The combined organic extracts 
were dried (MgS04) and evaporated to dryness to afford methyl 2-(1H-benzo[d]imidazo1-2-
ylsulfanyl)ethanoate 181 as off white crystals (1.86 g, 8.4 mmol, '8:7 %), mp 114-117 °C; (Found: 
M+, 222.0467. CIJIION202S requires 222.0463); vmax (Nujol)/cm·l 2923,2853, 1743, 1459, 1376 
and 1165; bH 3.78 (3 H, s, OCH3), 4.01 (2 H, s, CH2), 7.19-7.26 (2 H, m, ArH) and 7.51-7.53 (2 H, 
m, ArH); be 34.30 (CH2), 53.20 (OCH3), 114.48 (2 x ArCH), 122.29 (ArCH), 122.60 (ArCH), 
139.19 (2 x ArC), 148.31 (ArC 2-C) and 170.90 (C=O); m/z El 222 (M+, 54%), 221 (58), 190 (50), 
163 (100), 149 (32) and 118 (38). 
Attempted synthesis of methy12-[(1-methyl-1H-benzo[d]imidazol-2-yl)sulfanyl]ethanoate 188 
Methyl2-(1H-benzo[d]imidazol-2-ylsulfanyl)ethanoate 181 (0.20 g, 0.9 mmol) was added slowly to 
a suspension of NaH (26 mg, 1.08 mmol) in dry THF (60 mL), followed by dropwise addition of 
Mel (0.06 mL, 0.9 mmol). The mixture was stirred and heated under reflux for 3 h. The salts 
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formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a colourless oil, crude product contained non-isolable species by chromatography. 
2-Chloro-1-( triphenylmethyl)-1H-benzo[ d]imidazole 193 
(Jc)-c1 
\ 
193 CPh3 
2-Chlorobenzimidazole 163 (1.96 g, 12.9 mmol) was dissolved in DCM (200 mL). Triphenylmethyl 
chloride ( 4.30 g, 15.4 mmol) was added over 20 min and the mixture stirred until the solution was 
complete. Triethylamine (2.58 mL, 18.5 mmol) was added slowly to the stirred solution and the 
stirring was continued overnight at ambient temperature. The solution was evaporated to dryness to 
give the crude product. The crude product was purified by column chromatography using neutral 
silica as absorbent with light petroleum and EtOAc as eluents to afford 2-chloro-1-
(triphenylmethyl)-1H-benzo[d]imidazole 193 as white needles (1.50 g, 3.9 mmol, 30 %), mp 157-
160 °C; (Found: M+, 395.1315. C2Jf19CIN2 requires 395.1315); (Found: C, 79.25; H, 4.91; N, 6.48. 
Cz6H19ClN2 requires C, 79.08; H, 4.85; N, 7.09 %); Vmax (KBr)/cm-1 3061,2369, 1482, 1442, 1274, 
1023,749 and 701; oH 5.70 (1 H, d, J = 8.8, 417-H), 6.85 (1 H, dd, J = 7.9 and 7.9, 5/6-H), 7.15 (1 
H, dd, J = 7.6 and 7.6, 5/6-H), 7.26-7.36 (15 H, m, ArH) and 7.66 (1 H, d, J = 8.1, 417-H); be 
114.61(benzimidazole 417-C), 119.36 (benzimidazole 417-C), 122.27 (benzimidazole 5/6-C), 122.55 
(benzimidazole 5/6-C), 127.83 (3 x ArCH), 127.93 (6 x ArCH), 130.22 (6 x ArCH), 136.75 (ArC), 
141.76 (3 x ArC), 142.07 (ArC) and 142.97 (benzimidazole 2-C); mlz FAB 395 (M+, 12 %), 243 
c+CPh3, 100), 165 (20) and 136 (17). 
2-Chloro-1-methyi-1H -benzo[ d]imidazole 195 
(Jc)-c1 
195 \ 
2-Chlorobenzimidazole 163 (2.0 g, 13.1 mmol) was added slowly to NaH (0.47 g, 19.7 mmol) in dry 
THF (150 mL). The mixture was stirred and heated under reflux for 1 h and methyl iodide (0.82 
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mL, 13.1 mmol) in THF (10.0 mL) was added dropwise to the reaction mixture. The mixture was 
heated under reflux for a further 2 h. The salts formed were removed by filtration on a celite bed 
and the solution was evaporated to dryness to yield a white solid. The solid was purified by column 
chromatography using neutral alumina as absorbent with light petroleum and EtOAc as eluent to 
afford 2-chloro-1-methyl-1H-benzo[d]imidazole 195 as white crystals (1.40 g, 8.4 mmol, 64 %), mp 
114-117 oc (lit.5 mp 114-116 °C); (Found: M+, 166.0297. CgH7ClN2 requires 166.0298); (Found: 
C, 58.04; H, 4.41; N, 16.22. C8H7ClN2 requires C, 57.67; H, 4.23; N, 16.81 %); vmax (KBr)/cm·1 
3054, 2928, 1616, 1474, 1428, 1368, 1349, 1330, 1115, 1006 and 735; ()H 3.78 (3 H, s, CH3), 7.26-
7.31 (3 H, m, ArH) and 7.68-7.70 (1 H, d, J = 8.4, ArH); Oc 30.50 (CH3), 109.23 (benzimidazole 
417-C), 119.43 (benzimidazole 417-C), 122.70 (benzimidazole 5/6-C), 123.13 (benzimidazole 5/6-
C), 135.67 (3a/7a-C), 140.97 (3a/7a-C), 141.70 (2-C); mlz El 166 (M+, 100 %), 129 (15), 90 (14) 
and 77(19). 
1-Methyl-1H-benzo[d]imidazol-2-yl phenyl sulfide 196 
(X}-sPh 
196 \ 
Benzenesulfanyll (0.31 mL, 3.0 mmol) was dissolved in EtOH (30 mL) containing KOH (0.17 g, 3.0 
mmol) and the mixture was left stirring for 5 min. 2-Chloro-1-methyl-1H-benzimidazole 195 (0.50 
g, 3.0 mmol) was added to the reaction mixture and the reaction mixture was heated under reflux for 
18 h. The reaction mixture was filtered and evaporated to dryness to give 1-methyl-1H-
benzo[d]imidazol-2-yl phenyl sulfide 196 as white crystals (0.62 g, 2.6 mmol, 85 % ), mp 66-69 oc; 
(Found: M+, 240.0726. cl4H12N2S requires 240.0721); Vmax (KBr)/cm"1 2373, 1577, 1441, 1409, 
1324, 1276, 1078 and 739; C>H 3.69 (3 H, m, CH3), 7.20-7.29 (6 H, m, ArH), 7.34 (2 H, dd, J = 8.2 
and 1.1, ArH) and 7.75-7.77 (1 H, m, ArH); be 30.72 (CH3), 109.45 (benzimidazole 417-C), 119.83 
(benzimidazole 417-C), 122.38 (benzimidazole 5/6-C), 123.23 (benzimidazole 5/6-C), 127.62 
(ArCH), 129.43 (2 x ArCH), 130.17 (2 x ArCH), 132.15 (benzimidazole 3a/7a-C), 136.47 
(benzimidazole 3a/7a-C), 143.12 (ArC) and 147.58 (benzimidazole 2-C); m/z El 239 (M+, 100 %), 
224 (11), 207 (14), 91 (14) and 77 (15). 
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1H-Benzo[d]imidazol-2-yl phenyl sulfide 152110 
()c)-SPh 
H 
152 
PhSH (0.61 mL, 6.8 mmol) was dissolved in EtOH (18 mL) followed by KOH (0.35 g, 6.2 mmol) 
and the mixture was stirred for 5 min. 2-Chlorobenzimidazole 163 (1.0 g, 6.6 mmol) was added to 
the reaction mixture which was heated at reflux for 6 h. The reaction mixture was filtered and 
evaporated to give the crude product as a pale yellow crystalline powder. The crude product was 
purified by column chromatography using alumina as absorbent with light petroleum and ethyl 
acetate (4:1) as eluents to afford 1H-benzo[d]imidazol-2-yl phenyl sulfide 152 as white crystals 
(0.98 g, 4.3 mmol, 66 %), mp 202-205 oc (lit.1, mp 201.5-202.5 °C); (Found: M+, 226.0559. 
C13H10N2S requires 226.0565); vmax (KBr)/cm-1 1617, 1510, 1412, 1348, 1265, 1233,977,739 and 
686; l>iDMSO) 7.15-7.51 (9 H, m, ArH); mlz El 226 (M+ 60 %), 225 (100), 192 (10), 167 (5), 77 
(8). 
4-(lH-Benzo[ d]imidazol-2-ylsulfanyl)benzene-1-carboxylic acid 190 
a43N3 32 : ~S~COOH 7 7a ~1 5 6 
190 
4-Mercaptobenzoic acid 189 (1.05 mL, 6.8 mmol) was dissolved in EtOH (30 mL) followed by 
KOH (0.35 g, 6.2 mmol) and the mixture was stirred for 5 min. 2-Chlorobenzimidazole 163 (1.00 g, 
6.6 mmol) was added to the reaction mixture and the reaction mixture was heated under reflux 
overnight. The reaction mixture was filtered and evaporated to dryness to give the crude product as 
a pale yellow crystalline powder which was recrystallised from methanol to give 4-(lH-
benzo[d]imidazol-2-ylsulfanyl)benzene-1-carboxylic acid 190 as off-white crystals (1.20 g, 4.4 
mmol, 68 %), mp 270-275 °C; (Found: MH+, 271.0541. C14H1oN20 2S requires 271.0544); vmax 
(DCM slurry)/cm-1 3500, 3054, 2987, 1690, 1593, 1567, 1506, 1423 and 1265; 6H(DMSO) 7.23-
7.26 (2 H, m, benzimidazole 5-H and 6-H), 7.50-7.53 (2 H, d, J = 8.2, 3-H and 5-H), 7.50-7.70 (2 H, 
m, benzimidazole, 4-H, 7-H) and 7.93-7.96 (2 H, d, J = 8.3, 2-H and 6-H); i>c(DMSO) 122.0 
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(benzimidazole 4-C and 7-C), 126.48 (benzimidazole 5-C and 6-C), 129.54 (3-C and 5-C), 130.10 
(1-C), 130.61 (2-C and 6-C), 138.56 (4-C), 144.79 (benzimidazole 2-C) and 167.08 (C=O); mlz El 
270 (M+, 72 %), 269 (100), 225 (15), 150 (16), 77 (18) and 44 (91). 
4-( { 1-[3-Phenylselanyl)propyl]-1H-benzo[ d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 
197 
~ 3aN _ 4 3 -V-
aN)Ls ~ ,f CO,H 
7 7a1~ 5 6 
Se Ph 
197 
4-Mercaptobenzoic acid 189 (0.34 g, 2.2 mmol) was dissolved in EtOH (25 mL) followed by KOH 
(0.11 g, 2.03 mmol) and the mixture was stirred for 5 min. 2-Chloro-1-[(3-phenylselanyl)propyl]-
1H-benzo[d]imidazole 164 (0.74 g, 2.1 mmol) was added to the reaction mixture and the reaction 
mixture was heated under reflux 18 h. The reaction mixture was filtered and evaporated to dryness 
to give the crude product as a pale yellow crystalline powder. The solid was recrystallised from 
methanol to give 4-( {1-[3-phenylselanyl)propyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-
carboxylic acid 197 as off-white crystals (0.60 g, 1.3 mmol, 61 %), mp 158.5-159.9 oc; (Found: 
M+, 468.0416. C23H2oN20 2SSe requires 468.0411); (Found: C, 58.79; H, 4.28; N, 6.00. 
C23H2oN20 2SSe requires C, 59.10; H, 4.31; N, 5.99 %); vmax (KBr)/cm-1 3200,3000,2472,2346, 
1924,1701,1654,1594,1560,1476,1465,1420,1382,1270,1251,1169, 1016,860,764and747; 
<>H 2.19-2.25 (2 H, m, CH2), 2.94 (2 H, t, J = 6.8, PhSeCH2), 4.37 (2 H, t, J = 7.1, NCHz), 7.24-7.33 
(6 H, m, ArH), 7.48-7.52 (2 H, m, ArH), 7.55 (2 H, dd, J = 7.2, 1.2, 3-H and 5-H), 7.72-7.76 (1H, m, 
ArH) and 7.90 (2 H, dd, J = 7.2, 1.2, 2-H and 6-H); <>c 24.38 (CH2), 29.71 (PhSeCH2), 44.12 
(NCH2), 109.27 (benzimidazole 417-C), 118.65 (benzimidazole 417-C), 122.94 (benzimidazole 5/6-
C), 123.23 (benzimidazole5/6-C), 127.44(ArCH), 129.15(ArC), 129.31 (2xArCH), 131.13 (2x 
ArCH), 131.97 (ArC), 133.13 (2 X ArCH), 133.38 (2 X ArCH),133.46 (ArC), 135.39 (ArC), 142.22 
(ArC), 149.63 (ArC) and 167.81 (C=O); mlz FAB 468 (M+, 8 %), 329 (11), 307 (45), 289 (35), 176 
(48), 154 (100) and 107 (85). 
129 
4-({1-[4-Phenylselanyl)butyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 
198 
198 
4-Mercaptobenzoic acid 189 (0.33 g, 2.1 mmol) was dissolved in EtOH (30 mL) followed by KOH 
(0.37 g, 3.3 mmol) and the mixture was stirred for 5 min. 2-Chloro-1-[(4-phenylselanyl)butyl]-1H-
benzo[d]imidazole 165 (0.79 g, 2.2 mmol) was added to the reaction mixture and the reaction 
mixture was heated under reflux overnight. The reaction mixture was filtered and evaporated to 
dryness to give the crude product as a pale yellow crystalline powder which was recrystallised from 
methanol to give 4-( { 1-[4-phenylselanyl)butyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-
carboxylic acid 198 as off-white crystals (1.00 g, 2.1 mmol, 98 %), mp 104-108 °C; (Found: M+, 
482.0578. C24H22N20 2SSe requires 482.0568); vmax (.KBr)/cm-1 3448, 3055, 2930, 2479, 2374, 1896, 
1701, 1461, 1385, 1263, 1170, 1015,747 and 693; <>H(DMSO) 1.53-1.61 (2 H, m, CH2), 1.75-1.83 
(2 H, m, CH2), 2.88 (H, t, J = 7.2, PhSeCH2), 4.29 (2 H, t, J = 7.0, NCH2), 7.22-7.36 (8 H, m, ArH), 
7.39 (2 H, d, J = 8.4, 3-H and 5-H), 7.61-7.68 (1 H, m, ArH) and 7.90 (2 H, d, J = 8.4, 2-H and 6-
H); oc(DMSO) 26.51 (CH2), 26.91 (CH2), 29.56 (PhSeCH2), 44.03 (NCH2), 111.19 (benzimidazole 
4/7-C), 119.50 (benzimidazole 417-C), 122.62 (benzimidazole 5/6-C), 123.57 (benzimidazole 5/6-
C), 126.93 (ArCH), 129.29 (2 X ArCH), 129.51 (2 X ArCH), 130.08 (ArC), 130.59 (2 X ArCH), 
131.93 (ArCH), 131.98 (ArCH), 135.98 (ArC), 137.34 (ArC), 143.17 (ArC), 145.78 (ArC) and 
167.35 (C=O); mlz FAB 482 (M+, 10 %), 393 (10), 322 (22), 281 (12), 213 (24), 192 (20), 154 (75) 
and 136 (100). 
4-({1-[5-Phenylselanyl)pentyl]-1H-benzo[d]imidazole-2-yl}sulfanyl)benzene-1-carboxylic acid 
199 
199 
130 
4-Mercaptobenzoic acid 189 (1.27 g, 8.2 mmol) was dissolved in EtOH (40 mL) followed by 
potassium tert-butoxide (1.39 g, 12.4 mmol) and the mixture was stirred for 5 min. 2-Chloro-1-[5-
(phenylselanyl)pentyl]-1H-benzo[d]imidazole 166 (3.12 g, 8.3 mmol) was added to the reaction 
mixture and the reaction mixture was heated under reflux overnight. The reaction mixture was 
filtered and evaporated to dryness to give 4-( {1-[5-phenylselanyl)pentyl]-1H-benzo[d]imidazole-2-
yl}sulfanyl)benzene-1-carboxylic acid 199 as off-white sticky gum (4.00 g, 8.1 mmol, 98 %); 
(Found: M+, 496.0716. C25H24N20 2SSe requires 496.0724); vmax (KBr)/cm-1 3379, 3047, 2922, 1927, 
1693, 1590, 1546, 1383, 1268, 1012, 839 and 739; bH(DMSO) 1.29-1.37 (2 H, m, CH2), 1.55-1.70 
(4 H, m, CH2CH2), 2.86 (2 H, t, J = 7.2, PhSeCH2), 4.24 (2 H, t, J = 7.2, NCH2), 7.21-7.28 (5 H, m, 
ArH), 7.32 (2 H, d, J = 8.4, 3-H and 5-H), 7.41 (2 H, d, J = 8.0, ArH), 7.57 (1 H, d, J = 7.9, 
benzimidazole 7-H), 7.63 (1 H, d, J = 7.4, benzimidazole 4-H) and 7.84 (2 H, d, J = 8.4, 2-H and 6-
H); bc(DMSO) 26.49 (CH2), 26.75 (CH2), 28.99 (PhSeCH2), 29.45 (CH2), 44.33 (NCH2), 111.04 
(benzimidazole 417-C), 119.35 (benzimidazole 417-C), 122.45 (benzimidazole 5/6-C), 123.33 
(benzimidazole 5/6-C), 126.80 (ArCH), 129.45 (2 x ArCH), 129.55 (2 x ArCH), 130.00 (ArC), 
130.46 (2 x ArCH), 131.75 (2 x ArCH), 135.99 (3a-C and 7a-C), 143.16 (ArC), 145.00 (ArC) and 
167.54 (C=O); m/z El 496 (M+, 19 %), 388 (42), 322 (62), 203 (100), 131 (58), 91 (39) and 69 (68). 
4-(Tritylsulfanyl)·benzoic acid 201 
201 
4-Mercaptobenzoic acid 189 (2.00 g, 13.0 mmol) and triphenylmethanol (3.37 g, 13.0 mmol) were 
dissolved by gentle shaking in TFA (20 mL). The reaction mixture was heated under reflux for 2 h. 
Then the mixture was evaporated to dryness to afford pure 4-(ritylsulfanyl)-benzoic acid 201 as light 
brown crystals (2.57 g, 6.5 mmol, 100 %), mp 215-220 oc; (Found: M+, 396.1179. C26H200 2S 
requires 396.1184); vmax (KBr)/cm-1 3017,2546, 1685, 1654, 1592, 1489, 1443, 1426, 1292, 1130, 
935,853, 810, 763 and 698; bH(DMSO) 6.99 (2 H, d, J = 8.1, 3-H and 5-H), 7.29-7.34 (15 H, m, 
ArH) and 7.58 (2 H, d, J = 8.1, 2-H and 6-H); bc(DMSO) 127.13 (3 x ArCH), 128.05 (6 x ArCH), 
128.92 (2 x ArCH), 129.44 (6 x ArCH), 131.33 (2 x ArCH), 143.53 (ArC) and 167.04 (C=O); mlz 
El 396 (M+, 4 %), 243 (100), 228 (12), 165 (95), 154 (22), 142 (27), 91 (18) and 44 (30). 
131 
N-( 4-Methylbenzyl)-4-( tritylsulfanyl)benzamide 202 
4-(Tritylsulfanyl)-benzoic acid 201 (1.00 g, 2.5 mmol) was dissolved in DCM (50 mL) and cooled 
to - 15 oc followed by addition of HOAT (0.34 g, 2.5 mmol), EDCI (0.48, 2.5 mmol) and then 4-
methylbenzylamine (0.32 mL, 2.5 mmol). The reaction mixture was stirred for 4 h at the same 
temperature and then left stirring for 2 h at rt. Ice cooled 1 M HCl (30 mL) was added and the 
aqueous layer was extracted with DCM (3 X 30 mL). The combined organic layers were extracted 
with saturated sodium bicarbonate (30 mL). The aqueous layer was washed again with DCM (3 X 
30 rnL) and the combined organics were dried and the solution was evaporated to dryness to afford 
N-[(4-methylbenzyl)-4-(tritylsulfanyl)benzamide 202 as off white crystals (1.08 g, 2.2 mmol, 86% ), 
mp 174-177 °C; (Found: M+, 500.2054. ~H29NOS requires 500.2048); vmax (KBr)/cm-1 3299, 
3054,3023,2921,1718,1652,1635,1593,1539,1443,1317,1298,1181,1154,1034,1015,741 
and 699; bH 2.34 (3 H, m, CH3}, 4.53 (2 H, d, J = 5.5, CH2), 6.21 (1 H, s, NH), 6.92 (2 H, d, J = 8.3, 
ArH), 7.17-7.28 (15 H, m, ArH) and 7.36-7.39 (6 H, m, ArH); be 21.10 (CH3}, 43.91 (CH2), 70.88 
(Cq}, 126.51 (2 X ArCH), 126.99 (3 X ArCH), 128.09 (2 X ArCH), 128.29 (6 X ArCH}, 129.44 (2 X 
ArCH), 129.95 (6 X ArCH), 132.20 (2 X ArCH), 134.98 (ArC), 137.40 (ArC), 140.17 (ArC), 144.03 
(3 x ArC), 146.88 (ArC) and 166.67 (C=O); m/z FAB 500 (M+, 12% ), 243 CCPh3, 100), 165 (17), 
136 (9) and 105 (13). 
4-(Acetylsulfanyl)benzene-1-carboxylic acid 20393 
s-Q-cooH 
-i 
203 
4-Mercaptobenzoic acid 189 (2.0 g, 13.0 mmol) was treated with acetic anhydride (2.0 mL, 21.4 
mmol) in pyridine (2.3 mL) overnight. The reaction mixture was evaporated to dryness and then the 
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residue was dissolved in EtOAc, washed with 2 M HC1 (30 mL) and then with brine (30 mL). The 
organic layer was dried (MgS04), and the solution was evaporated to dryness to give 4-
(acetylsulfanyl)benzene-1-carboxylic acid 203 as white crystals (2.54 g, 13.0 mmol, 100 %), mp 
194-200 oc (lit.93 mp 200.2-203.5 °C); (Found: M+, 196.0197. CJI80 3S requires 196.0194); vmax 
(KBr)/cm-1 3200,2844, 2669, 2551, 1703, 1690, 1674, 1593, 1565, 1426, 1398. 1317, 1292, 1180, 
1120, 936, 858 and 764; bH 2.46 (3 H, s, CH3), 7.54 (2 H, d, J = 8.4, 3-H and 5-H) and 8.14 (2 H, d, 
J = 8.4, 2-H and 6-H); be 30.49 (CH3), 129.86 (ArC), 130.72 (2 x ArCH), 134.05 (2 x ArCH), 
134.72 (ArC), 170.78 (C=O) and 192.51 (C=O); m/z El 196 (M+, 7 %), 154 (56), 136 (71), 109 (16) 
and 43 (1 00). 
4-Mercapto-1-( 4-methylbenzyl)benzamide 200 
N-(4-Methylbenzyl)-4-(tritylsulfany1)benzamide 202 (0.23 g, 0.5 mmol) was dissolved in 
DCMITFAIE~SiH (4.5/5/0.5 mL) and the reaction mixture was stirred for 2 hat rt. The reaction 
mixture was evaporated to dryness to give crude product. The residue was dissolved in 1 M sodium 
hydroxide (20 mL) and washed with light petroleum (3 x 20 mL). Then the aqueous layer was 
acidified with 1 M hydrochloric acid and extracted with ethyl acetate (3 x 30 mL). The combined 
organics were dried and the solution was evaporated to dryness to afford 4-mercapto-1-(4-
methylbenzyl)benzamide 200 as light brown crystals (22 mg, 0.09 mmol, 17 %), mp 163-165 oc; 
(Found: M+, 258.0946. C15H15 NOS requires 258.0953); vmax (KBr)/cm-1 3321, 1652, 1637, 1594, 
1539, 1487, 1319, 1301, 1099,842 and 789; i>H 2.35 (3 H, m, CH3), 3.57 (1 H, s, SH), 4.59 (2 H, s, 
CH2), 6.35 (1 H, s, NH), 7.18-7.29 (6 H, m, ArH) and 764 (2 H, d, J = 7.4, ArH); be 21.11 (CH3), 
43.94 (CH2), 127.61 (2 X ArCH), 127.97 (2 X ArCH), 128.56 (2 X ArCH), 129.47 (2 X ArCH), 
131.38 (ArC), 134.95 (ArC), 135.05 (ArC), 136.21 (ArC) and 166.58 (C=O); m/z FAB 258 (M+, 
100 %), 176 (20), 154 (82), 136 (70), 120 (13) and 105 (80). 
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Wang resin-bound benzimidazole derivative 205 
~N ____;=='\_go ~N-,_8~o 
~SePh 0 
205 
To a portion of Wang resin (1.0 g, 1.7 mmol) was added DCM (20 mL). The resin was left to swell 
for 1 h under N2• 4-( { 1-[3-Phenylselanyl)propyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-
carboxylic acid 197 (0.55 g, 1.2 mmol), DMAP (0.36 g, 2.9 mmol) and DIC (1.0 mL, 5.8 mmol) 
were added sequentially. The suspension was shaken for 48 h at rt. The reaction mixture was 
filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The resin was dried 
at 40 °C under vacuum for 24 h. The coupling reaction was repeated. 
The (MAS) magic angle 1H NMR (see appendix) spectrum showed complete immobilisation of the 
compound onto the Wang resin. 
IR Vmax (KBr)/cm-1 3025,2920, 1713, 1591, 1511, 1447, 1265, 1173, 1097, 1010,822,738 and 693. 
Wang resin-bound benzoimidazole derivative 206 
206 
To a portion ofWang resin (1.0 g, 1.7 mmol) was added DCM (20 mL). The resin was left to swell 
for 1 h under N2• 4-( { 1-[4-Phenylselanyl)butyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)-benzene-1-
carboxylic acid 198 (1.21 g, 2.5 mmol), DMAP ( 0.62 g, 5.1 mmol) and DIC (1.1 mL, 6.8 mmol) 
were added sequentially. The suspension was shaken for 48 h at rt. The reaction mixture was 
filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The resin was dried 
at 40 °C under vacuum for 24 h. The coupling reaction was repeated with equimolar reagents. 
The (MAS) magic angle 1H NMR spectrum (see appendix) showed complete immobilisation of the 
compound onto the Wang resin. 
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IR vmax (KBr)/cm-1 3026,2921,2363, 1713, 1591, 1512, 1447, 1356, 1265,1173, 1097, 1011,822, 
739and694. 
Wang resin-bound benzoimidazole derivative 207 
CXN -cMO ~s N ~ # o-Q 
~SePh . 
207 
To a portion ofWang resin (2.00 g, 3.4 mmol) was added DCM (20 mL). The resin was left to 
swell for 1 h under N2• 4-( {1-[5-(Phenylselanyl)pentyl]-1H-benzo[d]imidazole-2-yl}sulfanyl)-
benzene-1-carboxylic acid 199 (2.00 g, 4.0 mmol), DMAP (2.45 g, 20.1 mmol) and DIC ( 4.26 mL, 
27.2 mmol) were added sequentially. The suspension was shaken for48 hat rt. The reaction 
mixture was filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The 
resin was dried at 40 oc under vacuum for 24 h. The coupling reaction was repeated under similar 
conditions. 
The (MAS) magic angle 1H NMR spectrum (see appendix) showed complete immobilisation of the 
compound onto the Wang resin. 
IR Vmax (KBr)/cm-1 3024,2921,2851, 1943, 1717, 1592, 1511, 1451, 1421, 1374, 1353, 1266, 1238, 
1173, 1098, 1013,824,758,738 and 697. 
Amino-Merrifield resin-bound benzimidazole derivative 208 
()c)-s-Q-{ 
~SePh 0 
208 
To a portion of amino-Merrifield resin (0.40 g, 0.48 mmol) was added DCM (15 mL). The resin 
was left to swell for 1 h under N2• 4-( { 1-[3-(Phenylselanyl)propyl]-1H-benzoimidazol-2-
yl}sulfanyl)-benzene-1-carboxylic acid 197 (0.5 g, 1.1 mmol), DMAP (0.12 g, 1.0 mmol) and DIC 
(0.23 mL, 1.4 mmol) were added sequentially. The suspension was shaken for 72 hat rt. The 
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reaction mixture was filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). 
The resin was dried at 40 °C under vacuum for 24 h. 
IR Vmax (KBr)/cm·1 3424,3024, 2923, 1655, 1594, 1511, 1478, 1422, 1245, 1014, 838,736 and 691. 
Rink resin-bound benzoimidazole derivative 209 
~N}--s-D----_1? VL-~~NQ 
209 
To a portion of Rink resin (0.62 g, 0.5 mmol) was added DCM (15 mL). The resin was left to swell 
for I h under N2• 4-( { 1-[4-Phenylselanyl)butyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)-benzene-1-
carboxylic acid 198 (0.3 g, 0.6 mmol), HOAT (0.25 g, 1.8 mmol) and DIC (0.5 mL, 3.15 mmol) 
were added sequentially. The suspension was shaken for 48 hat rt. The reaction mixture was 
filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The resin was dried 
at 40 °C under vacuum for 24 h. The coupling reaction was repeated with equimolar reagents. 
The (MAS) magic angle 1H NMR spectrum (see appendix) showed immobilisation of the 
compound onto the Rink resin. 
IR vmax (KBr)/cm·1 3413, 2921, 1659, 1503, 1349, 1207,1026, 827, 742 and 695. 
Resin-bound 4-(tritylsulfanyl)-benzoic acid moiety 210 
Ph 
P~-~s~o 
'=IJ_ H1N 
210 0 
To a portion of Amino-Merrifield resin (0.50 g, 0.6 mmol) was added DCM (15 mL). The resin was 
left to swell for 1 h under N2• 4-(Tritylsufanyl)-benzoic acid 201 (0.71 g, 1.8 mmol), HOAT (0.24 g, 
1.8 mmol) and DIC (0.28 mL, 1.8 mmol) were added sequentially. The suspension was shaken for 
48 h at rt. The reaction mixture was filtered and washed with DCM, MeOH, H20, MeOH and DCM 
(30 mL each). The resin was dried at 53 °C under vacuum for 12 h. 
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IR Vmax (KBr)/cm-1 3421,3056,2917, 1719, 1654, 1595, 1509, 1490, 1448, 1151,1015 and 753. 
Radical cyclisations of resin-bound benzimidazole 205 
ff~ ~~N~ 
8 Sa 9~~ 1 2 
161 
4 3 -V-s~N -6~N~S ~ ;j C02H 
7 7a1~ 5 6 
212 
Method A (thermal method, Bu3SnH and toluene) 
A solution of tributyltin hydride (0.10 mL, 0.4 mmol) and AIBN (26 mg, 0.16 mmol) in toluene (2.0 
mL) was added to refluxing suspension of resin-bound benzimidazole moiety 205 (170 mg, 0.16 
mmol) in toluene (4.0 mL) over 26 min using a syringe pump. The reaction was stirred at reflux for 
3 hand then a further portion of tributyltin hydride/AIBN (0.008 mL/5 mg) in toluene (1 mL) was 
added over 5 min and the reaction mixture was heated at reflux for a further 1.5 h. Then the reaction 
mixture was filtered and washed with toluene, DCM and MeOH (20 mL each). The resin was dried 
at 40 oc under vacuum for 24 h. The LC-MS analysis of the filtrate showed cyclised product 161 (3 
mg, 0.018 mmol, 11 % ). The remaining products were cleaved from the resin using TFA/DCM 
(9/1). The LC-MS analysis of the cleaved sample from the resin showed the reduced product 212 
mainly. 
Data for the cyclised product 161 was recorded; 6H 2.70 (2 H, quintet, J = 7.4, 2-H), 3.05 (2 H, t, J 
= 7.6, 3-C), 4.1 (2 H, t, J = 7.2, 1-C), 7.25-7.40 (3 H, m, ArH) and 7.67-7.73 (1 H, m, ArH). 
Spectral data for the reduced product 4-[(1-propyl-1H-benzo[d]imidazol-2-yl)sulfanyl]benzene-1-
carboxylic acid 212 was recorded; (Found: M+, 313.1010. C17H16N20 2S requires 313.1011); vmax 
(KBr)/cm-1 3400,3065,2973,2877,2465,2345, 1918, 1701, 1654, 1594, 1460, 1429, 1389, 1254, 
1182, 1135 and 1015; bH(DMSO) 0.82 (3 H, t, J = 7.4, CH3), 1.66-1.75 (2 H, m, CH2), 4.26 (2 H, t, 
J = 7.2, NCH2), 7.26-7.33 (2 H, m, ArH), 7.46 (2 H, d, J = 6.6, 3-H and 5-H), 7.65-7.68 (2 H, m, 
ArH) and 7.91 (2 H, d, J = 6.6, 2-H and 6-H); bc(DMSO) 10.9 (CH3), 22.6 (CH2), 45.6 (NCH2), 
110.9 (benzimidazole 417-C), 119.0 (benzimidazole 417-C), 122.20 (benzimidazole 5/6-C), 123.20 
(benzimidazole 5/6-C), 128.8 (2 x ArCH), 129.6 (1-C), 130.20 (2 x ArCH), 135.6 (7a-C), 138.10 (4-
C),142.17 (3a-C), 145.1 (benzimidazole 2-C) and 166.6 (C=O); mlz FAB 313 (M+, 90 %), 176 (39), 
154 (100) and 136 (85). 
137 
Method B (thermal method, Bu3SnH and benzene) 
A solution of tributyltin hydride (0.12 mL, 0.43 mmol) and AIBN (42 mg, 0.26 mmol) in benzene (7 
mL) was added to refluxing suspension of resin-bound benzimidazole moiety 205 (100 mg, 
0.097mmol) in benzene (8 mL) over 7 h using a syringe pump. After that the reaction mixture was 
heated at reflux for a further 1 h. Then the reaction mixture was cooled to room temperature, 
filtered and washed with toluene, DCM and MeOH (20 mL each). The resin was dried at 40 °C 
under vacuum for 24 h. The LC-MS analysis of the filtrate only had tributyltin impurities and 
cyclised product 161 (3% ). The yield was determined by 1H NMR spectroscopy using the internal 
standard. 
The remaining products were cleaved from the resin using TFA/DCM (9/1). The LC-MS analysis 
of the cleaved sample from the resin showed the reduced product 212 ( 4 mg, O.Olmmol, 10 %) and 
the starting material197 (18 mg, 0.04 mmol, 41 %). 
Radical cyclisations of resin-bound benzimidazole moiety 206 
6 5a 5 7~NU4a4 8~N 3 
9 1 
1 2 
162 
(!4 ~ 32 0 51 ~ ~8__41\1 ;) 6 
_.a ~1 ~OH 77a1~5 6 
213 
u:~S~:H 
7 a1~ }-[ ~ 
214 
Method A (thermal method, Bu3SnH and benzene) 
A solution of tributyltin hydride (0.06 mL, 0.23 mmol) and AIBN (16 mg, 0.095 mmol) in benzene 
(3.0 mL) was added to refluxing suspension of resin-bound benzimidazole moiety 206 (100 mg, 
0.095 mmol) in benzene (3.0 mL) over 2 h using a syringe pump. After 3 h reflux, a further portion 
of tributyltin hydride/AIBN (0.008 mU5 mg) in toluene (1.0 mL) was added over 5 min and the 
reaction mixture was heated at reflux for a further 1.5 h. Then the reaction mixture was cooled to 
room temperature, filtered and washed with toluene (3 x 10 mL). The filtrate only had tributyltin 
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impurities and cyclised product (which were removed using Flex HPLC system) to afford 1,2,3,4-
tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 as white crystals (9.3 mg, 0.054 mmol, 57%), mp 
96-100 oc (lit.111 mp, 99.8-100.1 °C); (Found: M+, 172.1003. C11H12N2 requires 172.1001); vmax 
(KBr)/cm·• 1610, 1505, 1425, 1397, 1328, 1278, and 745; oH 1.98-2.09 (2 H, m, 3-H), 2.10-2.13 (2 
H, m, 2-H), 3.09 (2 H, t, J = 7.0, 4-H), 4.06 (2 H, t, J = 7.0, 1-H), 7.21-7.30 (3 H, m, ArH) and 7.66-
7.69 (1 H, m, ArH); be 20.73 (3-C), 22.65 (2-C), 25.39 (4-C), 42.43 (1-C), 108.71 (6/9-C), 118.82 
(6/9-C), 121.67 (7/8-C), 122.10 (7/8-C), 134.51 (7a-C), 142.65 (3a-C) and 151.71 (4a-C); mlz FAB 
172 (M+, 100 %), 144 (28), 117 (10) and 77 (8). 
The resin was dried at 40 °C under vacuum for 24 h. The remaining products were cleaved from the 
resin using TFA/DCM (9/1). The LC-MS analysis of the cleaved sample from the resin showed the 
reduced product 213 and the by-product (which were purified using Flex HPLC system). 
Data for 4-[( 1-butyl-1H-benzo[d]imidazol-2-yl)sulfanyl]benzene-1-carboxylic acid 213 was 
recorded; (Found: MH+, 327.1170. Cu#18N20 2S requires 327.1167); Vmax (KBr)/cm·1 3490,2934, 
2363, 1700, 1594, 1420, 1364, 1258, 1199, 1179, 1122 and 1017; bH(DMSO) 0.78 (3 H, t, J = 7.4, 
CH3), 1.16-1.25 (2 H, m, CH2), 1.56-1.63 (2 H, m, CH2), 4.27 (2 H, t, J = 7.3, NCH2), 7.23-7.31 (2 
H, m, ArH), 7.43 (2 H, d, J = 6.6, 3-H and 5-H), 7.62-7.65 (2 H, m, ArH) and 7.88 (2 H, d, J = 6.4, 
2-H and 6-H); bc(DMSO) 13.44 (CH3), 19.33 (CH2), 31.35 (CH2), 44.04 (NCH2), 110.92 
(benzimidazole 4/7-C), 119.03 (benzimidazole 417-C), 122.37 (benzimidazole 5/6-C), 123.33 
(benzimidazole 5/6-C), 128.94 (2 x ArCH), 129.68 (1-C), 130.27 (2 x ArCH), 135.58 (7a-C), 138.08 
(4-C),142.51 (3a-C), 145.12 (2-C) and 166.63 (C=O); mlz FAB 327 (MH+, 100 %), 271 (12), 176 
(12), 154 (33) and 136 (31). 
Data for 4-[(1-but-3-enyl-1H-benzo[d]imidazol-2-yl)sulfanyl]benzene-1-carboxylic acid 214 was 
recorded; (Found: MH+, 325.1005. C18H16N20 2S requires 325.1011); vmax (KBr)/cm·• 3447,2458, 
2368, 1936, 1686, 1592, 1467, 1430, 1387, 1262, 1204, 1167, 1137, 1015 and 922; l>H(DMSO) 
2.42-2.44 (2 H, m, CH2), 4.38 (2 H, t, J = 7.04, NCH2), 4.88-4.92 (2 H, m, CH2), 5.70-5.82 (1 H, m, 
CH), 7.26-7.33 (2 H, m, ArH), 7.44 (2 H, d, J = 6.7, 3-H and 5-H), 7.67 (2 H, d, J = 6.9, ArH) and 
7.91 (2 H, d, J = 6.7, 2-H and 6-H); bc(DMSO) 33.55 (CH2), 43.55 (NCH2), 110.95 (benzimidazole 
417-C), 117.71 (=CH2), 119.10 (benzimidazole 417-C), 122.22 (benzimidazole 5/6-C), 123.20 
(benzimidazole 5/6-C), 128.69 (2 x ArCH), 129.52 (1-C), 130.18 (2 x ArCH), 134.25 (-CH=), 
135.47 (3a/7a-C), 138.31 (4-C), 142.70 (3a/7a-C), 145.03 (2-C) and 166.57 (C=O); mlz FAB 325 
(MH+, 100 %), 271 (14), 176 (46), 154 (76) and 136 (80). 
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Method B (thermal method, Bu3SnH and toluene) 
A solution of tributyltin hydride (0.06 mL, 0.23 mmol) and AIBN ( 16 mg, 0.095 mmol) in toluene 
(3.0 mL) was added to refluxing suspension of resin-bound benzimidazole moiety 206 (100 mg, 
0.095 mmol) in toluene (3.0 mL) over 2 h using a syringe pump. After 3 h reflux, a further portion 
of tributyltin hydride/AIBN (0.008 rnU5 mg) in toluene (1.0 mL) was added over 5 min and the 
reaction mixture was heated at reflux for a further 1.5 h. The reaction mixture was cooled to room 
temperature, filtered and washed with toluene (3 x 10 mL). The filtrate only had tributyltin 
impurities and cyclised product (which were removed using Hex HPLC system) to afford 1,2,3,4-
tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162 as white crystals (8 mg, 0.047 mmol, 49 %). 
The resin was dried at 40 °C under vacuum for 24 h. The LC-MS analysis of the cleaved sample 
from the resin showed the reduced product 213 mainly. 
Method C (thermal method, TTMSS and benzene) 
To refluxing suspension of resin-bound benzimidazole moiety 206 (55 mg, 0.052 mmol) in benzene 
(10 mL) was added TTMSS (65 ~L, 0.21 mmol) followed by portion wise addition of AIBN (34 mg, 
0.2 mmol). The reaction mixture was heated at reflux for 10 h. Then the reaction mixture was 
cooled to room temperature, filtered and washed with toluene, DCM and MeOH (20 mL each). The 
LC-MS analysis of the filtrate only had TTMSS impurities and cyclised product (which were 
removed using Hex HPLC system) to afford 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 
162 as white crystals (1.8 mg, 0.01 mmol, 20 %). 
The resin was dried at 40 °C under vacuum for 24 h. The LC-MS analysis of the cleaved sample 
from the resin showed the reduced product 213. 
Method D (thermal method, Bu3GeH and toluene) 
To refl.uxing suspension of resin-bound benzimidazole 206 ( 100 mg, 0.095 mmol) in toluene 
(15mL) was added Bu3GeH (0.11 mL, 0.43 mmol) followed by portion wise addition of AIBN (43 
mg, 0.26 mmol). The reaction mixture was heated at reflux for 8 h. Then the reaction mixture was 
cooled to room temperature, filtered and washed with toluene, DCM and MeOH (20 mL each). The 
filtrate only had germanium based impurities and cyclised product (which were removed using acid 
extraction method) to afford 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162 as white 
crystals ( 4 mg, 0.021 mmol, 22 % ). 
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The resin was dried at 40 °C under vacuum for 24 h. The remaining products were cleaved from the 
resin using TFAIDCM (9/1). The LC-MS analysis of the cleaved sample from the resin showed the 
starting material198. 
Method E (thermal method, using Rink resin 209, Bu3SnH and benzene) 
A solution of tributyltin hydride (0.12 mL, 0.43 mmol) and AIBN ( 42 mg, 0.26 mmol) in toluene (7 
mL) was added to refluxing suspension of resin-bound benzimidazole 209 (200 mg, 0.12 mmol) in 
benzene (7 mL) over 6 h using a syringe pump. Mter that the reaction mixture was heated at reflux 
for a further 1 h. Then the reaction mixture was cooled to room temperature, filtered and washed 
with toluene, DCM and MeOH (20 mL each). The resin was dried at 40 °C under vacuum for 24 h. 
The LC-MS analysis of the filtrate only had tin impurities and cyclised product (which were 
removed using Flex HPLC system) to afford 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 
162 as white crystals (8.6 mg, 0.05 mmol, 44% ). 
The remaining products were cleaved from the resin using TFA/DCM (9/1). The LC-MS analysis 
of the cleaved sample from the resin showed the reduced product 213. 
Method F (Microwave irradiation, using Wang resin-bound benzimidazole 206) 
General method; A suspension of resin was prepared in various solvents in a microwave pyrex 
tube, followed by addition of the radical reagent and the initiator, the pyrex tube was then sealed and 
placed in an automated microwave. 
(i) Time: 10 + 10 min (double addition of reagents); Temperature: 100 °C; Solvents: Propan-1-
ol/benzene (1.25/1.25 mL); Reagents: Wang resin (22 mg, 0.021 mmol), B~SnH (2 x 3.57 eq.) and 
AIBN (2 x 3.57 eq.). After 20 min the reaction vessel was removed from the microwave, cooled to 
room temperature and unsealed. The reaction mixture was filtered and washed with toluene, DCM 
and MeOH (20 mL each). The LC-MS analysis of the filtrate showed the presence of the cyclised 
product. The filtrate only had tin based impurities and 1,2,3,4-tetrahydrobenzo[4,5]imidazo[l,2-
a]pyridine 162 (52%). The yield was determined by 1H NMR spectroscopy using the internal 
standard. 
(ii) Time: 10 + 10 min (double addition of reagents); Temperature: 100 °C; Solvents: t-
Butanol/benzene (1.25/1.25 mL); Reagents: Wang resin (25 mg, 0.024 mmol), B~SnH (2 x 3.58 
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eq.) and AMBN (2 x 3.58 eq.). After 20 min the reaction vessel was removed from the microwave, 
cooled to room temperature and unsealed. The reaction mixture was filtered and washed with 
toluene, DCM and MeOH (20 mL each). The resin was dried at 40 oc under vacuum for 24 h. The 
LC-MS analysis of the filtrate showed the presence of the cyclised product. The filtrate only had tin 
based impurities and 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine 162 (36 %). The yield 
was determined by 1H NMR spectroscopy using the internal standard. 
(iii) Time: 10 min; Temperature: 135 °C; Solvents: Propan-1-ol/benzene (1.25/1.25 mL); 
Reagents: Wang resin (25 mg, 0.024 mmol), B~SnH (2 x 3.58 eq.) and AMBN (2 x 3.58 eq.). Mter 
20 min the reaction vessel was removed from the microwave, cooled to room temperature and 
unsealed. The reaction mixture was filtered and washed with toluene, DCM and MeOH (20 mL 
each). The resin was dried at 40 °C under vacuum for 24 h. The LC-MS analysis of the filtrate 
showed the presence of the cyclised product. The filtrate only had tin based impurities and 1,2,3,4-
tetrahydrobenzo[4,5]imidazo[l,2-a]pyridine 162 (44 %). The yield was determined by 1H NMR 
spectroscopy using the internal standard. 
Radical cyclisations of resin-bound benzimidazole moiety 207 
4 4a ~ 3~D5as 2~ 7 111~~ 
10 8 9 
(14 ~ -{:MO s ~s4-1 6 ~ /; 7 ?a1~s OH 
215 216 
A solution of tributyltin hydride (0.14 mL, 0.50 mmol) and AIBN (28 mg, 0.17 mmol) in tert-
butylbenzene (2.0 mL) was added to a suspension of refluxing resin-bound benzimidazole adduct 
207 ( 125 mg, 0.11 mmol) in tert-butylbenzene (3.0 mL) over 2.25 h using a syringe pump. Then the 
reaction mixture was heated at 130 °C for a further 9 h. The reaction mixture was filtered and 
washed with toluene, DCM and MeOH (20 mL each). The LC/MS analysis of the filtrate showed 
the 7,8,9,10-tetrahydro-6H-benzo[4,5]imidazo[1,2-a]azepine 215 (1 mg, 0.004 mmol, 4 %). The 
yield was determined by 1H NMR spectroscopy using the internal standard. 
The 1H NMR data for the cyclised product 215 is as follows; 5H 1.73-1.95 (6 H, m, 7-H, 8-H and 9-
H), 3.07-3.11 (2 H, m, 6-H), 4.14-4.18 (2 H, m, 10-H), 7.18-7.28 (3 H, m, ArH) and 7.65-7.69 (1 H, 
m, ArH). The resin was dried at 40 °C under vacuum for 24 h. The remaining products were 
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cleaved from the resin using TFA/DCM (9/1). The LC-MS analysis of the cleaved sample from the 
resin showed the pure reduced product 216 (27 mg, 0.08 mmol, 72 % ). 
Spectral data for 4-[(1-pentyl-1H-benzo[d]imidazol-2-yl)sulfanyl]benzene-1-carboxylic acid 216 
was recorded; (Found: M+, 340.1242. C1J12oN20 2S requires 340.1246); vmax (KBr)/cm-1 3056,2928, 
2477, 1910, 1689, 1596, 1463, 1385, 1272, 1115, 1007,836 and 742; oH(DMSO) 0.76 (3 H, t, J = 
6.9, CH3), 1.15-1.24 (4 H, m, CH2CH2), 1.62-1.68 (2 H, m, CH2), 4.28 (2 H, t, J = 7.3, NCH2), 7.26 
(1 H, t, J = 8.1, ArH), 7.31 (1 H, t, J = 7.9, ArH), 7.44 (2 H, d, J = 7.7, 3-H and 5-H), 7.64 (1 H, d, J 
= 8.0, benzimidazole 7-H), 7.67 (1 H, d, J = 7.9, benzimidazole 4-H) and 7.91 (2 H, d, J = 6.7, 2-H 
and 6-H); oc(DMSO) 13.56 (CH3), 21.56 (CH2), 28.09 (CH2), 28.83 (CHJ, 44.14 (NCH2), 110.81 
(benzimidazole 4/7-C), 119.12 (benzimidazole 417-C), 122.19 (benzimidazole 5/6-C), 123.20 
(benzimidazole 5/6-C), 128.70 (2 x ArCH), 130.0 (1-C), 130.18 (2 x ArCH), 135.56 (3a/7a-C), 
138.23 (3a/7a-C), 142.72 (4-C), 144.93 (benzimidazole 2-C) and 166.55 (C=O); mlz El 339 (M+, 
100 %), 307 (14), 297 (34), 269 (86), 225 (26), 187 (28), 150 (30), 131 (24) and 73 (28). 
Methyl1H-benzo[d]imidazole-5-carboxylate 222112 
0 
'o~N~ ~N 
H 
222 
Acetyl chloride (7.0 mL, 98.4 mmol) was added dropwise over 10 min to MeOH (100 mL) cooled in 
ice. The solution was stirred for 5 min and solid 5-benzimidazole carboxylic acid 221 (5.00 g, 30.8 
mmol) was added in one portion and the solution slowly heated to reflux. Heating under reflux was 
continued overnight. The solution was cooled and evaporated to dryness to give the crude methyl 
ester. Distilled water (50 mL) was added to the crude methyl ester hydrochloride and the aqueous 
layer basified to pH 14 with sodium carbonate and 1 M sodium hydroxide (few drops). The basic 
solution was extracted with DCM (3 x 50 mL). The combined organic extracts were dried (MgS04) 
and evaporated to dryness to afford methyl1H-benzo[d]imidazole-5-carboxylate 222 as light brown 
coloured crystals (5.00 g, 28.4 mmol, 92 %), mp 134-137 oc (lit.112 mp 134-136 °C); (Found: M+, 
176.0585. CJ18N20 2 requires 176.0586); (Found: C, 60.86; H, 4.66; N, 15.57. requires C, 61.35; H, 
4.58; N, 15.90 %); Vmax (Nujol)/cm-1 2922, 1725, 1713, 1462, 1377, 1296 and 746; oH(DMSO) 3.89 
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(3 H, s, OCH3), 7.70 (1 H, d, J = 8.0, 7-H), 7.86 (1 H, d, J = 8.0, 6-H), 8.25 (1 H, s, 4-H) and 8.43 (1 
H, s, 2-H); 6c(DMSO) 52.27 (OCH3), 115.27 (7-C), 118.03 (4-C), 123.26 (6-C), 123.58 (ArC, 5-C), 
138.78 (ArC, 3a), 141.45 (ArC, 7a), 144.96 (2-C) and 167.15 (C=O); mlz El 176 (M+, 62 %), 160 
(20), 145 (100) and 117 (42). 
PhenylmethyllH-benzo[d]imidazole-5-carboxylate 223 
223 
A solution of PPh3 (0.81 g, 3.1 mmol) and benzyl alcohol (0.48 g, 4.6 mmol) in THF (10 mL) was 
added dropwise to a solution of DEAD (0.49 mL, 3.1 mmol) and 5-benzimidazole carboxylic acid 
221 (0.50 g, 3.1 mmol) in THF (10 mL) at room temperature. The mixture was stirred overnight at 
room temperature. The solution was evaporated to dryness, 2 M aqueous HCI (50 mL) was added 
and the acidic solution was washed with DCM (2 x 50 mL). The aqueous layer contained 
benzimidazole compounds and was basified to pH 14 with sodium carbonate and 1 M sodium 
hydroxide (few drops). The basic solution was extracted with DCM (3 x 50 mL). The combined 
organic extracts were dried (MgS04) and evaporated to dryness to afford phenylmethyl lH-
benzo[d]imidazole-5-carboxylate 223 as a pale yellow oil (60 mg, 0.24 mmol, 8 %); (Found: M+, 
252.0898. c,5H12N202requires 252.0899); Vmalt (DCM slurry)/cm"1 1711, 1624, 1297, 1227, 1084 
and 749; 6H 5.38 (2 H, s, OCH2Ph), 7.25-7.44 (5 H, m, ArH), 7.65 (1 H, d, J = 8.0, benzimidazole 7-
H), 8.03 (1 H, d, J = 8.0, benzimidazole 6-H), 8.23 (1 H, s, benzimidazole 4-H) and 8.46 (1 H, s, 
benzimidazole 2-H); be 66.79 (OCH2Ph), 115.03 (benzimidazole 7-C), 118.40 (benzimidazole 4-C), 
124.52 (benzimidazole 6-C), 124.89 (ArC, 5-C), 128.04 (2 x ArCH), 128.24 (ArCH), 128.62 (2 x 
ArCH), 136.12 (ArC), 137.79 (ArC, 3a), 140.91 (ArC, 7a), 143.09 (ArCH, 2-C) and 167.03 (C=O); 
mlz El 252 (M+, 40 %), 207 (12) and 145 (92). 
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Methyll-(triphenylmethyl)-lH-benzo[d]imidazole-5-carboxylate 224 and methyll-
( triphenylmethyl)-lH-benzo[ d]imidazole-6-carboxylate 225 
rrrN~ 
/0~~ 
0 CPh3 
225b 
Methyl1H-benzo[d]irnidazole-5-carboxylate 222 (7.25 g, 41.2 mmol) was dissolved in DCM (600 
mL). Triphenylmethyl chloride (13.43, 49.3 mmol) was added over 20 min and the mixture stirred 
until dissolution was complete. Triethylamine (9.32 mL, 66.9 mmol) was added slowly to the 
stirred solution and heated at reflux. overnight. The solution was evaporated to dryness and purified 
by column chromatography using neutral alumina as absorbent and light petroleurn!EtOAc (9: 1) as 
eluents to yield a non-separable mixture of methyl 1-(triphenylmethyl)-1H-benzo[d]imidazole-5-
carboxylate 224 and methyl 1-(triphenylmethyl)-1H-benzo[d]irnidazole-6-carboxylate 225 as cream 
coloured crystals (16.0 g, 38.3 mmol, 93 %), mp 154-160 °C; (Found: M+, 418.1682. C28H22N20 2 
requires 418.1681); (Found: C, 76.87; H, 5.06; N, 6.38. requires C, 77.04; H, 5.08; N, 6.42 %); vmax 
(Nujol)/cm-1 2922,2853, 1713, 1459, 1376,752 and 701; bH3.75 (3 Hb, s, OMe), 3.89 (3 Ha, s, 
OMe), 6.50 (1 Ha, dd, 1 = 8.7, 0.5, 7-H), 7.17 (16 Hb, m, ArH), 7.33 (15 Ha, m, ArH), 7.62 (1 Ha, dd, 
1 = 8.7, 1.6, 6-H), 7.78 (1 Hb, dd, 1 = 8.6, 0.6, 4-H), 7.87 (1 Hb, dd, 1 = 8.6, 1.5, 5-H), 7.% (1 Ha, s, 
2-H), 8.03 (1 Hb, s, 2-H) and 8.50 (1 Ha, dd, 1 = 1.6, 0.6, 4-H); oc 51.91 (CH3), 52.01 (CH3), 75.78 
(Cq), 75.84 (Cq), 115.05 (ArCH), 117.62 (ArCH), 119.96 (ArCH), 122.15 (ArCH), 123.45 
(ArCH), 123.66 (ArCH), 124.38 (ArC), 124.44 (ArC), 128.27 (ArCH), 128.29 (ArCH), 129.91 
(ArCH), 129.93 (ArCH), 134.51 (ArC), 138.05 (ArC), 140.99 (ArC, CPh3), 141.03 (ArC, CPh3), 
144.36 (ArC), 145.69 (ArCH, 2-C), 146.61 (ArCH, 2-C), 148.04 (ArC), 167.16 (C=O) and 167.44 
(C=O); mlz El 418 (M+, 15 %), 387 (M+, 12), 359 (6) and 243 (100). 
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Methyl2-(phenylsulfanyl)-1H-benzo[d]imidazole 226 
226 
Methyl1-(triphenylmethyl)-1H-benzo[d]imidazole-5-carboxylate 224 and methyl1-
(triphenylmethyl)-1H-benzo[d]imidazole-6-carboxylate 225 (4.0 g, 9.6 mmol) were dissolved in 
THF (150 mL) and the mixture was stirred at ambient temperature. The temperature of the stirred 
solution was lowered to -78 oc and a solution of n-butyllithium added dropwise ( 12.0 mL, 18.0 
mmol). The solution turned brown and was stirred at 0 °C for a further 20 min. A solution of 
diphenyl disulfide (3.14 g, 14.4 mmol) in THF (50 mL) was added dropwise and the stirring was 
continued for a further 3 h. The solution was evaporated to give the crude sticky brown oil, 
hydrolysis performed using 99% TFA in DCM cleaved trityl group. Deionised water (50 mL) was 
added to the crude product which was extracted with light petroleum to remove by-products. The 
aqueous layer contained the protonated benzimidazole compounds and was basified to pH 14 with 
sodium carbonate and 1 M aqueous sodium hydroxide solution (few drops). The basic solution was 
extracted with DCM (3 x 40 mL). The combined organic extracts were dried (MgS04) and 
evaporated to dryness to yield a crude oil. The oil was purified by column chromatography using 
alumina as absorbent and light petroleum/ethyl acetate (9: 1) as eluents to afford methyl 2-
(phenylsulfanyl)-1H-benzo[d]imidazole 226 which still does not seem to be pure and it has been 
submitted for GC-MS analysis. 
[1-(Triphenylmethyl)-lH-benzo[ d]imidazol-5-yl]-methanol 228 and [1-( triphenylmethyl)-1H-
benzo[d]imidazol-6-yl]-methanol227 
HO~N" ~N 
228 a 
\ 
CPh3 
227 b 
An isomeric mixture of methyl 1-(triphenylmethyl)-1H-benzo[d]imidazole-5-carboxylate 224 and 
methyl1-(triphenylmethyl)-1H-benzo[d]imidazole-6-carboxylate 225 (6.0 g, 14.4 mmol) in THF 
(100 mL) was added dropwise to a suspension of LiAIH4(0.41 g, 10.8 mmol) in THF (150 mL) at 0 
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°C (ice bath). After stirring for 6 h at rt, the mixture was carefully hydrolysed by addition of H20 (1 
mL) and 20% NaOH (0.80 mL). The reaction mixture was dried (MgS04) and evaporated to give 
pure pale yellow powder containing two isomers [ 1-(triphenylmethyl)-1H-benzo[d]imidazol-5-yl]-
methanol228 and [1-(triphenylmethyl)-1H-benzo[d]imidazol-6-yl]-methanol227 (3.8 g, 9.72 mmol, 
68%), mp 100-105 °C; (Found: MH+, 391.1802. C27H22N20 requires 391.1810); (Found: C, 82.55; 
H, 5.58; N, 7.06. requires C, 83.05; H, 5.68; N, 7.17 %); vmax (Nujol)/cm·1 3384,3054,2924, 1445, 
1265, 1114, 895 and 739; 6H 4.45 (2 Hb, s, CH2), 4.71 (2 Ha, s, CH2), 6.45 (1 Ha, d, J = 8.3, 7-H), 
6.93 (1 Ha, dd, J = 8.6, 1.6, 6-H), 7.15-7.34 (33 H, m, ArH), 7.72 (1 Hb, d, J = 7.4, 4-H), 7.74 (1 Hb, 
s, 2-H) and 7.88 (1 Ha, s, 2-H); 6c 65.61 (2 X CH2), 75.49 (2 X Cq), 113.87 (ArCH), 115.48 (ArCH), 
118.88 (ArCH), 120.28 (ArCH), 121.70 (ArCH), 122.11 (ArCH), 128.06 (6 X ArCH), 128.17 (12 X 
ArCH), 129.98 (12 X ArCH), 134.35 (ArC), 134.90 (ArC), 135.07 (ArC), 135.52 (ArC), 141.26 
(ArC), 144.25 (ArC), 144.58 (2 x 2-C) and 144.69 (ArC); mlz El 390 (M+, 1 %), 243 (100) and 165 
(88). 
1·(1, 1-dimethylethyl)-1, 1-dimethylsilyl{[1·( triphenylmethyl)-1H-benzo[ d]imidazol-5-
yl]methyl} ether 230 and 1-(1,1-dimethylethyl)-1, 1-dimethylsilyl{[l-(triphenylmethyl)-lH-
benzo[d]imidazol-6-yl]methyl} ether 229 
[1-(Triphenylmethyl)-1H-benzo[d]imidazol-5-yl]-methanol 228 and [1-(triphenylmethyl)-1H- ' 
benzo[djimidazol-6-yl]-methanol227 (1.6 g, 4.1 mmol), tert-butyldimethylsilyl chloride (1.79 g, 
11.9 mmol) and imidazole (0.22 g, 3.2 mmol) were dissolved in DMF (25 mL) and the solution was 
stirred overnight. Saturated sodium chloride (75 mL) was added and the solution extracted with 
DCM (2 x 75 mL). The combined organic extracts were combined and dried (MgS04). The crude 
product was purified by column chromatography using neutral alumina as absorbent with light 
petroleum/EtOAc (9:1) as eluents to yield 1-(1,1-dimethylethyl)-1,1-dimethylsilyl{[l-
(triphenylmethyl)-1H-benzo[d]imidazol-5-yl]methyl} ether 230 and 1-(l, 1-dimethylethyl)-1, 1-
dimethylsilyl{[l-(triphenylmethyl)-1H-benzo[d]imidazol-6-yl]methyl} ether 229 as a brown oil 
(1.00 g, 2.0 mmol, 50%); (Found: [MH+], 505.2674. ~3H36N20Si requires 505.2675); vmax 
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(neat)/cm-1 3058,2955,2856, 1735, 1695, 1598, 1493, 1446, 1265, 1087, 839; ()H -0.12 (9 Hb, s, 
CH3), 0.09 (6 Hb, s, CH3), 0.78 (9 Ha, s, CH3), 0.93 (6 Ha, s, CH3), 4.54 (2 Ha, s, CH2), 4.78 (2 Hb, s, 
CH2), 6.42 (1 Ha, d, J = 8.6, 7-H), 6.53 (1 Ha, s, 4-H), 6.88 (1 Ha, d, J = 8.6, 6-H), 7.10 (1 Hb, d, J = 
8.3, 5-H), 7.16-7.32 (30 H, m, ArH), 7.70 (1 Hb, d, J = 8.3, 4-H), 7.74 (1 Hb, d, J = 0.7, 7-H), 7.85 (1 
Ha, s, 2-H) and 7.86 (1 Hb, s, 2-H); be 5.32 (2 X CH3), 5.22 (2 X CH3), 25.94 (3 X CH3), 26.01 (3 X 
CH3), 65.05 (CH2), 65.19 (CH2), 113.08 (ArCH), 115.06 (ArCH), 117.67 (ArCH), 119.68 (ArCH), 
120.83 (ArCH), 121.13 (ArCH), 127.12 (ArCH), 128.12 (ArCH), 129.94 (ArCH), 133.00 (ArC), 
134.74 (ArC), 135.50 (ArC), 135.97 (ArC), 141.28, (ArC), 141.31 (ArC), 144.10 (2 x 2-C) and 
147.09 (ArC); mlz El 505 (MH+, 1 %), 447 (5), 243 (100), 165 (65) and 131 (28). 
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EXPERIMENTAL FOR CHAPTER FOUR 
1-Iodo-2-(iodomethyl)benzene 241 
I 
6~1 5~ 
4• 
241 
1-Iodo-2-(chloromethyl)benzene 240 (10.0 g, 39.6 mmol) and sodium iodide (30.0 g, 200 mmol) 
were added to dry acetonitrile (250 mL) and heated under reflux for 18 h. The precipitated sodium 
chloride was removed by filtration on a celite bed and the solution was evaporated to dryness. The 
solid residue was triturated with diethyl ether and the solution filtered a second time. The ether 
solution was evaporated to dryness to afford 1-iodo-2-(iodomethyl)benzene 241 as a dark brown oil 
(13.48 g, 39.2 mmol, 99 %); (Found: M+, 343.8552. c;H6I2 requires 343.8559); vmax (neat)/cm·1 
2360, 2342, 1580, 1560, 1464, 1433, 1424, 1273, 1212, 1152, 1012, 827, 757 and 644; ba 4.54 (2 
H, s, CH2), 6.92 (1 H, dd, J = 7.6 and 7.6, 5-H), 7.28 (1 H, dd, J = 7.6 and 7.6, 4-H), 7.47 (1 H, d, J 
= 8.0, 3-H), 7.80 (1 H, d, J = 8.0, 6-H); be 12.17 (CH2), 99.74 (1-C), 129.32 (4-C), 129.51 (5-C), 
129.76 (3-C), 140.23 (6-C) and 141.43 (2-C); m/z El 344 (MH+, 5 %), 254 (12), 217 (100) and 90 
(47). 
(2-Iodophenyl)methyl methanesulfonate 243 
~o~~t 
5 
243 
To a flask containing 2-iodobenzyl alcohol242 (10.0 g, 42.7 mmol) was added DCM (80 mL) and 
triethylamine (17.86 mL, 128.2 mmol). The solution was cooled to 0 oc in an ice bath and 
methanesulfonyl chloride (4.97 mL, 64.1 mmol) was added. The reaction mixture was stirred at rt 
for 18 h. The reaction mixture was extracted into water and DCM. The DCM layers were collected 
and dried (MgS04) and evaporated to afford (2-iodophenyl)methyl methanesulfonate 243 as a pale 
yellow oil (8.0 g, 25.6 mmol, 60 %); vmax (neat)/cm·1 3031, 2932, 1575, 1443, 1367, 1173, 1014, 
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966, 815, 745 and 668; 6H 3.65 (3 H, s, CH3), 4.67 (2 H, s, CH2), 6.99 (1 H, ddd, J = 8.3, 8.3 and 
1.6, 4-H), 7.34 (1 H, ddd, J = 7.6, 7.6 and 0.8, 5-H), 7.47 (1 H, dd, J = 7.6 and 1.6, 6-H) and 7.85 (1 
H, d, J = 7.9, 3-H); be 51.66 (CH3), 53.10 (CH2), 100.19 (2-C), 129.37 (5-C), 130.73 (4-C), 130.85 
(6-C), 140.26 (1-C) and 140.30 (3-C); m/z El 252 (lOO%), 217 (lOO) and 90 (51). 
2-(2-Bromophenyl)ethyl methanesulfonate 24S 
Br 
:~0'sO,Me 
5 
245 
To a flask containing 2-bromophenylethyl alcohol 244 (0.5 mL, 3.7 mmol) was added toluene (30 
mL) and triethylamine (1.54 mL, 11.1 mmol). The solution was cooled to 0 oc in an ice bath and 
methanesulfonyl chloride (0.43 mL, 5.6 mmol) was added. The reaction mixture was stirred at rt for 
18 h. The reaction mixture was extracted into water and DCM. The DCM layers were collected and 
dried (MgS04) and evaporated to afford 2-(2-bromophenyl)ethyl methanesulfonate 24S as a pale 
yellow oil (1.0 g, 3.7 mmol, 99 %); (Found: M+, 277.9611. CJI11Br03S requires 277.9612); vma" 
(neat)/cm-1 3057, 3024, 2939, 1594, 1568, 1473, 1442, 1353, 1173, 1038, 1022, 958, 905, 858, 805, 
755 and 657; 6H 2.88 (3 H, s, CH3), 3.21 (2 H, t, J = 6.8, CH2), 4.45 (2 H, t, J = 6.8, OCH2), 7.11-
7.15 (1 H, m, ArH), 7.28-7.29 (2 H, m, ArH) and 7.55 (1 H, d, J = 8.1, 3-H); be 35.86 (CH2Ph), 
37.22 (CH3), 68.51 (OCH~. 124.41 (ArC), 127.72 (ArCH), 128.93 (ArCH), 131.53 (ArCH), 132.93 
(ArCH) and 135.60 (ArC); mlz El 278 (M+, 3 %), 220 (26), 182 (68), 169 (100), 103 (38), 90 (40) 
and 77 (34). 
1· Bromo-2-(2-chloroethyl)benzene 246 
Br 
6~CI 
su; 
4 
246 
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A mixture of 2-bromophenylethyl alcohol244 (0.7 mL, 5.2 mmol) and concentrated hydrochloric 
acid (5 mL) was heated in a Reacti-Vial at 115 °C for 18 h. Mter cooling tort the mixture was 
poured into water and extracted with diethyl ether. The organic layers were dried (MgS04) and 
evaporated to dryness to give 1-bromo-2-(2-chloroethyl)benzene 246 as a clear oil (0.75 g, 3.41 
mmol, 66 %); (Found: M+, 217.9498. C8H8BrCl requires 217.9498); vmax (neat)/cm-1 3058,2959, 
1590, 1568, 1471, 1440, 1329, 1304, 1280, 1248, 1109, 1026, 944, 901,754, 699 and 659; bH 3.15 
(2H, t, J = 7.4, PhCHJ, 3.69 (2 H, t, J = 7.3, ClCHJ, 7.03-7.09 (1 H, m, ArH), 7.20-7.22 (2 H, m, 
ArH) and 7.50 (1 H, d, J = 8.1, 6-H); be 39.23 (PhCH2), 43.07 (CH2Cl), 124.34 (ArC), 127.48 
(ArCH), 128.59 (ArCH), 131.27 (ArCH), 132.86 (ArCH) and 137.16 (ArC); m/z El 218 (M+, 33 %), 
169 (100), 103 (25), 90 (32), 77 (35) and 49 (49). 
2-Chloro-1-[ (2-iodophenyl)methyl]-1H-benzo[ d]imidazole 247 
4 3 s~N 6~~CI 
"7 ?a1~3 !U4 
5 
247 
2-Chlorobenzimidazole 163 (3.00 g, 19.7 mmol) was added to a vigorously stirred suspension of 
ground potassium hydroxide (3.30 g, 59.0 mmol) in dry DMF (80 mL) and stirred for 30 min. 1-
Iodo-2-(iodomethyl)benzene 241 (13.53 g, 39.3 mmol) was added in one portion. The reaction was 
stirred for 24 h, partitioned between ethyl acetate and water and the organic layer was removed. The 
organic extract was washed with water followed by brine, dried (MgS04) and evaporated to dryness. 
The residue was purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (4:1) as eluents to afford 2-chloro-1-[(2-iodophenyl)methyl]-18-
benzo[d]imidazole 247 as cream coloured crystals (6.87 g, 18.7 mmol, 95 %), mp 106.2-109.3 °C; 
(Found: M+, 367.9573. C14H10 CIIN2 requires 367.9577); vmax (KBr)/cm-1 3059, 2920, 1700, 1615, 
1455, 1428, 1329, 1282, 1240, 1198, 1013, 986, 749 and 650; i>H 5.38 (2 H, s, CH2), 6.48 (1 H, d, J 
= 8.0, 6-H), 7.00 (1 H, dd, J = 8.0 and 8.0, 4-H), 7.08-7.34 (4 H, m, ArH), 7.75 (1 H, d, J = 8.0, 
ArH) and 7.91 (1 H, d, J = 8.0, 3-H); be 52.93 (CH2), 96.74 (Ar 2-C), 109.88 (benzimidazole 417-
C), 119.66 (benzimidazole 417-C), 123.13 (benzimidazole 5/6-C), 123.62 (benzimidazole 5/6-C), 
126.61 (ArCH), 128.88 (ArCH), 130.08 (ArCH), 135.04 (3a-C), 136.84 (7a-C), 139.74 (ArCH), 
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141.04 (benzimidazole 2-C) and 141.83 (Ar 1-C); m/z El 368 (M+, 62 %), 241 (35), 217 (100), 205 
(13), 152 (19) and 90 (47). 
4-({1-[(2-Iodophenyl)methyi]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 
248 
5ct4 a~ 3_2 0 ~, s~ 6~ N I~OH 7 a1))s 6 2 3 
11 ~ 
#4 
5 
248 
4-Mercaptobenzoic acid 189 (1.54 g, 10.0 mmol) was dissolved in EtOH (60 mL) followed by 
potassium tert-butoxide (1.70 g, 15.2 mmol) and the mixture was stirred for 5 min. 2-Chloro-1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazole 247 (3.74 g, 10.1 mmol) was added to the reaction 
mixture and heated under reflux overnight. The reaction mixture was filtered and evaporated to 
dryness to give the crude product. The residue was purified by column chromatography using silica 
gel as absorbent and light petroleum/ethyl acetate (1:1) as eluents to afford 4-( {1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-carboxylic acid 248 as a pale 
yellow crystalline powder (4.88 g, 10.0 mmol, 99 %), mp 98.2-103.5 °C; (Found: M+, 485.9915. 
c;1H1.JN20 2S requires 485.9905); vmax (KBr)/cm-1 3382,3056,2964, 1924, 1695, 1591, 1544, 1434, 
1385, 1271, 1185, 838 and 734; 6H 5.49 (2 H, s, CH2), 6.31 (1 H, dd, J = 7.6, 1.2, 6-H), 7.02 (1 H, 
ddd, J = 7.6, 7.6, 1.6, 4-H), 7.19 (1 H, ddd, J = 7.6, 7.6, 0.8, 5-H), 7.25-7.28 (2 H, m, ArH), 7.34 (2 
H, dd, J = 6.6, 1.8, 3-H and 5-H), 7.40-7.44 (1 H, m, ArH), 7.69-7.73 (1 H, m, ArH), 7.81 (2 H, dd, 
J = 6.6, 1.6, 2-H and 6-H), and 7.91 (1 H, dd, J = 7.8, 1.0, 3-H); 6c 52.81 (CH2), 97.96 (2-C), 
111.07 (benzimidazole 417-C), 119.55 (benzimidazole 4/7-C), 122.85 (benzimidazole 5/6-C), 123.77 
(benzimidazole 5/6-C), 126.83 (4-C), 129.03 (5-C), 129.89 (6-C), 129.95 (2 x ArCH), 130.39 (2 x 
ArCH), 133.03 (1-C), 136.28 (3a-C), 137.81 (4-C), 138.26 (7a-C), 139.73 (3-C), 143.21 
(benzimidazole 2-C), 147.88 (1-C) and 167.92 (C=O); mlz El 486 (M+, 4 %), 465 (48), 431 (8), 378 
(7), 262 (22), 217 (100), 178 (20), 154 (50), 90 (61) and 73 (58). 
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Methyl4-({1-[(2-iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-
carboxylate 249 
4 3 3 2 sa3aN WO I ~s 4 :1 6 ~ N I ~ ;} 0 
7 a;X): -
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~4 
5 
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Acetyl chloride (2.0 mL, 28.0 mmol) was added dropwise over 10 min to MeOH (25 mL) cooled in 
an ice bath. The solution was stirred for 5 min and 4-( { 1-[(2-iodophenyl)methyl]-1H-
benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylic acid 248 (0.62 g, 1.3 mmol) was added in one 
portion and the solution slowly heated to reflux. Heating under reflux was continued overnight. 
The solution was cooled and evaporated to dryness to give the crude methyl ester. Distilled water 
(10 mL) was added to the crude methyl ester hydrochloride and the aqueous layer was basified to 
pH 14 with sodium carbonate and 1 M aqueous sodium hydroxide solution (few drops). The basic 
solution was extracted with DCM (3 x 25 mL). The combined organic extracts were dried (MgS04) 
and evaporated to dryness. The residue was purified by column chromatography using neutral 
alumina as absorbent and light petroleum/ethyl acetate (1:1) as eluents to afford methyl4-( {1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-carboxylate 249 as white 
crystals (0.5 g, 1.0 mmol, 78 %), mp 179.1-181.2 °C; (Found: MH+, 501.0131. C2~17IN202S 
requires 501.0134); vmax (KBr)/cm-1 2940, 1713, 1589, 1544, 1428, 1351, 1277, 1107, 1012,841, 
824,748 and 689; oH 3.79 (3 H, s, CH3), 5.33 (2 H, s, CH2), 6.19 (1 H, d, J = 7.2, 6-H), 6.81 (1 H, 
dd, J = 7.6, 1.0, 4-H), 6.94 (1 H, dd, J = 7.6, 1.0, 5-H), 7.07 (1 H, d, J = 7.6, ArH), 7.17-7.27 (2 H, 
m, ArH), 7.30 (2 H, d, J = 8.8, 3-H and 5-H), 7.72-7.74 (2 H, m, ArH) and 7.76 (2 H, d, J = 8.4, 2-H 
and 6-H); Oc 51.18 (CH3), 52.30 (CH2), 95.79 (2-C), 109.22 (benzimidazole 417-C), 119.29 
(benzimidazole 417-C), 122.08 (benzimidazole 5/6-C), 123.14 (benzimidazole 5/6-C), 125.60 (4-C), 
127.58 (5-C), 128.14 (1-C), 128.35 (6-C), 128.45 (2 X ArCH), 129.31 (2 X ArCH), 134.84 (4-C), 
136.20 (3a-C), 136.98 (7a-C), 138.51 (3-C), 142.35 (benzimidazole 2-C), 145.55 (1-C) and 165.24 
(C=O); m/z FAB 501 (MH+, 32 %), 327 (19), 281 (22), 217 (40), 147 (54) and 136 (100). 
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11H-Benzo[4,5]imidazo[1,2-a]isoindole 250 and methyl4-{[1-(phenylmethyl)-1H-
benzo[ d]imidazole-2-yl]sulfanyl}benzene-1-carboxylate 251 
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Method A (TTMSS, AIBN and toluene) 
TIMSS (0.68 mL, 2.2 mmol) in toluene (20 mL) was added to methyl4-( { 1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-carboxylate 249 (0.55 g, 1.1 
mmol) in toluene (480 mL) at reflux over 5 h using a syringe pump. AIBN (0.27 g, 1.7 mmol) was 
added to the refluxing reaction mixture at equal intervals. The crude mixture was evaporated to 
dryness and purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (9:1) as eluents to afford 11H-benzo[4,5]imidazo[1,2-a]isoindole 250 as a 
crystalline white solid (45 mg, 0.22 mmol, 20 %), mp 144.0-149.0 °C; (Found: M+, 206.0841. 
C14H1oN'2 requires 206.0844); vmax (KBr)/cm·1 2927, 2367, 1657, 1433, 1399, 1269 and 740; ()H 5.27 
(2 H, s, CH2), 7.26-7.42 (7 H, m, ArH) and 7.70-7.72 (1 H, m, ArH); <>c 46.18 (CH2), 108.29 
(benzimidazole 6/9-C), 118.90 (benzimidazole 6/9-C), 122.12 (benzimidazole 7/8-C), 122.62 
(benzimidazole 7/8--C), 123.44 (11a-C), 127.09 (3-C), 127.47 ( 4-C), 127.81 (2-C), 128.83 (1-C), 
129.07 (4a-C), 134.69 (5a and 9a) and 143.89 (4b-C); m/z El 206 (M+, 46 %), 149 (17), 119 (8), 91 
(16) and 77 (18). We also isolated methyl4-{[1-(phenylmethyl)-1H-benzo[d]imidazole-2-
yl]sulfanyl}benzene-1-carboxylate 251 as a pale yellow oil (165 mg, 0.44 mmol, 40 %); (Found: 
M+, 375.1167. C22H18N20 2S requires 375.1167); vmax (KBr)/cm·1 2950, 1721, 1594, 1434, 1350, 
1276, 1181, 1108, 1016, 824 and 760; <>H 3.89 (3 H, s, CH3), 5.45 (2 H, s, CH2), 7.06-7.08 (2 H, m, 
ArH), 7.23-7.34 (8 H, m, ArH), 7.88 (1 H, d, J = 7.6, ArH) and 7.90 (2 H, d, J = 7.9, 2-H and 6-H); 
<>c 48.34 (CH3), 52.21 (CH2), 110.42 (benzimidazole 4/7-C), 120.28 (benzimidazole 417-C), 122.90 
(benzimidazole 5/6-C), 123.95 (benzimidazole 5/6-C), 126.72 (ArCH), 127.98 (ArCH), 128.74 
(ArCH), 128.87 (ArCH), 130.39 (ArCH), 128.95 (ArC), 135.51 (ArC), 135.98 (ArC), 138.85 (ArC), 
143.51 (ArC), 145.96 (2-C) and 166.40 (C=O); mlz FAB 375 (M+, 74 %), 322 (20), 243 (43), 167 
(87), 154 (100) and 136 (74). 
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Method B ( tributylgermanium hydride, AIBN and toluene) 
Tributylgermanium hydride (0.09 mL, 0.36 mmol) was added to methyl4-({1-[(2-
iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-carboxylate 249 (0.13 g, 0.25 
mmol) in toluene (40 mL) followed by portion wise addition of ACCN (excess) to the refluxing 
reaction mixture at equal intervals. The solution was stirred and heated under reflux for 9 h. The 
crude product was purified by column chromatography using neutral alumina as absorbent and light 
petroleum/ethyl acetate (9:1) as eluents to afford the reduced product methyl4-{[1-(phenylmethyl)-
1H-benzo[d]imidazole-2-yl]sulfanyl}benzene-1-carboxylate 251 as a pale yellow oil (68 mg, 0.18 
mmol, 60 %) exclusively. The TLC and 1H-NMR and IR spectra were identical to those of an 
authentic sample. 
Synthesis of resin-bound benzimidazole moiety 252 
252 
To a portion ofWang resin (1.0 g, 1.7 mmol) was added DCM (20 mL). The resin was left to swell 
for 1 h under N2• 4-( { 1-[(2-Iodophenyl)methyl]-1H-benzo[d]imidazol-2-yl}sulfanyl)benzene-1-
carboxylic acid 248 (1.40 g, 3.9 mmol), DMAP (0.62 g, 5.1 mmol) and DIC (1.33 mL, 8.5 mmol) 
were added sequentially. The suspension was shaken for 48 hat rt. The reaction mixture was 
filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The resin was dried 
at 40 °C under vacuum for 24 h. The coupling reaction was repeated under similar conditions. 
The loading on the resin was determined by cleaving a known amount of resin using [TFA/DCM 
(9/1)](0.60 mmol/g). 
IR vmax (KBr)/cm·1 3424,3058,3024, 2919,2365, 1944, 1717, 15%, 1510, 1492, 1445, 1371, 1266, 
1239, 1173, 1099, 1011,822,743 and 6%. 
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1-[2-(2· Bromophenyl)ethyl]-2-chloro-1H-benzo[ d) imidazole 253 
253 
2-Chlorobenzimidazole 163 (0.35 g, 2.3 mmol) was added slowly to a suspension ofNaH (0.12 g, 
5.0 mmol) in dry THF (60 mL). The mixture was stirred and heated under reflux for 1 hand 2-(2-
bromophenyl)ethyl methanesulfonate 245 (0.49 g, 1.8 mmol) in THF ( 10 mL) was added dropwise 
to the reaction mixture. The mixture was heated under reflux for a further 2 h. The salts formed 
were removed by filtration on a celite bed and the solution was evaporated to dryness to yield a tan 
solid. The solid was purified by column chromatography using silica gel as absorbent and light 
petroleum/ethyl acetate (9:1) as eluents to afford 1-[2-(2-bromophenyl)ethyl]-2-chloro-1H-
benzo[d]imidazole 253 as cream coloured crystals (0.58 g, 1.7 mmol, 98 %), mp 73.5-75.4 oc; 
(Found: M+, 333.9871. C1Jf12N2BrCl requires 333.9872); vmax (KBr)/cm-1 3042, 2932, 1614, 1473, 
1452, 1378, 1357, 1329, 1329, 1263, 1170, 1032, 1004,758,746,729 and 655; ~H 3.20 (2 H, t, J = 
7.3, CH2), 4.40 (2 H, t, J = 7.3, NCH:J, 6.89 (1 H, t, J = 6.5, ArH), 7.05-7.10 (2 H, m, ArH), 7.22-
7.23 (3 H, m, ArH), 7.51-7.54 (1 H, t, J = 8.0, ArH) and 7.64-7.68 (1 H, m, ArH); ~c 35.93 (CH2), 
43.84 (NCH2), 109.30 (benzimidazole 417-C), 119.37 (benzimidazole 417-C), 122.60 (benzimidazole 
5/6-C), 123.12 (benzimidazole 5/6-C), 124.40 (2-C), 127.84 (ArCH), 128.93 (ArCH), 131.06 
(ArCH), 132.99 (ArCH), 134.88 (ArC), 136.37 (ArC), 140.42 (ArC) and 141.58 (benzimidazole 2-
C); mlz El 334 (M+, 22 %), 255 (11), 182 (45), 165 (100), 129 (27), 90 (34) and 70 (32). 
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4-({1-[2-(2-Bromophenyl)ethyl]-1H-benzo[ d]imidazole-2-yl}sulfanyl) benzene-1-carboxylic acid 
254 
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4-Mercaptobenzoic acid 189 (2.06 g, 13.4 mmol) was dissolved in EtOH (60 mL) followed by 
potassium tert-butoxide (2.25 g, 20.1 mmol) and the mixture was left stirring for 5 min. 1-[2-(2-
Bromophenyl)ethyl]-2-chloro-1H-benzo[d]imidazole 253 (4.50 g, 13.4 mmol) was added to the 
reaction mixture and the reaction mixture was heated under reflux overnight. The reaction mixture 
was filtered and evaporated to dryness to give the crude product. The crude product was purified by 
column chromatography using silica gel as absorbent and light petroleum/ethyl acetate (1:1) as 
eluents to afford 4-( { 1-[2-(2-bromophenyl)ethyl]-1H-benzo[d]imidazole-2-yl}sulfanyl)benzene-1-
carboxylic acid 254 as white crystals (6.0 g, 13.4 mmol, 99 %), mp 203-207 °C; (Found: MH+, 
453.0279. C22H17BrN20 2S requires 453.0273); vmax (KBr)/cm-1 3423, 3054, 2372, 1699, 1592, 1539, 
1413, 1259, 1170, 1017,851 and 746; ()H(DMSO) 3.14 (2 H, t, J = 7.0, CH2), 4.53 (2 H, t, J = 7.0, 
NCH2), 7.02 (1 H, d, J = 7.2, ArH), 7.20-7.29 (4 H, m, ArH), 7.33 (2 H, d, J = 8.4, 3-H and 5-H), 
7.53-7.57 (2 H, m, ArH), 7.64 (1 H, d, J = 7.6, ArH) and 7.89 (2 H, d, J = 8.8, 2-H and 6-H); 
()c(DMSO) 35.81 (CH2), 44.28 (NCH2), 110.94 (benzimidazole 417-C), 119.47 (benzimidazole 4/7-
C), 122.64 (benzimidazole 5/6-C), 123.55 (benzimidazole 5/6-C), 124.39 {1-C), 128.28 (ArCH), 
129.27 (2 X ArCH), 129.40 (ArCH),130.58 (2 X ArCH), 131.70 (ArCH), 132.94 (ArCH), 135.80 (4-
C), 137.09 (3a-C and 7a-C), 143.17 (ArC), 146.32 (benzimidazole 2-C) and 168.56 (C=O); mlz 
FAB 453 (MH+, 25 %), 373 (4), 307 (10), 289 (80), 154 (100) and 136 (83). 
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Methyl4-({1-[2-(2-bromophenyl)ethyl]-1H-benzo[d]imidazol-2-yl)sulfanyl)benzene-1-
carboxylate 255 
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Acetyl chloride (0.46 mL, 6.6 mmol) was added dropwise over 10 min to MeOH (25 mL) cooled in 
an ice bath. The solution was stirred for 5 min and 4-( {1-[2-(2-bromophenyl)ethyl]-1H-
benzo[d]imidazole-2-yl}sulfanyl)benzene-1-carboxylic acid 254 (0.30 g, 0.7 mmol) was added in 
one portion and the solution slowly heated to reflux. Heating under reflux was continued overnight. 
The solution was cooled and evaporated to dryness to yield the crude methyl ester. Distilled water 
(10 mL) was added to the crude methyl ester hydrochloride and the aqueous layer basified to pH 14 
with sodium carbonate and 1 M aqueous sodium hydroxide solution (few drops). The basic solution 
was extracted with DCM (3 x 25 mL). The combined organic extracts were dried (MgS04) and 
evaporated to dryness to afford methyl4-( { 1-[2-(2-bromophenyl)ethy1]-J H-benzo[d]imidazol-2-
yl)sulfanyl)benzene-1-carboxylate 255 as light brown crystals (0.23 g, 0.5 mmol, 76 %), mp 102.5-
103.5 °C; (Found: M+, 466.0353. C23H1J3rN20 2S requires 466.0351); vmax (KBr)/cm-1 3037, 2948, 
1724,1594,1475,1456,1428,1352,1284,1272,1182,1168,1108,1012,851,822,768,764,750 
and 691; <>H 3.14 (2 H, t, J = 7.3, CH2), 4.48 (2 H, t, J = 7.2,NCH2), 3.87 (3 H, s, OCH3), 6.79 (1 H, 
d, J = 6.2, ArH), 7.07-7.10 (2 H, m, ArH), 7.31-7.37 (5 H, m, ArH), 7.52 (1 H, d, J = 7.2, ArH), 
7.78-7.80 (1 H, m, ArH) and 7.92 (2 H, d, J = 8.3, 2-H and 6-H); <>c 36.45 (CH2), 44.29 (NCH2), 
52.18 (OCH3), 109.94 (benzimidazole 417-C), 120.23 (benzimidazole 417-C), 122.73 
(benzimidazole 5/6-C), 123.78 (benzimidazole 5/6-C), 124.51 (2-C), 127.83 (ArCH), 128.43 
(ArCH), 128.89 (ArCH), 130.40 (ArCH), 131.04 (ArCH),133.02 (ArCH), 135.64 (ArC), 136.59 
(ArC), 139.25 (ArC), 143.37 (1-C), 145.42 (ArC) and 166.35 (C=O); mlz El 466 (M+, 100 %), 387 
(97), 322 (10), 297 (22), 284 (45), 253 (38), 238 (45), 220 (33), 169 (27), 103 (39) and 77 (55). 
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5,6-Dihydrobenzo[ 4,5]imidazo[2,1-a ]isoquinoline 256 
256 
A solution of tributyltin hydride (0.19 mL, 0.7 mmol) in toluene (20 mL) was added to methyl4-
( { 1-[2-(2-bromophenyl)ethyl]-J H-benzo[d]imidazol-2-yl }sulfanyl)benzene-1-carboxylate 255 (0.13 
g, 0.28 mmol) in toluene (150 mL) at reflux over 5 h using a syringe pump. AIBN (69 mg, 0.42 
mmol) was added portion wise to the refluxing reaction mixture at equal intervals. The solution was 
stirred and heated under reflux for a further 3 h. The reaction mixture was evaporated to dryness 
and then purified by column chromatography using silica gel as absorbent with light petroleum and 
ethyl acetate as eluents to give product which still had traces of tin impurity. Dil. hydrochloric acid 
was added to the cooled reaction mixture to extract the protonated benzimidazole compounds into 
the aqueous layer and washed with light petroleum to remove Bu3Sn-residues. The acidic aqueous 
layer was basified with sodium carbonate and aqueous sodium hydroxide (few drops) to pH 14. The 
basic solution was extracted with DCM (3 x 20 mL). The combined organic extracts were dried 
(MgS04) and evaporated to dryness to give 5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256 as 
off-white crystals (31 mg, 0.14 mmol, 50%), mp 125.0-130.0 °C; (Found: M+, 220.1000. C15H12N2 
requires 220.1001); vmax (KBr)/cm-1 2922,2370,2344, 1480, 1458, 1406, 1325, 1171 and 736; bH 
3.30 (2 H, t, J = 6.9, 5-H), 4.35 (2 H, t, J = 6.9, 6-H), 7.26-7.43 (6 H, m, ArH), 7.81-7.85 (1 H, m, 
ArH) and 8.29-8.32 (1 H, m, ArH); be 28.26 (5-C), 40.42 (6-C), 109.05 (benzimidazole 8/11-C), 
119.76 (benzimidazole 8111-C), 122.5 (benzimidazole 9/10-C), 122.71 (benzimidazole 9/10-C), 
125.70 (ArCH), 126.64 (12b-C), 127.76 (ArCH), 128.08 (ArCH), 130.18 (ArCH), 134.27 (11a-C), 
134.65 (7a-C), 143.86 (4a-C) and 149.10 (12a-C); m/z El 220 (M+, 100 %), 109 (9), 86 (10) and 77 
(9). 
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Synthesis of solid-supported benzimidazole adduct 257 
257 
To a portion of Wang resin (0.6 g, 1.0 mmol) was added DCM/DMF (15/5 mL). The resin was left 
to swell for 1 h under N2• 4-( { 1-[2-(2-Bromophenyl)ethyl]-1H-benzo[d]imidazole-2-
yl}sulfanyl)benzene-1-carboxylic acid 254 (0.6 g, 1.3 mmol), DMAP (0.48 g, 3.9 mmol) and DIC 
( 1.03 mL, 6.6 mmol) were added sequentially. The suspension was shaken for 48 hat rt. The 
reaction mixture was filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). 
The resin was dried at 40 °C under vacuum for 24 h. The coupling reaction was repeated under 
similar conditions. 
The loading on the resin was determined by cleaving a known amount of resin using [TFA/DCM 
(9/1)](0.98 mmollg). 
IR Vmax (KBr)/cm-1 3023, 2919, 1713, 1590, 1441, 1263, 1170, 1095, 1090, 1010,821,742 and 694. 
Radical cyclisations of resin-bound benzimidazole moiety 256 
256 
Method A (thermal, tributylgermanium hydride and toluene) 
To refluxing suspension of the resin-bound benzimidazole 257 (140 mg, 0.14 mmol) in toluene (15 
mL) was added tributylgermanium hydride (0.11 mL, 0.4 mmol), followed by portion wise addition 
of AIBN ( 43 mg, 0.26 mmol). The mixture was heated at reflux for 8 h, followed by another 
addition of tributylgermanium hydride (0.11 mL, 0.43 mmol) and AIBN ( 43 mg, 0.26 mmol). The 
reaction mixture was heated at reflux for another 8 h. The reaction mixture was filtered and washed 
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with toluene (20 mL), DCM (20 mL) and MeOH (20 mL) to give 5,6-
dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256 as off-white crystals (20 mg, 0.1 mmol, 71% ), 
mp 125.0-130.0 °C; (Found: M+, 220.1000. C15H12N2 requires 220.1001); vmax (KBr)/cm-1 2922, 
2370, 2344, 1480, 1458, 1406, 1325, 1171 and 736; oH 3.30 (2 H, t, J = 6.9, 5-H), 4.35 (2 H, t, J = 
6.9, 6-H), 7.26-7.43 (6 H, m, ArH), 7.81-7.85 (1 H, m, ArH) and 8.29-8.32 (1 H, m, ArH); be 28.26 
(5-C), 40.42 (6-C), 109.05 (benzimidazole 8/11-C), 119.76 (benzimidazole 8/11-C), 122.5 
(benzimidazole 9/10-C), 122.71 (benzimidazole 9/10-C), 125.70 (ArCH), 126.64 (12b-C), 127.76 
(ArCH), 128.08 (ArCH), 130.18 (ArCH), 134.27 (lla-C), 134.65 (7a-C), 143.86 (4a-C) and 149.10 
(12a-C); mlz El 220 (M+, 100 %), 109 (9), 86 (10) and 77 (9). 
Method B ( thermal, tributyltin hydride and toluene) 
A solution of tributyltin hydride (0.12 mL, 0.44 mmol) and AIBN ( 43 mg, 0.26 mmol) in toluene (5 
mL) was added to refluxing suspension of the resin-bound benzimidazole 257 (lOO mg, 0.098 
mmol) in toluene (10 mL) over 7 h using a syringe pump. The reaction mixture was cooled, filtered 
and washed with toluene (20 mL), DCM (20 ml) and MeOH (20 mL) to give 5,6-
dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256 as off-white crystals (10 mg, 0.04 mmol, 44% ), 
mp 125.0-130.0 °C; (Found: M+, 220.1000. C15H12N2 requires 220.1001); vmax (KBr)/cm-1 2922, 
2370, 2344, 1480, 1458, 1406, 1325, 1171 and 736; oH 3.30 (2 H, t, J = 6.9, 5-H), 4.35 (2 H, t, J = 
6.9, 6-H), 7.26-7.43 (6 H, m, ArH), 7.81-7.85 (lH, m, ArH) and 8.29-8.32 (1 H, m, ArH). 
Method C (TTMSS, BE~ and toluene) 
To a suspension of the resin-bound benzimidazole 257 (111 mg, 0.11 mmol) in toluene (15 mL), 
TTMSS (0.06 mL, 0.19 mmol) and E~B (1.0 M in cyclohexane, 0.2 mmol) were added dropwise. 
The flask was fitted with a rubber septum and air was introduced through a needle during stirring at 
rt for 5 h. Further addition ofTTMSS (0.12 mL, 0.38 mmol) and E~B (1.0 M in hexane, 0.3 mmol) 
were carried out at equal intervals and the reaction mixture was stirred for another 10 h. The 
reaction mixture was filtered and washed with toluene (20 mL), DCM (20 ml) and MeOH (20 mL) 
to give 5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline 256 as off-white crystals (7 mg, 0.03 
mmol, 29 % ). The TLC, 1H-NMR and IR spectra for the cyclised product were identical to an 
authentic sample. 
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Ethy16-[(1H-imidazol-2-yl)sulfanyl]pyridine-3-carboxylate 260 
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2-Mercaptoimidazole 259 (2.00 g, 20.0 mmol) was added slowly to a suspension of NaH (0.58 g, 
24.2 mmol) in dry DMF ( 40 mL). The mixture was stirred and heated at 80 °C for 1 h, followed by 
addition of ethyl6-chloronicotinate (3.71 g, 20.0 mmol) in DMF (10 mL) and the reaction mixture 
was heated at 80 oc for 12 h. The reaction mixture was evaporated to dryness and the crude product 
was purified by column chromatography using silica gel as absorbent and light petroleum/ethyl 
acetate (1:1) as eluents to afford ethyl6-[(1H-imidazol-2-yl)sulfanyl]pyridine-3-carboxylate 260 as 
white crystals (2.49 g, 10.0 mmol, 50%), mp 145.7-146.9 °C; (Found: M+, 249.0573 C11H11N30 2S 
requires 249.0572); vmax (KBr)/cm-1 3079, 2986,2745,2502, 1866, 1715, 1574, 1444, 1275, 1113, 
1011, 965, 851 and 767; bH 1.40 (3 H, t, J = 7.2, CH3), 4.40 (2 H, q, J = 7.2, CH2), 7.12 (1 H, d, J = 
8.6, 5-H), 7.23-7.26 (2 H, s, imidazole 5-H and 4-H), 8.10 (1 H, d, J = 8.6, 4-H) and 9.02 (1 H, s, 2-
H); be 14.25 (CH3), 61.55 (CH2), 121.31 (5-C), 123.31 (imidazole 4-C and 5-C), 133.18 (ArC), 
135.09 (imidazole 2-C), 137.58 (4-C), 150.48 (2-C), 162.62 (C=O) and 164.77 (6-C); mlz El 250 
(MH+, 100 %), 232 (33), 221 (7), 163 (11), 130 (12), 103 (21), 91 (10) and 77 (11). 
Ethy16-({ 1-[2-(2-bromophenyl)ethyl]-1H-imidazol-2-yl}sulfanyl)pyridine-3-carboxylate 261 
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Ethyl 6-[(lH-imidazol-2-yl)sulfanyl]pyridine-3-carboxylate 260 (0.90 g, 3.6 mmol) was added 
slowly to a suspension of NaH (0.22 g, 9.2 mmol) in dry DMF (30 mL). The mixture was stirred for 
1 hand 2-(2-bromophenyl)ethyl methanesulfonate 245 (1.30 g, 4.7 mmol) in DMF (10 mL) was 
added dropwise to the reaction mixture. The mixture was stirred at rt for a further 24 h. The salts 
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formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a brown solid. The crude product was purified by column chromatography using neutral 
alumina as absorbent and light petroleum/ethyl acetate (1: 1) as eluents to afford ethyl6-( { 1-[2-(2-
bromophenyl)ethyl]-1H-imidazol-2-yl }sulfanyl)pyridine-3-carboxylate 261 as a pale yellow oil 
(1.16 g, 2.70 mmol, 75 %); (Found: M+, 431.0312. CIJIJsBrN3S02 requires 431.0303); vmax 
(neat)/cm-1 3105,3056,2981, 1716, 1584, 1472, 1456, 1429, 1366, 1283, 1269, 1173, 1128, 1025, 
854 and 766; ~ 1.38 (3 H, t, J = 7.2, CH3), 3.13 (2 H, t, J = 7.2, CH2), 4.31-4.39 (4 H, m, NCH2, 
OCH2), 6.88 (1 H, dd, J = 8.4, 0.4, 5-H), 6.96 (1 H, dd, J = 7.6, 1.6, Ar 6-H), 7.08 (1 H,ddd, J = 7.4, 
7.4 and 1.2, Ar 5-H), 7.10 (1 H, s, imidazole 4-H or 5-H), 7.16 (1 H, ddd, J = 7.4, 7.4 and 1.2, Ar 4-
H), 7.27 (1 H, s, imidazole 4-H/5-H), 7.49 (1 H, dd, J = 8.0 and 1.2, Ar 3-H), 8.04 (1 H, dd, J = 8.4 
and 2.0, 4-H) and 8.96 (1 H, s, 2-H); be 14.23 (CH3), 37.88 (CH2), 46.73 (NCH2), 61.36 (OCH2), 
120.40 (5-C), 123.15 (Ar 2-C), 123.41 (imidazole 4-C), 124.39 (3-C), 127.75 (imidazole 5-C), 
128.86 (Ar 5-C), 131.04 (Ar 6-C), 131.19 (Ar 4-C), 132.99 (Ar 3-C), 134.43 (Ar 1-C), 136.32 
(imidazole 2-C), 137.67 (4-C), 150.86 (2-C), 164.40 (C=O) and 164.89 (6-C); mlz El 431 (M+, 4 
%), 352 (11), 249 (46), 181 (100), 153 (64), 84 (45) and 49 (39). 
5,6-Dihydroimidazo[2,1-a]isoquinoline 262 
Method A (tributyltin hydride, AffiN and toluene) 
A solution of tributyltin hydride (0.26 mL, 1.0 mmol) in toluene ( 40 mL) was added to ethyl 6-( { 1-
[2-(2-bromophenyl)ethyl]-1H-imidazol-2-yl}sulfanyl)pyridine-3-carboxylate 261 (0.15 g, 0.4 mmol) 
in toluene (210 mL) at reflux over 7 h using a syringe pump. AIBN (0.14 g, 0.85 mmol) was added 
to the refluxing reaction mixture at equal intervals. The solution was stirred and heated under reflux 
for a further 3 h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the 
protonated imidazole compounds into the aqueous layer and washed with light petroleum to remove 
Bu3Sn-residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The crude product was 
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purified by column chromatography using neutral alumina as absorbent and light petroleum/ethyl 
acetate (7:3) as eluents to afford 5,6-dihydroimidazo[2,1-a]isoquinoline 262 as a clear oil (22 mg, 
0.13 mmol, 37 %); (Found: M+, 170.0847. C11H1oN2 requires 170.0844); vmax (neat)/cm-1 3171, 
2923,1708, 1499, 1466, 1329, 1250, 1195, 1099,911,772,738 and 714; 6H 3.16 (2 H, t, J = 6.8, 
CH2), 4.17 (2 H, t, J = 6.8, NCHJ, 6.94 (1 H, s, 2/3-H), 7.15 (1 H, s, 2/3-H), 7.26-7.27 (3 H, m, 
ArH) and 8.02 (1 H, d, J = 8.0, 10-H); 6c 28.59 (6-C), 43.33 (5-C), 119.12 (2-C), 123.57 (3-C), 
127.62 (9-C), 127.76 (10-C), 128.35 (817-C), 129.08 (817-C), 132.35 (lOa-C and 6a-C) and 142.92 
(lOb-C); m/z El 170 (M+, 4 %), 149 (5), 128 (16), 115 (16), 77 (21), and 57 (23). Unreacted 
starting material 261 was also recovered (28 mg, 0.07 mmol, 19% ). 
Method B (TTMSS, AffiN and toluene) 
A solution ofTIMSS (0.41 mL, 1.33 mmol) in toluene (30 mL) was added to ethyl6-({1-[2-(2-
bromophenyl)ethyl]-1H-imidazol-2-yl }sulfanyl)pyridine-3-carboxylate 261 (0.23 g, 0.5 mmol) in 
toluene (220 mL) at reflux over 8 h using a syringe pump. AIBN (0.16 g, 1.00 mmol) was added to 
the refluxing reaction mixture at equal intervals. The solution was stirred and heated under reflux 
for a further 4 h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the 
protonated imidazole compounds into the aqueous layer and washed with light petroleum to remove 
TTMSS-residues. The acidic aqueous layer was basified with sodium carbonate and aqueous 
sodium hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). 
The combined organic extracts were dried (MgS04) and evaporated to dryness. The residue was 
purified by column chromatography using neutral alumina as absorbent and light petroleum/ethyl 
acetate (7:3) as eluents to afford 5,6-dihydroimidazo[2,1-a]isoquinoline 262 as a clear oil (41 mg, 
0.24 mmol, 45% ). The TLC and 1H-NMR and IR spectra were identical to those of an authentic 
sample. 
Method C ( tributylgermanium hydride, AIBN and toluene) 
Tributylgermanium hydride (0.12 mL, 0.46 mmol) was added to ethyl 6-( { 1-[2-(2-
bromophenyl)ethyl]-18-imidazol-2-yl}sulfanyl)pyridine-3-carboxylate 261 (80 mg, 0.19 mmol) in 
toluene (30 mL) followed by portion wise addition of AIBN (75 mg, 0.46 mmol) to the refluxing 
reaction mixture at equal intervals. The solution was stirred and heated under reflux for a further 8 
h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the protonated 
imidazole compounds into the aqueous layer and washed with light petroleum to remove Bu3Ge-
residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
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hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The crude product was 
purified by column chromatography using neutral alumina as absorbent and light petroleum/ethyl 
acetate (7:3) as eluents to afford 5,6-dihydroimidazo[2,1-a]isoquinoline 262 as a clear oil (7 mg, 
0.04 mmol, 20 % ). The TLC and 1H-NMR and IR spectra were identical to those of an authentic 
sample. 
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EXPERIMENTAL FOR CHAPTER FIVE 
Methyl1[(2-iodophenyl)methyl]-1H-imidazole-4-carboxylate 271 
Methyl4-imidazole-carboxylate 270 (0.50 g, 4.0 mmol) was added slowly to a suspension of NaH 
(0.29 g, 11.9 mmol) in dry DMF ( 40 mL). The mixture was stirred and heated under reflux for 1 h 
and (2-iodophenyl)methyl methanesulfonate 241 (2.47 g, 7.9 mmol) in DMF (10 mL) was added 
dropwise to the reaction mixture. The mixture was heated under reflux for a further 12 h. The salts 
formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a pale yellow oil. The oil was purified by column chromatography using neutral alumina as 
absorbent and light petroleum/ethyl acetate (1:4) as eluents to afford methyl 1-[(2-
iodophenyl)methyl]-1H-imidazol-4-carboxylate 271 as a clear oil (0.58 g, 1.7 mmol, 43% ); (Found: 
M+, 341.9860. C12H11N2102 requires 341.9865); vmax (neat)/cm-1 2947, 1718, 1545, 1437, 1380, 
1224, 1204, 1119, 1014, 765, 742 and 660; oH 3.88 (3 H, s, CH3), 5.20 (2 H, s, CH2), 7.02 (1 H, dd, 
1 = 7.6, 1.2, 6-H), 7.07 (1 H, ddd, 1 = 7.6, 7.6 and 1.6, 4-H), 7.36 (1 H, ddd, 1 = 7.6, 7.6 and 1.2, 5-
H), 7.59 (1 H, s, imidazole 5-H), 7.60 (1 H, s, imidazole 2-H) and 7.89 (1 H, dd, 1 = 8.0, 1.2, 3-H); 
oc 51.71 (CH3), 55.86 (CH2), 98.62 (2-C), 125.38 (imidazole 5-C), 129.12 (4-C), 129.18 (5-C), 
130.52 (6-C), 134.15 (imidazole 4-C), 137.37 (1-C), 138.41 (imidazole 2-C), 140.15 (Ar 3-C) and 
163.16 (C=O); mlz El 342 (M+, 27 %), 311 (12), 284 (13), 217 (100), 183 (46), 121(15) and 90 
(43). 
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Attempted radical cyclisation ofmethyl1[(2-iodophenyl)methyl]-1H-imidazole-4-carboxylate 
271 
274 
Method A (tribntyltin hydride, AIBN and toluene) 
A solution oftributyltin hydride (0.39 mL, 1.5 mmol) in toluene (40 mL) was added to methyl1-[(2-
iodophenyl)methyl]-1H-imidazol-4-carboxylate 271 (0.20 g, 0.6 mmol) in toluene (120 mL) at 
reflux over 7 h using a syringe pump. AIBN (0.12 g, 0.7 mmol) was added to the refluxing reaction 
mixture at equal intervals. The solution was stirred and heated under reflux for a further 5 h. Dil. 
hydrochloric acid was added to the cooled reaction mixture to extract the protonated imidazole 
compounds into the aqueous layer and washed with light petroleum to remove Bu3Sn-residues. The 
acidic aqueous layer was basified with sodium carbonate and aqueous sodium hydroxide (few drops) 
to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The combined organic extracts 
were dried (MgS04) and evaporated to dryness. The residue was purified by column 
chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate (1:1) as 
eluents to afford methyl1-(phenylmethyl)-1H-imidazole-4-carboxylate 274 as a colourless oil (41 
mg, 0.19 mmol, 33 %); (Found: MH+, 217.0976. C12H12N20 2 requires 217.0977); vmax (neat)/cm-1 
2363, 1720, 1545, 1440, 1380, 1224, 1119,997 and 713; bH 3.88 (3 H, s, OCH3), 5.14 (2 H, s, CH2), 
7.17-7.20 (2 H, m, ArH), 7.25-7.26 (1 H, m, ArH), 7.37-7.41 (2 H, m, ArH), 7.56 (1 H, s, imidazole 
5-H) and 7.60 (1 H, m, imidazole 2-H); be 51.39 (CH2), 51.73 (0CH3), 118.58 (imidazole 4-C), 
125.40 (imidazole 5-C), 127.58 (ArCH), 128.78 (ArCH), 129.24 (ArCH), 138.07 (imidazole 2-C), 
142.92 (1-C) and 163.23 (C=O); mlz El 216 (M+, 10 %), 185 (5), 158 (8), 128 (4), 91 (100), 77 (8) 
and 65 (18). 
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Method B (tributylgermanium hydride, AIBN and toluene) 
Tributylgermanium hydride (0.16 mL, 0.6 mmol) was added to methyl1-[(2-iodophenyl)methyl]-
1H-imidazol-4-carboxylate 271 (86 mg, 0.25 mmol) in toluene (30 mL) followed by portion wise 
addition of AIBN (102 mg, 0.63 mmol) to the refluxing reaction mixture at equal intervals. The 
solution was stirred and heated under reflux for 10 h. Dil. hydrochloric acid was added to the 
cooled reaction mixture to extract the protonated imidazole compounds into the aqueous layer and 
washed with light petroleum to remove Bu3Ge-residues. The acidic aqueous layer was basified with 
sodium carbonate and aqueous sodium hydroxide (few drops) to pH 14. The basic solution was 
extracted with DCM (3 x 20 mL). The combined organic extracts were dried (MgS04) and 
evaporated to dryness. The crude oil was purified by column chromatography using neutral alumina 
as absorbent and light petroleum/ethyl acetate (1:1) as eluents to afford methyl1-(phenylmethyl)-
1H-imidazole-4-carboxylate 274 as a colourless oil (30 mg, 0.14 mmol, 56%). The TLC and 1H-
NMR and IR spectra for the reduced product were identical to an authentic sample. 
Methyll-[2-(2-bromophenyl)ethyl]-lH-imidazole-4-carboxylate 275 and 
methyll-[2-(2-bromophenyl)ethyl]-lH-imidazole-5-carboxylate 276 
275 276 
Methyl4-imidazole-carboxylate 270 (0.50 g, 4.0 mmol) was added slowly to a suspension of 
sodium hydride (0.30 g, 12.5 mol) in dry DMF ( 40 mL). The mixture was stirred and heated at 80 
°C for 1 hand 2-(2-bromophenyl)ethyl methanesulfonate 245 (2.00 g, 7.2 mmol) in DMF (10 mL) 
was added dropwise to the reaction mixture and it was heated at 80 oc for 12 h. The reaction 
mixture was evaporated to dryness and the crude product was purified by column chromatography 
using silica gel as absorbent and light petroleum/ethyl acetate (1: 1) and ethyl acetate as eluents to 
afford methy11-[2-(2-bromophenyl)ethyl]-1H-imidazole-4-carboxylate 275 as a pale yellow oil 
(0.61 g, 1.98 mmol, 50%); (Found: M+, 308.0157. C13H13BrN20 2 requires 308.0160); vmax 
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(neat)/cm-1 2948, 1724, 1547, 1472, 1439, 1382, 1225, 1197, 1120, 1029,997,757 and 660; bH 3.10 
(2 H, t, J = 7.2, CH2), 3.79 (3 H, s, OCH3), 4.16 (2 H, t, J = 7.2, NCH2), 6.88 ( 1 H, dd, J = 7.2 and 
1.6, Ar 6-H), 7.04 (1 H, ddd, J = 7.6, 7.6 and 1.6, Ar 4-H), 7.11 (1 H, ddd, J = 7.6, 7.6 and 1.6, Ar 5-
H), 7.24 (1 H, s, imidazole 5-H) and 7.47-7.50 (2 H, m, imidazole 2-H and Ar 3-H); be 37.04 (CH2), 
45.95 (NCH2), 50.61 (OCH3), 123.16 (Ar 2-C), 124.11 (imidazole 5-C), 126.98 (ArCH), 128.14 
(ArCH), 129.97 (ArCH), 132.18 (ArCH), 132.84 (imidazole 4-C), 134.93 (Ar 1-C), 136.89 
(imidazole 2-C) and 162.19 (C=O); mlz El 309 (MH+, 1 %), 229 (34), 197 (95), 169 (52), 115 (53), 
108 (100), 89 (68), 77 (69) and 53 (77). The column chromatography also yielded the other 
regioisomer methyl1-[2-(2-bromophenyl)ethyl]-1H-imidazole-5-carboxylate 276 as a white 
crystalline powder (0.59 g, 1.90 mmol, 48% ), mp 92.0-95.9 °C; (Found: MH+, 309.0239. 
C13H13BrN20 2 requires 309.0238); (Found: C, 50.29; H, 4.05; N, 8.25. requires C, 50.50; H, 4.24; 
N, 9.06 %); vmax (KBr)/cm-1 3079, 1715, 1539, 1475, 1437, 1362, 1236, 1162, 1108, 1025,947,867, 
761 and 660; bH 3.22 (2 H, t, J = 7.0, CH2), 3.89 (3 H, s, OCH3), 4.55 (2 H, t, J = 7.0, NCH2), 6.98 
(1 H, d, J = 7.4, Ar 6-H), 7.10 (1 H, ddd, J = 7.4, 7.4 and 1.9, Ar 4-H), 7.17 (1 H, ddd, J = 7.4, 7.4 
and 1.9, Ar 5-H), 7.28 (1 H, s, imidazole 4-H), 7.56 (1 H, d, J = 7.4, Ar 3-H) and 7.73 (1 H, s, 
imidazole 2-H); be 37.65 (CH2), 46.42 (NCH2), 51.55 (0CH3), 122.09 (imidazole 5-C), 124.40 (Ar 
2-C), 127.81 (ArCH), 128.70 (ArCH), 131.13 (ArCH), 132.99 (ArCH), 136.76 (Ar 1-C), 138.05 
(imidazole 4-C), 142.15 (imidazole 2-C) and 160.72 (C=O); m/z El 309 (MH+, 1 %), 277 (2), 229 
(100), 197 (15), 182 (8), 169 (25), 103 (18), 89 (13) and 77 (29). 
Methyl5,6-dihydroimidazo[ 5, l-a ]isoquinoline-1-carboxylate 277 and methyl 5,6-
dihydroimidazo[2, l-a ]isoquinoline-2-carboxylate 278 
Method A (tributyltin hydride, AIBN and toluene) 
A solution of tributyltin hydride (0.31 mL, 1.1 mmol) in toluene (20 mL) was added to methyl1-[2-
(2-bromophenyl)ethyl]-1H-imidazole-4-carboxylate 275 (0.14 g, 0.5 mmol) in toluene (120 mL) at 
reflux over 5 h using a syringe pump. AIBN (0.11 g, 0.68 mmol) was added to the refluxing 
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reaction mixture at equal intervals. The solution was stirred and heated under reflux for a further 5 
h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the protonated 
imidazole compounds into the aqueous layer and washed with light petroleum to remove Bu3Sn-
residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The crude product was 
purified by column chromatography using neutral alumina as absorbent and light petroleum/ethyl 
acetate ( 1: 1) and ethyl acetate as eluents to afford methyl 5,6-dihydroimidazo[5, 1-a]isoquinoline-1-
carboxylate 277 as a crystalline white needles (16 mg, 0.07 mmol, 16 %), mp 179.0-182.9 °C; 
(Found: M+, 228.0900. C 13H12N20 2 requires 228.0900); vmax (KBr)/cm-1 3118, 2951,2368, 1689, 
1546, 1469, 1432, 1347, 1217, 1182, 1164, 1107, 939, 769 and 655; i>H 3.10 (2 H, t, J = 6.5, CH2), 
3.96 (3 H, s, OCH3), 4.17 (2 H, t, J = 6.5, NCH2), 7.27 (1 H, dd, J = 8.0 and 1.0, 7-H), 7.32 (1 H, 
ddd, J = 8.0, 8.0 and 1.0, 9-H), 7.38 (1 H, ddd, J = 8.0, 8.0 and 1.0, 8-H), 7.54 (1 H, s, 3-H) and 8.74 
(1 H, dd, J = 8.0 and 1.0, 10-H); be 29.60 (5-C), 42.47 (6-C), 51.91 (OCH3), 125.93 (1-C), 127.65 
(9-C), 127.80 (10-C), 128.23 (lOb-C), 128.37 (817-C), 129.07 (7/8-C), 133.01 (lOa-C), 133.80 (6a-
C), 135.51 (3-C) and 164.17 (C=O); mlz El 228 (M+, 74 %), 197(100), 170 (54), 140 (13) and 115 
(25). The X-Ray crystallography also confirmed the structure of methyl5,6-dihydroimidazo[5,1-
a ]isoquinoline-1-carboxylate. Further elution yielded the other cyclised product, methyl 5,6-
dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 as a pale yellow oil (11 mg, 0.05 mmol, 4 %); 
(Found: M+, 228.0900. C13H12N20 2 requires 228.0900); vmax (neat)/cm-1 3134,2953,2925,2359, 
1723,1542,1461,1437,1349,1326,1258,1225,1199,1181,1124,1103, 1006,808,777,737and 
718; 6H 3.11 (2 H, t, J = 7.2, CH2), 3.84 (3 H, s, OCH3), 4.15 (2 H, t, J = 7.20, NCH2), 7.17 (1 H, dd, 
J = 6.8 and 2.0, 7-H), 7.23-7.30 (2 H, m, ArH), 7.58 (1 H, s, 3-H) and 8.10 (1 H, dd, J = 7.6 and 2.0, 
10-H); be 27.24 (6-C), 42.73 (5-C), 50.79 (0CH3), 123.55 (ArCH), 124.40 (ArCH), 125.15 (2-C), 
126.70 (ArCH), 126.81 (ArCH), 127.29 (lOa-C), 128.34 (3-C), 131.68 (6a-C), 144.02 (lOb-C) and 
162.52 (C=O); mlz El 228 (M+, 100 %), 197 (92), 170 (75), 140 (12), 115 (28) and 77 (10). 
Method B (tributylgermanium hydride, benzenethiol, AIBN and toluene) 
Tributylgermanium hydride (0.12 mL, 0.46 mmol) was added to methyl 1-[2-(2-
bromophenyl)ethyl]-lH-imidazole-4-carboxylate 275 (0.13 g, 0.41 mmol) and benzenethiol (4 f.tL, 
10 mol%) in toluene (55mL), followed by portion wise addition of AIBN (102 mg, 0.62 mmol) to 
the refluxing reaction mixture at equal intervals. The solution was stirred and heated under reflux 
for 10 h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the protonated 
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imidazole compounds into the aqueous layer and washed with light petroleum to remove Bu3Ge-
residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The residue was purified 
by column chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate 
(7:3) as eluents to afford methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 as a 
crystalline white solid (41 mg, 0.18 mmol, 44 %), mp 179.0-182.9 ° C. The TLC and 1H-NMR and 
IR spectra were identical to those of an authentic sample. The 1H-NMR spectrum of the crude 
product showed the presence of starting material and traces of other unidentifiable materials. The % 
recovery of unaltered starting material was not recorded. 
Method C (tributylgermanium hydride, AIBN and toluene) 
Tributylgermanium hydride (0.20 mL, 0.8 mmol) was added to methyl 1-[2-(2-bromophenyl)ethyl]-
1H-imidazole-4-carboxylate 275 (98 mg, 0.32 mmol) in toluene (40 mL), followed by portion wise 
addition of AIBN (130 mg, 0.8 mmol) to the refluxing reaction mixture at equal intervals. The 
solution was stirred and heated under reflux for 10 h. Dil. hydrochloric acid was added to the 
cooled reaction mixture to extract the protonated imidazole compounds into the aqueous layer and 
washed with light petroleum to remove B~Ge-residues. The acidic aqueous layer was basified with 
sodium carbonate and aqueous sodium hydroxide (few drops) to pH 14. The basic solution was 
extracted with DCM (3 x 20 mL). The combined organic extracts were dried (MgS04) and 
evaporated to dryness. The crude product was purified by column chromatography using neutral 
alumina as absorbent and light petroleum/ethyl acetate (1:1) and ethyl acetate as eluents to afford 
methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-carboxylate 277 as a crystalline white solid (27 
mg, 0.12 mmol, 38 %), mp 179.0-182.9 °C. Further elution yielded the other product, methyl5,6-
dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 as a pale yellow oil (14 mg, 0.06 mmol, 19 
% ). The TLC and 1H-NMR and IR spectra for products were identical to authentic samples. The 
1H-NMR spectrum of the crude product showed the presence of starting material only. 
Method D (TTMSS, AIBN and toluene) 
A solution of TTMSS (0.48 mL, 1.54 mmol) in toluene (30 mL) was added to methyl 1-[2-(2-
bromophenyl)ethyl]-18-imidazole-4-carboxylate 275 (0.19 g, 0.62 mmol) in toluene (170 mL) at 
reflux over 8 h using a syringe pump. AIBN (0.25 g, 1.54 mmol) was added to the refluxing 
reaction mixture at equal intervals. The solution was stirred and heated under reflux for a further 4 
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h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the protonated 
imidazole compounds into the aqueous layer and washed with light petroleum to remove TIMSS-
residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The residue was purified 
by column chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate 
(1:1) and ethyl acetate as eluents to afford methyl5,6-dihydroimidazo[5,1-a]isoquinoline-1-
carboxylate 277 as a crystalline white solid (43 mg, 0.19 mmol, 30 %), mp 179.0-182.9 °C. Further 
elution yielded the other product, methyl5,6-dihydroimidazo[2,1-a]isoquinoline-2-carboxylate 278 
as a pale yellow oil ( 42 mg, 0.19 mmol, 30 % ). The TLC and 1H-NMR and IR spectra for the 
products were identical to authentic samples. 
Methyl5,6-dihydroimidazo[2,1-a ]isoquinoline-3-carboxylate 282 
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Method A (tributyltin hydride, AIBN and toluene) 
A solution of tributyltin hydride (0.40 mL, 1.5 mmol) in toluene (20 mL) was added to methyl1-[2-
(2-bromophenyl)ethyl]-1H-imidazole-5-carboxylate 276 (0.18 g, 0.6 mmol) in toluene (180 mL) at 
reflux over 5 h using a syringe pump. AIBN (0.23 g, 1.40 mmol) was added to the refluxing 
reaction mixture at equal intervals. The solution was stirred and heated under reflux for a further 7 
h. Dil. hydrochloric acid was added to the cooled reaction mixture to extract the protonated 
imidazole compounds into the aqueous layer and washed with light petroleum to remove B11:3Sn-
residues. The acidic aqueous layer was basified with sodium carbonate and aqueous sodium 
hydroxide (few drops) to pH 14. The basic solution was extracted with DCM (3 x 20 mL). The 
combined organic extracts were dried (MgS04) and evaporated to dryness. The residue was purified 
by column chromatography using neutral alumina as absorbent and light petroleum/ethyl acetate 
( 1: 1) as eluents to afford methyl 5,6-dihydroimidazo[2, 1-a]isoquinoline-3-carboxylate 282 as a 
crystalline white solid (95 mg, 0.42 mmol, 71 %), mp 122.0-124.9 oc; (Found: MH+, 229.0981. 
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C13H,3N20 2 requires 229.0977); vmax (K.Br)/cm-1 2372, 1710, 1509, 1441, 1387, 1337, 1252, 1184, 
1108, 1072 and 980; ()H 3.17 (2 H, t, J = 7.2, CH2), 3.88 (3 H, s, OCH3), 4.62 (2 H, t, J = 7.2, 
NCH2), 7.26-7.28 (1 H, m, 9-H), 7.33-7.39 (2 H, m, 8-H and 7-H), 7.83 (1 H, s, imidazole 2-H) and 
8.07 (1 H, m, 10-H); 6c 28.14 (6-C), 42.17 (5-C), 51.48 (OCH3), 122.14 (3-C), 124.68 (ArCH), 
126.23 (lOa-C), 127.65 (ArCH), 127.75 (ArCH), 129.80 (ArCH), 133.19 (6a-C), 137.87 (imidazole 
2-C), 148.34 (lOb-C) and 161.01 (C=O); m/z El 228 (M+, 100 %), 213 (8), 197 (42), 183 (7), 169 
(17), 140 (13), 128 (17), 115 (35) and 84 (29). 
Method B (tributylgermanium hydride, AIBN and toluene) 
Tributylgennanium hydride (0.15 rnL, 0.59 mmol) was added to methyl1-[2-(2-
bromophenyl)ethyl]-1H-imidazole-5-carboxylate 276 (0.12 g, 0.39 mmol) in toluene (55 rnL), 
followed by portion wise addition of AIBN (149 mg, 0.91 mmol) to the refluxing reaction mixture at 
equal intervals. The solution was stirred and heated under reflux for 12 h. Dil. hydrochloric acid 
was added to the cooled reaction mixture to extract the protonated imidazole compounds into the 
aqueous layer and washed with light petroleum to remove B~Ge-residues. The acidic aqueous layer 
was basified with sodium carbonate and aqueous sodium hydroxide (few drops) to pH 14. The basic 
solution was extracted with DCM (3 x 20 mL). The combined organic extracts were dried (MgS04) 
and evaporated to dryness. The residue was purified by column chromatography using neutral 
alumina as absorbent and light petroleum/ethyl acetate (1: 1) as eluents to afford methyl 5,6-
dihydroimidazo[2,1-a]isoquinoline-3-carboxylate 282 as a crystalline white solid (48 mg, 0.21 
mmol, 54%), mp 122.0-124.9 °C. The TLC and 1H-NMR and IR spectra were identical to an 
authentic sample. X-Ray crystallography confirmed the structure of methyl 5,6-
dihydroimidazo[2,1-a]isoquinoline-3-carboxylate. The 1H-NMR spectrum of the crude product 
showed the starting material (24 mg, 0.08 mmol, 20 % ). 
Methyll-[2-(2-bromophenyl)ethyl]-lH-indole-3-carboxylate 284 
0" 
284 
173 
Methyl indole-3-carboxylate 283 (1.50 g, 8.6 mmol) was added slowly to a suspension of sodium 
hydride (0.31 g, 12.84 mol) in dry DMF (20 mL). The mixture was stirred for 1 h and 2-(2-
bromophenyl)ethyl methanesulfonate 245 (3.57 g, 12.8 mmol) in DMF (10 mL) was added dropwise 
to the reaction mixture and it was stirred for 20 h. The reaction mixture was evaporated to dryness 
and the crude product was purified by column chromatography using neutral alumina as absorbent 
and toluene as eluent to afford methyl1-[2-(2-bromophenyl)ethyl]-1H-indole-3-carboxylate 284 as 
white crystals (1.20 g, 3.4 mmol, 40 %), mp 111.7-112.8 oc; (Found: M+, 357.0371. C18H16BrN02 
requires 357.0364); (Found: C, 60.84; H, 4.27; N, 3.80. requires C, 60.35; H, 4.50; N, 3.91 %); vmax 
(KBr)/cm-1 2946, 1696, 1534, 1470, 1442, 1267, 1224, 1162, 1116, 1093, 1026 and 747; i'IH 3.27 (2 
H, t, J = 7.6, CH2), 3.90 (3 H, s, OCH3), 4.40 (2 H, t, J = 7.6, NCH2), 6.93 (1 H, dd, J = 7.2 and 2.0, 
6-H), 7.08-7.16 (1 H, m, ArH), 7.25-7.30 (1 H, m, ArH), 7.40-7.42 (1 H, m, ArH), 7.57 (1 H, dd, J = 
7.2 and 2.0, Ar 3-H), 7.70 (1 H, s, indole 2-H) and 8.15-8.19 (1 H, m, indole 4-H); i'lc 37.10 (CH2), 
46.60 (NCH2), 51.00 (0CH3), 107.17 (indole 3-C), 109.89 (ArCH), 121.76 (ArCH), 121.88 (ArCH), 
122.81 (ArCH), 124.24 (Ar 2-C), 126.63 (indole 3a-C), 127.82 (ArCH), 128.88 (ArCH), 131.07 
(ArCH), 133.08 (ArCH), 134.23 (ArCH), 136.36 (indole 7a-C), 136.84 (Ar 1-C) and 165.48 (C=O); 
mlz El 357 (M+, 14 %), 278 (8), 138 (100), 129 (10) and 77 (8). 
Methyl5,6-dihydroindolo[2,1-a ]isoquinoline-12·carboxylate 285 
285 
Tributylgermanium hydride (0.16 mL, 0.63 mmol) was added to methyl1-[2-(2-
bromophenyl)ethyl]-1H-indole-3-carboxylate 284 (0.15 g, 0.4 mmol) in toluene (55 mL), followed 
by portion wise addition of AIBN (150 mg, 0.91 mmol) to the refluxing reaction mixture at equal 
intervals. The solution was stirred and heated under reflux for 12 h. The reaction mixture was 
evaporated to dryness. The residue was purified by column chromatography using silica gel as 
absorbent, hexane/toluene (1:1) and toluene as eluents to afford methyl5,6-dihydroindolo[2,1-
a]isoquinoline-12-carboxylate 285 as a clear oil (80 mg, 0.29 mmol, 68%); (Found: M+, 277.1104. 
C18H15N02 requires 277.1103); vmax (neat)/cm-1 2947, 1698, 1530, 1468, 1455, 1404, 1282, 1224, 
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1188, 1154, 1110, 1022, 768 and 747; bH 3.15 (2 H, t, J = 6.5, CH2), 3.99 (3 H, s, OCH3), 4.24 (2 H, 
t, J = 6.5, NCH2), 7.25-7.40 (6 H, m, ArH), 8.19 (1 H, m, 11-H) and 8.53 (1 H, dd, J = 7.2 and 1.8, 
1-H); be 29.75 (5-C), 40.36 (6-C), 51.12 (OCH3), 103.02 (12-C), 109.13 (indole 8-C), 122.04 
(indole 11/10/9-C), 122.40 (indole 11/10/9-C), 122.91 (indole 11/10/9-C), 126.67 (ArCH), 127.66 
(ArCH), 129.28 (ArCH), 129.73 (ArCH), 133.18 (lla-C), 134.76 (12b-C), 135.31 (4a-C), 138.05 
(12a-C), 139.96 (7a-C) and 166.38 (C=O); mlz El 277 (M+, 100 %), 246 (92), 217 (38), 188 (30), 
108 (14) and 77 (9). 
Ethyl 1-[2-(2-bromophenyl)ethyl]-lH-pyrrole-2-carboxylate 287 
4 3 
~0-./ 
1 0 
287 
Ethyl pyrrolo-2-carboxylate 286 (2.50 g, 18.0 mmol) was added slowly to a suspension of NaH 
(1.72 g, 71.7 mmol) in dry DMF (45 mL). The mixture was stirred and heated at 80 oc for 1 hand 
2-(2-bromophenyl)ethyl methanesulfonate 245 (6.0 g, 21.59 mmol) in DMF (10 mL) was added 
drop wise to the reaction mixture. The mixture was stirred and heated at 80 °C overnight. The salts 
formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a pale yellow oil. The oil was purified by column chromatography using silica gel as 
absorbent and toluene as eluent to afford ethyl1-[2-(2-bromophenyl)ethyl]-1H-pyrrole-2-
carboxylate 287 as a pale yellow oil (5.59 g, 17.4 mmol, 97 % ); (Found: M+, 321.0367. 
C1.Jf16BrN02 requires 321.0364); vmax (neat)/cm-1 3109,3056,2979,2869, 1694, 1567, 1531, 1470, 
1415, 1325, 1241, 1171, 1101, 1077, 1027, 917, 738 and 657; bH 1.36 (3 H, t, J = 7.2, CH3), 3.20 (2 
H, t, J = 7.2, CH2), 4.30 (2 H, q, J = 7.1, OCHJ, 4.52 (2 H, t, J = 7.3, NCH2), 6.02 (1 H, dd, J = 3.9 
and 2.5, pyrrole 4-H), 6.59 (1 H, dd, J = 2.5 and 1.9, pyrrole 5-H), 6.95 (1 H, dd, J = 3.9 and 1.9, 
pyrrole 3-H), 7.02-7.16 (3 H, m, ArH) and 7.53 (1 H, dd, J = 7.9 and 1.2, Ar 3-H); be 14.48 (CH3), 
37.23 (CH2), 48.73 (NCH2), 59.78 (OCH2), 107.76 (pyrrole 4-C), 118.23 (pyrrole 3-C), 121.63 
(pyrrole 2-C), 124.45 (Ar 2-C), 126.75 (ArCH), 127.53 (ArCH), 128.30 (pyrrole 5-C), 131.27 
175 
(ArCH), 132.66 (ArCH), 137.72 (Ar 1-C) and 161.11 (C=O); mlz El 321 (M+, 2 %), 276 (11), 242 
(100), 169 (98), 152 (22), 124 (100), 103 (24), 94 (46) and 77 (25). 
Ethyl S,6-dihydropyrrolo[2,1-a ]isoquinoline-3-carboxylate 288 
288 
Tributylgermanium hydride (0.19 mL, 0.8 mmol) was added to ethyl1-[2-(2-bromophenyl)ethyl]-
1H-pyrrole-2-carboxylate 287 (0.16 g, 0.5 mmol) in toluene (40 mL), followed by portion wise 
addition of AIBN (246 mg, 1.5 mmol) to the refluxing reaction mixture at equal intervals. The 
solution was stirred and heated under reflux for 12 h. The reaction mixture was evaporated to 
dryness. The residue was purified by column chromatography using silica gel as absorbent, 
hexane/toluene (1:1) as eluents to afford ethyl5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate 
288 as a clear oil (99 mg, 0.41 mmol, 82 %); (Found: M+, 241.1103. C1Jf1_sN02 requires 241.1103); 
vmax (neat)/cm·1 2928, 1694, 1489, 1446, 1260, 1224, 1150, 1105, 1068 and 749; bH 1.37 (3 H, t, J = 
7.2, CH3), 3.08 (2 H, t, J = 6.8, CH2), 4.31 (2 H, q, J = 7.0, OCH2), 4.64 (2 H, t, J = 6.8, NCH2), 6.52 
(1 H, d, J = 4.0, pyrrole 1-H), 7.02 (1 H, d, J = 4.0, pyrrole 2-H), 7.20-7.28 (3 H, m, ArH) and 7.56 
(1 H, d, J = 7.6, Ar 10-H); be 14.49 (CH3), 28.94 (CH2), 42.18 (NCH2), 59.85 (OCH2), 104.40 
(pyrrole 1-C), 113.71 (pyrrole 3-C/lOb-C), 118.22 (pyrrole 2-C), 122.12 (pyrrole 3-C/lOb-C), 
123.62 (ArCH), 127.15 (ArCH), 127.39 (ArCH), 128.39 (ArCH), 131.74 (Ar lOa-C), 136.04 (Ar 6a-
C) and 161.43 (C=O); mlz El 241 (M+, 100 %), 213 (39), 196 (28), 168 (32), 139 (11), 115 (11) and 
77 (3). 
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Ethyl1-[2-(2-bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxyJate 291 
Ethyl3-(trifluoromethyl)pyrazole-4-carboxylate 290 (2.0 g, 9.6 mmol) was added slowly to a 
suspension of NaH (0.96 g, 40 mmol) in dry DMF (30 mL). The mixture was stirred and heated at 
80 °C for 1 hand 2-(2-bromophenyl)ethyl methanesulfonate 245 (5.34 g, 19.2 mmol) in DMF (5 
mL) was added drop wise to the reaction mixture. The mixture was heated at 80 °C overnight. The 
salts formed were removed by filtration on a celite bed and the solution was evaporated to dryness to 
yield a pale yellow oil. The oil was purified by column chromatography using silica gel as 
absorbent and light petroleum/ethyl acetate (2:1) and (1:1) as eluents to afford ethyl 1-[2-(2-
bromophenyl)ethyl]-3-(trifluoromethyl)-lH-pyrazole-4-carboxylate 291 as a pale yellow oil (3.69 g, 
9.45 mmol, 85 %); (Found: MH+, 391.0269. C15H14BrF3N20 2 requires 391.0269); vmax (neat)/cm-' 
3135,3070,2984, 1732, 1543, 1474, 1443, 1368, 1303, 1223, 1143, 1054,847,776 and 752; i>H 
1.33 (3 H, t, J = 7.2, CH3), 3.32 (2 H, t, J = 7.2, CH2), 4.30 (2 H, q, J = 7.2, OCH2), 4.42 (2 H, t, J = 
7.2, NCH2), 6.99 (1 H, dd, J = 7.4 and 1.8, ArH), 7.12 (1 H, ddd, J = 7.4, 7.4 and 1.2, ArH), 7.20 (1 
H, ddd, J = 7.6, 7.6 and 1.6, ArH), 7.58 (1 H, dd, J = 8.0 and 1.2, ArH) and 7.74 (1 H, s, pyrazole 5-
H); i>c 14.08 (CH3), 36.78 (CH2), 52.36 (NCH2), 60.88 (OCH2), 112.97 (CF3), 119.07 (pyrazole 4-
C), 121.75 (pyrazole 3-C), 124.26 (Ar 2-C), 127.91 (ArCH), 129.08 (ArCH), 131.08 (ArCH), 
133.16 (ArCH), 135.80 (pyrazole 5-C), 136.07 (Ar 1-C) and 160.80 (C=O); m/z El 391 (M+, 1 %), 
345 (10), 311 (100), 283 (29), 265 (18), 182(100), 169 (48), 103 (78) and 77 (51). 
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Ethyl 2·( trifluoromethyl)-5,6-dihydropyrazolo[ 5,1-a ]isoquinoline-1-carboxylate 293 
293 
Tributylgermanium hydride (0.21 mL, 0.8 mmol) was added to ethyl1-[2-(2-bromophenyl)ethyl]-3-
(trifluoromethyl)-1H-pyrazole-4-carboxylate 291 (0.16 g, 0.4 mmol) in toluene (35 mL), followed 
by portion wise addition of AIBN (167 mg, 1.02 mmol) to the refluxing reaction mixture at equal 
intervals. The solution was stirred and heated under reflux for 12 h. The reaction mixture was 
evaporated to dryness. The residue was purified by column chromatography using silica gel as 
absorbent, hexane/toluene (1:1) as eluents to afford ethyl2-(trifluoromethyl)-5,6-
dihydropyrazolo[5,1-a]isoquinoline-1-carboxylate 293 as a clear oil (72 mg, 0.23 mmol, 57%); 
(Found: M+, 310.0926. C15H13F3N20 2 requires310.0929); vmax (neat)/cm-1 2928,2369, 1717, 1473, 
1199, 1142 and 1042; ~H 1.39 (3 H, t, J = 7.2, CH3), 3.19 (2 H, t, J = 6.8, 6-H), 4.36-4.42 (4 H, m, 
5-H and OCH2), 7.30-7.40 (3 H, m, ArH) and 8.30-8.32 (1 H, m, 10-H); ~c 13.82 (CH3), 29.31 (6-
C), 47.15 (5-C), 61.37 (OCH2), 109.00 (CF3), 119.46 (pyrazole 1-C), 122.13 (pyrazole 2-C), 125.00 
(Ar lOa-C), 127.60 (ArCH), 127.83 (ArCH), 128.07 (ArCH), 130.23 (10-C), 133.34 (6a-C), 141.54 
(lOb-C) and 162.56 (C=O); mlz El 310 (M+, 43 %), 282 (10), 265 (100), 238 (14), 140 (5), 104(38), 
91 (10), and 77 (6). 
1-[2-(2-Bromophenyl)ethyl]-1H-pyrrole-2-carboxylic acid 294 
~OH 
1 0 
294 
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Ethyl 1-[2-(2-bromophenyl)ethyl]-1H-pyrrole-2-carboxylate 287 (0.1 g, 0.31 mmol) was dissolved 
in ethanol (2.5 mL) followed by addition of aqueous sodium hydroxide (2 M, 5.0 mL). The reaction 
mixture was heated under reflux for 8 h and followed by TLC. Then the reaction mixture was 
cooled and washed with diethyl ether (3 x 20 mL). The aqueous layer was acidified to pH 3 with 
hydrochloric acid and thoroughly extracted with dichloromethane (3 x 30 mL). The organic layers 
were washed with water, dried (MgS04) and evaporated to dryness to afford 1-[2-(2-
bromophenyl)ethyl]-1H-pyrrole-2-carboxylic acid 294 as white crystals (89 mg, 0.30 mmol, 98% ), 
mp 158-163 °C; (Found: M+, 293.0057. C13H12BrN02 requires 293.0051); vmax (KBr)/cm-1 3448, 
2925, 2629,2371, 1672, 1534, 1438, 1332, 1264, 1116, 1027,924 and 741; bH 3.23 (2 H, t, J = 7.2, 
CHJ, 4.56 (2 H, t, J = 7.2, NCH2), 6.08 (1 H, dd, J = 4.0 and 2.4, pyrrole 4-H), 6.66 (1 H, dd, J = 
4.0 and 2.4, pyrrole 5-H), 7.01 (1 H, dd, J = 7.6 and 2.0, Ar 6-H), 7.09 (1 H, ddd, J = 7.6, 7.6 and 
1.7, ArH), 7.11 (1 H, dd, J = 4.0 and 2.0, pyrrole 3-H), 7.19 (1 H, ddd, J = 7.6, 7.6 and 1.2, ArH) 
and 7.55 (1 H, dd, J = 7.6 and 1.2, Ar 3-H); be 38.22 (CH2), 48.93 (NCH2), 108.34 (pyrrole 4-C), 
120.45 (pyrrole 2-C), 120.49 (pyrrole 3-C), 124.49 (Ar 2-C), 127.60 (ArCH), 128.41 (ArCH), 
130.30 (pyrrole 5-C), 131.27 (ArCH), 132.76 (ArCH), 137.59 (Ar 1-C) and 164.96 (C=O); m/z El 
293 (M+, 1 %), 265 (4), 214 (100), 170 (60), 124 (87), 94 (46) and 77 (23). 
1· [2·(2-bromophenyl)ethyl]·3·( tri0uoromethyi)-1H-pyrazole-4-carboxylic acid 296 
296 
Ethyl 1-[2-(2-bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 291 (1.20 g, 3.1 
mmol) was dissolved in ethanol (10 mL) followed by addition of aqueous sodium hydroxide (2 M, 
15 mL). The reaction mixture was heated under reflux for 8 h and followed by TLC. Then the 
reaction mixture was cooled and washed with ethyl acetate (3 x 20 mL). The aqueous layer was 
acidified to pH 3 with hydrochloric acid and thoroughly extracted with dichloromethane (3 x 30 
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mL). The organic layers were washed with water, dried (MgS04) and evaporated to dryness to 
afford 1-[2-(2-bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 296 as light 
brown crystals (1.10 g, 3.0 mmol, 97 %); (Found: MH+, 362.9956. C13H1J3rF3N20 2 requires 
362.9961); Vmax (KBr)/cm-1 3300, 2953, 2683, 2600, 1697, 1547, 1499, 1438, 1309, 1236, 1191, 
1145, 1048, 945 and 754; bH 3.34 (2 H, t, J = 7.2, CH2), 4.45 (2 H, t, J = 7.2, NCH2), 6.97 (1 H, dd, 
J = 7.6 and 1.6, Ar 6-H), 7.12-7.22 (2 H, m, ArH), 7.15 (1 H, ddd, J = 7.6, 7.6 and 1.6, Ar 4-H), 
7.20 (1 H, ddd, J = 7.6, 7.6 and 1.6, Ar 5-H), 7.58(1 H, dd, J = 7.6 and 1.6, Ar 3-H) and 7.75 (1 H, s, 
pyrazole 5-H); be 36.72 (CH2), 52.67 (NCH2), 111.63 (CF3), 118.82 (pyrazole 4-C), 121.50 
(pyrazole 3-C), 124.22 (Ar 2-C), 127.92 (ArCH), 129.18 (ArCH), 131.06 (ArCH), 133.21 (ArCH), 
135.91 (Ar 1-C), 136.76 (pyrazole 5-C) and 165.57 (C=O); mlz El 283 (95 %), 182 (100), 169 (60), 
103 (62), 90 (52), 77(45) and 69 (32). 
Synthesis of solid-supported pyrrole moiety 295 
295 
To a portion of Wang resin (0.25 g, 0.43 mmol) was added DCM (8.0 mL). The resin was left to 
swell for 112 h under N2• 1-[2-(2-Bromophenyl)ethyl]-1H-pyrrole-2-carboxylic acid 294 (0.25 g, 0.9 
rnrnol) in DMF (8.0 rnL), DMAP ( 0.16 g, 1.3 mmol) and DIC (0.4 rnL, 2.6 mmol) were added 
sequentially. The suspension was shaken for 48 hat rt. The reaction mixture was filtered and 
washed with DCM, MeOH, DMF, MeOH and DCM (20 rnL each). The resin was dried at 40 oc 
under vacuum for 24 h. The coupling reaction was repeated with equimolar reagents. 
IR vmax (KBr)/cm-1 3455,3042,2916,2366, 1702, 1597, 1517, 1449, 1222, 1084, 1010,751 and 683. 
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Synthesis of solid-supported pyrazole moiety 297 
297 
To a portion of Wang resin (0.40 g, 0.7 mmol) was added DCM (8.0 mL). The resin was left to 
swell for 112 h under N2• 1-[2-(2-Bromophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic 
acid 296 (0.62 g, 1.7 mmol) in DMF (8.0 mL), DMAP ( 0.25 g, 2.1 mmol) and DIC (0.64 mL, 4.1 
mmol) were added sequentially. The suspension was shaken for 48 hat rt. The reaction mixture 
was filtered and washed with DCM, MeOH, DMF, MeOH and DCM (20 mL each). The resin was 
dried at 40 °C under vacuum for 24 h. The coupling reaction was repeated with equimolar reagents. 
IR vmax (KBr)/cm-1 3458,3026, 2922,2370, 1723, 1602, 1508, 1370, 1290, 1211, 1138, 1037,815, 
747 and693. 
Radical cyclisations of resin-bound pyrazole adduct 297 
0 
298 
Method A (thermal method, Bu3GeH and toluene) 
0 HO-:tJCF3 
" ~3 5 I N2 
N"" 
1 
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To refluxing resin-bound pyrazole 297 (140 mg, 0.11 mmol) in toluene (10 mL) was added B~GeH 
(0.55 mL, 2.1 mmol) followed by portion wise addition of AIBN (0.25 g, 1.5 mmol) to the refluxing 
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reaction mixture at equal intervals. The reaction mixture was heated at reflux for 30 h. Then the 
reaction mixture was cooled to room temperature, filtered and washed with toluene, DCM and 
MeOH (20 mL each). The resin was dried at 40 °C under vacuum for 24 h. The tethered products 
on the resin were cleaved using TFA/DCM (9/1) and a crystalline material was recovered (44 mg). 
The LC-MS of the cleaved sample from the resin confirmed the presence of cyclised adduct 2-
(trifluoromethyl)-5,6-dihydropyrazolo[S,l-a]isoquinoline-1-carboxylic acid 298 and the starting 
material 296. The 1H NMR spectrum of the cleaved sample was very clean and showed the cyclised 
product 298 (20%) and the unreacted starting material 296 (70% )( 1:3 .5). The separation of these 
compounds by column chromatography due to eo-elution was unsuccessful. 
The 1H NMR data for the cyclised product 298 has been recorded; <>H 3.20 (2 H, t, J = 6.8, 6-H), 
4.40 (2 H, t, J = 6.8, 5-H), 7.16-7.34 (3 H, m, ArH) and 8.33-8.35 (1 H, m, 10-H); <>c 29.35 
(pyrazole 6-C), 47.25 (pyrazole 5-C), 108.00 (CF3), 119.25 (pyrazole 1-C), 121.94 (pyrazole 2-C), 
124.75 (Ar lOa-C), 127.71 (ArCH), 128.09 (ArCH), 128.36 (ArCH), 130.55 (Ar 10-C), 133.68 (Ar 
6a-C), 142.73 (pyrazole lOb-C) and 166.91 (C=O). 
Method B (thermal method, TTMSS and toluene) 
TTMSS (1.3 mL, 4.2 mmol) and AIBN (0.20 g, 1.2 mmol) were added to refluxing resin-bound 
pyrazole moiety 297 ( 111 mg, 0.09 mmol) in toluene ( 15 mL) at equal intervals. The reaction 
mixture was heated at reflux for 30 h. Then the reaction mixture was cooled to room temperature, 
filtered and washed with toluene, DCM and MeOH (20 mL each). The resin was dried at 40 °C 
under vacuum for 24 h. The tethered products on the resin were cleaved using TFA/DCM (9/1) and 
red brown oil was recovered (30 mg). The LC-MS of the cleaved sample from the resin confirmed 
the presence of cyclised adduct 2-(trifluoromethyl)-5,6-dihydropyrazolo[S, 1-a]isoquinoline-1-
carboxylic acid 298 and the reduced product 299. The 1H NMR spectrum of the cleaved sample was 
very clean and showed the cyclised product 298 (53%) and the reduced product 299 (27% ). The 
separation of these compounds by column chromatography due to eo elution was unsuccessful. 
The 1H NMR data for the cyclised product 298 has been recorded; <>H 3.20 (2 H, t, J = 6.8, 6-H), 
4.40 (2 H, t, J = 6.8, 5-H), 7.16-7.34 (3 H, m, ArH) and 8.33-8.35 (1 H, m, 10-H); <>c 29.35 
(pyrazole 6-C), 47.25 (pyrazole 5-C), 108.00 (CF3), 119.25 (pyrazole 1-C), 121.94 (pyrazole 2-C), 
124.75 (Ar lOa-C), 127.71 (ArCH), 128.09 (ArCH), 128.36 (ArCH), 130.55 (Ar 10-C), 133.68 (Ar 
6a-C), 142.73 (pyrazole lOb-C) and 166.91 (C=O). The 1H NMR data for the reduced product 299 
182 
has also been recorded; bH 3.20 (2 H, t, J = 6.8, CH2), 4.40 (2 H, m, NCH2), 7.08 (1 H, d, J = 7.6, 
ArH), 7.16-7.34 (1 H, m, ArH), 7.39-7.42 (3 H, m, ArH) and 7.75 (1 H, s, 5-H); be 36.25 (CH2), 
54.77 (NCH2), 111.70 (CF3), 118.90 (pyrazole 4-C), 121.58 (pyrazole 3-C), 127.27 (ArCH), 128.60 
(ArCH), 128.94 (ArCH), 136.67 (pyrazole 5-C) and 165.37 (C=O). 
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APPENDIX: X-RAY CRYSTALLOGRAPHY DATA 
Table 1: Crystal data and structure refinement for methyl 5,6-dihydroimidazo[S, 1-a]isoquinoline-1-
carboxylate 277 
Chemical formula 
Formula weight 
Temperature 
Radiation, wavelength 
Crystal system, space group 
Unit cell parameters 
Cell volume 
z 
Calculated density 
Absorption coefficient f.!. 
F(OOO) 
Crystal colour and size 
Reflections for cell refinement 
· Data collection method 
8 range for data collection 
Index ranges 
Completeness to 8 == 26.00° 
Intensity decay 
Reflections collected 
Independent reflections 
Reflections with F2>2cr 
Absorption correction 
Min. and max. transmission 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data I restraints I parameters 
Final R indices [F2>.2cr] 
R indices (all data) 
Goodness-of-fit on F2 
Largest and mean shiftlsu 
Largest diff. peak and hole 
C1JHizNzOz 
228.25 
150(2) K 
MoKa, 0.71073 A 
triclinic, P l 
a == 7.077(3) A 
b == 7.830(3) A 
c == 9.856(4) A 
535.7(3) N 
2 
1.415 g/cm3 
0.098 mm-1 
240 
a== 100.317(6)0 
p = 92.468(6)0 
y = 93.062(6)0 
colourless, 0.74 x 0.57 x 0.05 mm3 
2403 (8 range 2.65 to 28.50°) 
Bruker SMART 1000 CCD diffractometer 
w rotation with narrow frames 
2.10 to 28.64° 
h -9 to 9, k -9 to 9, I -13 to 13 
95.5% 
0% 
4162 
2332 (Rint == 0.0314) 
1863 
semi-empirical from equivalents 
0.93 I and 0.995 
direct methods 
· Full-matrix least-squares on F 2 
0. I I 08, 0. 7470 
2332/0/155 
RI= 0.070I, wR2 = 0.2164 
RI = 0.0829, wR2 = 0.2253 
1. I06 
0.000 and 0.000 
0.398 and -0.396 e A-3 
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Table 2. Atomic coordinates and equivalent isotropic displacement parameters (N) 
for rbl. Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
X y z Ueq 
C(l) 0.2436(4) 0.2037(3) 0.0351(3) 0.0209(6) 
N(2) 0.2249(4) 0.0846(3) 0.1234(3) 0.0248(6) 
C(3) 0.2436(4) -0.0662(4) 0.0456(3) 0.0249(6) 
N(4) 0.2726(3) -0.0544(3) -0.0875(2) 0.0223(5) 
C(S) 0.2897(4) -0.1944(4) -0.2055(3) 0.0260(6) 
C(6) 0.1814(4) -0.1471(4) -0.3291(3) 0.0267(6)-
C(6A) 0.2477(4) 0.0324(4) -0.3504(3) 0.0233(6) 
C(7) 0.2587(4) 0.0726(4) -0.4819(3) 0.0275(6) 
C(8) 0.3208(4) 0.2381(4) -0.5005(3) 0.0289(7) 
C(9) 0.3757(4) 0.3649(4) .:..0.3864(3) 0.0276(7) 
C(lO) 0.3659(4) 0.3283(4) -0.2540(3) 0.0235(6) 
C(10A) 0.2976(4) 0.1640(3) -0.2351(3) 0.0197(6) 
C(10B) 0.2753(4) 0.1189(3) -0.0973(3) 0.0202(6) 
C(11) 0.2154(4) 0.3890(4) 0.0842(3) 0.0213(6) 
0(12) 9..2334(3) 0.5052(3) 0.0179(2) 0.0310(5) 
0(13) 0.1635,(3) 0.4168(3) 0.2156(2) 0.0287(5) 
C(14) 0.1215(5) 0.5933(4) 0.2716(3) 0.0302(7) 
Table 3. Bond lengths [A] and angles [0 ] for rbl. 
C(1)-C(10B) 1.387(4) C(1}-N(2) 1.390(3) 
C(1)-C(11) 1.472(4) N(2)-C(3) 1.304(4) 
C(3)-N(4) 1.355(4) N(4)-C(lOB) 1.376(3) 
N(4)-C(5) 1.463(4) C(5)-C(6) 1.523(4) 
C(6)-C(6A) 1.511(4) C(6A)-C(7) 1.392(4) 
C(6A)-C(10A) 1.409(4) C(7}-c(8) 1.392(4) 
C(8)-C(9) 1.386(5) C(9)-C(10) 
_,- 1.389(4) 
C(10)-C(lOA) 1.396(4) C(10A)-C(IOB) 1.476(4) 
C(11)-0(12) 1.217(3) C(11)-0(13) 1.344(3) -
0(13)-C(14) 1.4.45(4) 
C(10B)-C(l)-N(2) 11 0.3(2) C(10B)-C(1)-C(11) 128.9(2) 
N(2)-C(1)-C(11) - 120.5(3) C(3)-N(2)-C(1) 104.7(2) 
N(2)-C(3)-N(4) 112.8(2) C(3)-N(4)-C(10B) 107.6(2) 
C(3)-N(4)-C(S) 128.7(2) C(1 OB)-N( 4)-C(S) 123.6(2) 
N(4)-C(5)-C(6)' 107.7(2) C(6A)-C(6)-C(5) 11 0.4(2) 
C(7)-C(6A)-C(10A) 118.6(3) C(7)-C(6A)-C(6) 121.6(3) 
C(10A)-C(6A)-C(6) 119.7(3) C(6A)-C(7)-C(8) 121.2(3) 
C(9)-C(8)-C(7) 119h6(3) C(8)-C(9)-C( 1 0) 120.3(3) 
C(9)-C(10}-C(1 OA) 120.1(3) C(10}-C(10A}-C(6A) 120.1(3) 
C( 1 O)-C(10A)-C(1 OB) 122.9(3) C(6A}-C(lOA)-C(lOB) 117.1 (2) 
N( 4)-C(10B)-C(1) 104.5(2) N( 4)-C(l OB}-C(1 OA) 117.6(2) 
C(1)-C(10B}-C(l OA) 137.8(2) 0(12)-C(11)-0(13) 122.6(3) 
0(12)-C(11}-C(l) 126.3(3) ' 0(13)-C(l1 )-C(l) 111.0(2) 
C(11)-0(13)-C(l4) 115.6(2) 
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Table 4. Anisotropic displacement parameters (N) for rb 1. The anisotropic 
· . fi 2 2 2 ' 11 hk *b*U~' displacement factor exponent takes the orm:- 1t [h a*-U + ... + 2 a -] 
UJI 0 22 0 33 0 23 UI3 UI2 
C(l) 0.0264(13) 0.0155(13) 0.0231(13) 0.0094(10) 0.0029(10) 0.0019(10) 
N(2) 0.0334(13) 0.0178(12) 0.0261(r'2) 0.0107(9) 0.0037(10) 0.0026(9) 
C(3) 0.0345(15) 0.0165(13) 0.0260(14) 0.0100(11) 0.0038(11) 0.0018(10) 
N(4) 0.0281(12) 0.0146(11) 0.0252(12) 0.0058(9) 0.0031(9) 0.0029(8) 
C(5) 0.0369(16) 0.0139(13) 0.0279(15) 0.0042(11) 0.0035(12) 0.0044(11) 
C(6) 0.0329(16) 0.0188(14) 0.0277(15) . 0.0036(11) 0.0003(11) 0.0003(11) 
C(6A) 0.0238(14) 0.0198(13) 0.0275(15) 0.0066(11) 0.0023(11) 0.0044(10) 
. C(7) 0.0335(16) 0.0270(15) 0.0222(14} 0.0038(11) 0.0020(11) 0.0046(12) 
C(8) 0.0322(16) 0.0339(17) 0.0242(14) 0.0130(12) 0.0068(11) 0.0059(12) 
C(9) 0.0324(16) 0.0229(14) 0.0314(16) 0.0126(12) 0.0095(12) 0.0034(11) 
C(10) 0.0248(14) 0.0207(14) 0.0263(14) 0.0068(11) 0.0054(10) 0.0026(10) 
C(10A) 0.0189(12) 0.0197(13) 0.0228(13) 0.0079(10) 0.0039(10) 0.0050(9) 
C(10B) 0.0203(13) 0.0150(13) 0.0268(14) 0.0076(10) 0.0020(10) 0.0020(9) 
C(11) 0.0248(13) 0.0173(13) 0.0226(13) 0.0051(10) 0.0020(10) 0.0023(10) 
0(12) 0.0496(14) 0.0164(10) 0.0300(11) 0.0093(8) 0.0107(9) 0.0065(9) 
0(13) 0.0445(13) 0.0183(10) 0.0246(11) 0.0052(8) 0.0083(9) 0.0048(8) 
C(14) 0,0363(16) 0.0242(15) 0.0295(15) 0.0003(12) 0.0081(12) 0.0080(12) 
Table 5. Hydrogen coordinates and isotropic displacement parameters (N) for rbl. 
X y z u 
H(3) 0.2375 -0.1730 0.0787 0.030 
H(5A) 0.2359 . -0.3058 -0.1853 0.031 
H(5B) 0.4246 -0.2072 -0.2254 0.031 
H(6A) 0.2016 -0.2333 -0.4130 0.032 
- H(6B) 0.0441 -0.1503 -0.3136 0.032 .. 
H(7) 0.2231 -0.0145 -0.5604 0.033 
H(8) 0.3256 0.2641 -0.5909 0.035 
H(9) 0.4202 0.4774 -0.3988 0.033 
H(10) 0.4056 0.4150 -0.1763 0.028 
H(14A) 0.2380 0.6689 0.2807 0.045 
H(14B) 0.0694 0.5974 0.3626 0.045 
H(14C) 0.0287 0.6333 0.2095 0.045 
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Table 6. Torsion angles [0 ] for rbl. 
. C(lOB)-C(l)-N(2)-C(3) 
.~(l}-~(2)-{:(3)-N(4) 
N (2 )-C(3 }-~ ( 4 }-C( 5) 
C(10B}-N(4)-C(5}-C(6) 
C(5)-C(6)-C( 6A)-C(7) 
C( lOA)-C( 6A)-C(7}-C(8) 
C( 6A)-C(7)-C(8}-C(9) 
C(8)-C(9)-C( 1 O}-C(1 OA) 
C(9}-C(1 0)-C(l OA)-C(lOB) 
C(6)-C(6A)-C(10A}-C(10). 
C(6)-C(6A)-C(1 OA)-C(1 OB) 
C( 5}-~ ( 4 )-C( 1 OB )-C(l) 
C(5}-~(4)-C(lOB}-C(10A) 
C(11}-C(l)-C(lOB)-~(4) 
C(11}-C(1)-C(10B)-C(lOA) 
C(6A}-C(10A)-C(10B}-~(4) 
C(6A}-C(10A)-C(10B)-C(1) 
N(2)-C(1 )-C( 11 }-0(12) 
N(2}-C(1)~C(11)-0(13) 
C(l)-C(11}-0(13}-C(14) 
-0.4(3) 
-0.2(3) 
-176.4(3) 
-37.8(4) 
144.4(3) 
1.2(4) 
1.0(5) 
-1.0(4) 
-177.2(2) 
177.6(2) 
-2.1(4) 
176.4(2) 
-0.3(4). 
-174.2(3) 
1.4(5) 
22.0(4) 
-,-153.2(3) 
177.7(3) 
-2:9(4) 
-176.6(2) 
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C( 11 }-C( 1 }-N(2}-C(3) 
~ (2 )-C(3 )-N ( 4 )-C( 1 OB) 
C(3 }-N ( 4 )-C( 5)-C( 6) 
~(4)-C(5)-C(6)-C(6A) 
C(5)-C(6)-C(6A)-C(1 OA) 
C( 6)-C( 6A)-C(7)-C(8) 
C(7)-C(8)-C(9)-C(10) 
C(9)-C(10)-C(lOA)-C(6A) 
C(7)-C(6A)-C(10A)-C(10) 
C(7}-C(6A}-C(1 OA)-C(1 OB) 
C(3 }-N ( 4 )-C( 1 OB )-C( 1) 
C(3}-~(4)-C(lOB)-C(10A). 
N(2)-C(1 )-C(l OB}-~( 4) 
N(2)-C(l )-C( 1 OB)-C( 1 OA) 
C(10)-C(10A)-C(10B}-~(4) · . 
C(10)-C(10A)-C(10B}-C(1) . 
C(10B)-C(l)-C(l1)-0(12) 
C(10B)-C(l)-C(11}-0(13) 
0(12)-C(11}-0(13)-C(14) 
·. 
175.1(3) 
0.7(3) 
138.9(3) 
53.3(3) 
-36.5(4) 
-179.7(3) 
-1.1(5) 
- 3.3(4) 
-3.3(4) 
177._1(2) 
-0.9(3) 
~177.6(2) 
0.9(3) 
176.5(3) 
-157.6(3) 
27.2(5) 
-7.7(5) 
171.7(3) 
. 2.8(4) 
Table 1: Crystal data and structure refinement for methyl5,6-dihydroimidazo[2,1-a]isoquinoline-3-
carboxylate 282 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
z 
Density (calculated) 
Absorption coefficient 
F(OOO) 
Crystal size 
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta= 25.00° 
Absorption correction 
Refinement method 
Data I restraints I parameters 
Goodness-of-fit on F2 
Final R indices [I>2sigma(l)] 
R indices (all data) 
Largest diff. peak and hole 
CI3 Hl2N202 
228.25 
150(2) K 
0.71073 A 
Monoclinic 
P2(l)lc 
a= 11.9248(13) A 
b = 11.9615(13) A 
c = 7.6375(8) A 
1076.3(2) A3 
4 
1.409Mglm3 
0.097mm-1 
480 
0.38 x 0.38 x 0.08 mm3 
1.73 to 25.00°. 
fl= 98.895(2)0 • 
y = 90°. 
-14<=h<=l4, -14<=k<=l4, -9<=1<=7 
5967 
1861 [R(int) = 0.0292] 
98.5% 
None 
Full-matrix least-squares on F2 
1861101154 
1.042 
RI = 0.0363, wR2 = 0.0924 
RI = 0.0475, wR2 = 0.0985 
0.177 and -0.213 e.A-3 
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A2x 1oJ). U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
X y z U(eq) 
N(1) -1427(1) 6973(1) 1319(2) 25(1) 
C(1) -1310(1) 5747(1) 1364(2) 30(1) 
C(2) -2474(1) 5219(1) 844(2) 30(1) 
C(3) -3376(1) 5732(1) 1776(2) 28(1) 
C(4) -4297(1) 5125(1) 2173(2) 32(1) 
C(5) -5148(1) 5637(1) 2936(2) 34(1) 
C(6) -5081(1) 6767(1) 3309(2) 33(1) 
C(7) -4171(1) 7389(1) 2922(2) 29(1) 
C(8) -3318(1) 6875(1) 2166(2) 25(1) 
C(9) -2346(1) 7510(1) 1750(2) 24(1) 
N(2) -2221(1) 8620(1) 1761(2) 29(1) 
C(10) -1173(1) 8786(1) 1336(2) 30(1) 
C(11) -650(1) 7793(1) 1057(2) 26(1) 
C(12) 472(1) 7568(1) 609(2) 28(1) 
0(1) 894(1) 6660(1) 494(2) 43(1) 
0(2) 1010(1) 8529(1) 349(2) 39(1) 
C(13) 2143(1) 8412(1) -75(3) 40(1) 
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Table 3. Bond lengths [A] and angles [0 ]. 
N(1)-C(9) 1.3545(17) C(7)-C(8) 1.3888(19) 
N(1)-C(11) 1.3850(18) C(8)-C(9) 1.4605(19) 
N(1)-C(1) 1.4734(18) C(9)-N(2) 1.3361(18) 
C(l)-C(2) 1.520(2) N(2)-C(10) 1.3531(19) 
C(2)-C(3) 1.510(2) C(10)-C(11) 1.373(2) 
C(3)-C(4) 1.388(2) C(11)-C(12) 1.457(2) 
C(3)-C(8) 1.399(2) C(12)-0(l) 1.2051(17) 
C(4)-C(5) 1.388(2) C(12)-0(2) 1.3462(18) 
C(5)-C(6) 1.381(2) 0(2)-C(13) 1.4442(18) 
C(6)-C(7) 1.384(2) 
C(9)-N(l)-C(ll) 106.49{11) C(3)-C(8)-C(9) 118.48(12) 
C(9)-N{1)-C(1) 122.92{11) N(2)-C(9)-N(1) 112.24(12) 
C(11)-N(1)-C(1) 130.23{11) N(2)-C(9)-C(8) 127.38{13) 
N(1)-C(1)-C(2) 109.13{11) N(1 )-C(9)-C(8) 120.38(13) 
C(3)-C(2)-C(1) 113.38(13) C(9)-N(2)-C(10) 104.57(12) 
C(4)-C(3)-C(8) 118.64(13) N(2)-C(1 O)-C(11) 111.61(13) 
C(4)-C(3)-C(2) 122.48{13) C(10)-C(11)-N(l) 105.10(12) 
C(8)-C(3)-C(2) 118.79(12) C(10)-C(11)-C(12) 130.73(13) 
C(3)-C(4)-C(5) 121.05(14) N(1)-C(11)-C(12) 124.17(12) 
C( 6)-C( 5)-C( 4) 119.68(14) 0(1)-C(12)-0(2) 122.99(14) 
C( 5)-C( 6)-C(7) 120.28{14) O(l)-C(12)-C(11) 126.38{14) 
C( 6)-C(7)-C(8) 119.98{14) 0(2)-C(12)-C(11) 110.63(12) 
C(7)-C(8)-C(3) 120.38(13) C(12)-0(2)-C(13) 115.75(12) 
C(7)-C(8)-C(9) 121.14(13) 
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Table 4. Anisotropic displacement parameters (A2x 1 03). The anisotropic displacement factor exponent takes the 
form: -2:rt2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
uu U22 UJ3 U23 U13 u12 
N(1) 24(1) 22(1) 29(1) -2(1) 7(1) 1(1) 
C(1) 28(1) 22(1) 40(1) 0(1) 10(1) 3(1) 
C(2) 30(1) 22(1) 40(1) -1(1) 12(1) -1(1) 
C(3) 26(1) 27(1) 30(1) 2(1) 5(1) 1(1) 
C(4) 30(1) 29(1) 38(1) 2(1) 8(1) -3(1) 
C(5) 25(1) 40(1) 37(1) 6(1) 8(1) -5(1) 
C(6) 25(1) 41(1) 33(1) 0(1) 10(1) 2(1) 
C(7) 26(1) 31(1) 31(1) -1(1) 6(1) 3(1) 
C(8) 22(1) 28(1) 24(1) 2(1) 3(1) 1(1) 
C(9) 23(1) 25(1) 25(1) -1(1) 5(1) 2(1) 
N(2) 26(1) 26(1) 37(1) -2(1) 9(1) 0(1) 
C(10) 28(1) 27(1) 36(1) -2(1) 8(1) -3(1) 
C(ll) 25(1) 25(1) 29(1) -2(1) 6(1) -2(1) 
C(12) 26(1) 28(1) 30(1) -3(1) 5(1) -2(1) 
0(1) 29(1) 32(1) 73(1) -6(1) 18(1) 2(1) 
0(2) 27(1) 32(1) 61(1) -1(1) 19(1) -2(1) 
C(13) 25(1) 45(1) 54(1) -3(1) 16(1) -3(1) 
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A2x 10 3). 
X y z U(eq) 
H(1A) -977 5502 2571 35 
H(lB) -798 5506 531 35 
H(2A) -2705 5298 -452 36 
H(2B) -2420 4410 1119 36 
H(4) -4346 4348 1918 38 
H(5) -5774 5212 3200 40 
H(6) -5661 7119 3833 39 
H(7) -4130 8167 3175 35 
H(10) -841 9501 1243 36 
H(13A) 2463 9155 -225 60 
H(13B) 2115 7986 -1177 60 
H(13C) 2621 8017 889 60 
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Table 6. Torsion angles [0 ]. 
C(9)-N(l )-C(l )-C(2) 33.92(19) N(l}-C(ll)-C(12)-0(2) 176.85(14} 
C(11)-N(1)-C(1}-C(2} -154.00(14) 0(1)-C(12)-0(2)-C(13} -0.3(2) 
N(l}-C(l)-C(2}-C(3) -46.68(18) C(11)-C(12}-0(2)-C(13} 178.99(13) 
C(1)-C(2)-C(3)-C(4) -149.55(15} 
C(l )-C(2)-C(3}-C(8} 34.1(2} 
C(8)-C(3)-C( 4)-C(S) 0.2(2) 
C(2)-C(3)-C(4)-C(5) -176.12(15} 
C(3 )-C( 4 )-C( 5)-C( 6) 0.0(2} 
C(4)-C(5)-C(6)-C(7) 0.1(2) 
C( 5)-C( 6)-C(7}-C(8) -0.4(2) 
C( 6)-C(7)-C(8}-C(3) 0.5(2) 
C( 6)-C(7)-C(8}-C(9} -179.76(14) 
C(4)-C(3}-C(8)-C(7) -0.4(2) 
C(2)-C(3)-C(8}-C(7) 176.00(14) 
C(4)-C(3}-C(8}-C(9) 179.85(14) 
C(2)-C(3)-C(8}-C(9) -3.7(2) 
C(11}-N(1)-C(9}-N(2) 0.85(17) 
C(1 )-N(1 )-C(9)-N(2) 174.55(13) 
C(11}-N(1)-C(9)-C(8) -178.21(13) 
C(1 )-N(1 )-C(9)-C(8) -4.5(2) 
C(7)-C(8}-C(9)-N(2) -10.9(2) 
C(3)-C(8)-C(9)-N(2) 168.75(15) 
C(7)-C(8)-C(9)-N(1) 167.96(14} 
C(3)-C(8)-C(9)-N(1) -12.3(2) 
N(1 )-C(9)-N(2)-C(1 0) -0.67(17) 
C(8)-C(9)-N(2)-C(1 0} 178.32(15) 
C(9)-N(2}-C(10)-C(11) 0.22(17) 
N(2)-C(10)-C(11)-N(l) 0.27(17) 
N(2)-C(10}-C(11}-C(12) -178.82(15) 
C(9)-N(1)-C(11}-C(10} -0.65(16) 
C(1)-N(1)-C(11}-C(10} -173.72(15) 
C(9)-N(1 )-C(11 )-C(12} 178.52(15) 
C(1)-N(1)-C(11}-C(12} 5.5(2) 
C(10)-C(11)-C(12)-0(1} 175.02(17) 
N(1}-C(l1)-C(12)-0(1} -3.9(3) 
C(10)-C(11)-C(l2}-0(2) -4.2(2) 
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Proton NMR spectrum of CDC13-swollen gel 
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